Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 484
Encontrada(s) 5 página(s)

BULERIA. Repositorio Institucional de la Universidad de León
Publicación Artículo científico (JournalArticle)

Influence of 12-week concurrent training on exosome cargo and its relationship with cardiometabolic health parameters in men with obesity

  • Estébanez González, Brisamar
  • Amaro-Gahete, Francisco José
  • Gil-González, C.
  • González Gallego, Javier
  • Cuevas González, María José
  • Jiménez-Pavón, David
[EN] Exosome release varies depending on the physiological state of the cell, so they could play a fundamental role in obesity, the biggest pandemic in today's societies. The beneficial effects that physical activity has both on weight and cardiovascular parameters may be mediated by exosomes released in response to exercise. Thus, we aimed (I) to study the influence of a 12-week CT intervention on exosome cargo modifications in men with obesity and (II) to determine whether changes in exosomes after the intervention were related to changes in cardiometabolic health parameters in our cohorts. An experimental, controlled design was performed in twelve (nine with valid data) adult male obese patients (mean values: 41.6 years old, 97.6 kg and 32.4 kg/m2) who were randomly divided into a control group (n = 4) and a training group (n = 5), which completed 36 sessions of CT (concurrent training) for 12 weeks. Before and after the training period, cardiometabolic health parameters were evaluated and blood samples to measure exosomes and proteins were drawn. No changes were observed in the levels of any exosomal markers and proteins; however, associations of changes between CD81 and both fat mass and weight, Flot-1 and VO2max, HSP70 and both CRP and left ventricle diastolic diameter or CD14 and leptin were found (all p ≤ 0.05). Although the current CT was not able to clearly modify the exosome cargo, a certain medium to large clinical effect was manifested considering the nature of this study. Moreover, the associations found between the promoted changes in cardiometabolic parameters and exosome-carried proteins could indicate a relationship to be considered for future treatments in patients with obesity., SI, Current research activities of D.J.-P. are supported by a grant from the Spanish Ministry of Science and Innovation—MINECO (RYC-2014-16938) and the EXERNET Research Network on Exercise and Health in Special Populations (DEP2005-00046/ACTI). Technology Fund—FEDER funds (R&D&I Operating Program) was used by and for the benefit of companies (Technology Fund) INNTERCONECTA (BRISA Contract-University of Cádiz). The results of the study are presented clearly, honestly and without fabrication, falsification or inappropriate data manipulation., Biomedical Research Networking Center on Frailty and Healthy Aging (CIBERFES) and FEDER funds from the European Union (CB16/10/00477).
BULERIA. Repositorio Institucional de la Universidad de León
Publicación Artículo científico (JournalArticle)

Therapeutic implications of NK cell regulation of allogeneic CD8 T cell-mediated immune responses stimulated through the direct pathway of antigen presentation in transplantation

  • Rodríguez Barbosa, José Ignacio
  • Ferreras Estrada, María Del Carmen
  • Buhler, Leo
  • Jones, N. D.
  • Schneider, P.
  • Pérez Simón, José Antonio
  • Río González, María Luisa del
[EN]Natural killer (NK) cells are a population of innate type I lymphoid cells essential for early anti-viral responses and are known to modulate the course of humoral and cellular-mediated T cell responses. We assessed the role of NK cells in allogeneic CD8 T cell-mediated responses in an immunocompetent mouse model across an MHC class I histocompatibility barrier to determine its impact in therapeutic clinical interventions with polyclonal or monoclonal antibodies (mAbs) targeting lymphoid cells in transplantation. The administration of an NK cell depleting antibody to either CD8 T cell replete or CD8 T cell-depleted naïve C57BL/6 immunocompetent mice accelerated graft rejection. This accelerated rejection response was associated with an in vivo increased cytotoxic activity of CD8 T cells against bm1 allogeneic hematopoietic cells and bm1 skin allografts. These findings show that NK cells were impli-cated in the control host anti-donor cytotoxic responses, likely by competing for common cell growth factors in both CD8 T cell replete and CD8 T cell-depleted mice, the latter reconstituting in response to lymphopenia. Our data calls for precaution in solid organ transplantation under tolerogenic protocols involving extensive depletion of lymphocytes. These pharmacological biologics with depleting proper-ties over NK cells may accelerate graft rejection and promote aggressive CD8 T cell cytotoxic allore-sponses refractory to current immunosuppression., SI, This work has been supported by grant FIS PI# 1300029 (Fondo de Investigaciones Sanitarias, Ministry of Health, Spanish Government and co-funded by European Union ERDF/ESF, “Investing in your future”), LE093U13 and Unit of Excellence Research UIC #012 (Department of Education of the Regional Government, Junta de Castilla y Leon) and Gerencia Regional de Salud (BIO/01/15) to JIRB, and by Miguel Servet National Grant (Health National Organization Research) CP12/03063, CPII17/00002 and FIS PI16/00002 (Instituto de Salud Carlos III and co-funded by European Union ERDF/ESF, “Investing in your future”), and Gerencia Regional de Salud GRS963/A/2014, GRS1142/A/2015 and GRS 1505/A/2017 to M.L.R.G., This work has been partially funded by the National Network CIBER-ONC (oncology research) CB16/12/00480. P.S. is funded by grant 31003A-17-6256 of the Swiss National Science Foundation. We thank University of Leon for providing funding to cover publication expenses.
BULERIA. Repositorio Institucional de la Universidad de León
Publicación Artículo científico (JournalArticle)

The Role of the Inhibitory Ligand HVEM and Its Receptors CD160 and BTLA in the Regulation of Anti-retroviral T Cell Responses

  • David, Paul
  • Westmeier, Jaana
  • Drabczyk-Pluta, Malgorzata
  • Werner, Tanja
  • Ickler, Julia
  • Francois, Sandra
  • Bayer, Wibke
  • Sutter, Kathrin
  • Río González, María Luisa del
  • Rodríguez Barbosa, José Ignacio
  • Dittmer, Ulf
  • Zelinskyy, Gennadiy
[EN] Specific CD8+ T cells are crucial for the control of viruses. However, during many chronic viral infections these cells become dysfunctional. Immune checkpoint receptors, like PD-1 expressed on CD8+ T cells, contribute to this functional suppression during chronic infection. However, during the acute phase of infection virus-specific CD8+ T cells express high levels of PD-1 but are fully competent in killing virus-infected cells and there is increasing evidence that the biological activity of inhibitory receptors is strongly influenced by the availability of their respective ligands. We determined the expression of ligands for inhibitory receptors on infected myeloid cells during the acute phase of Friend retroviral (FV) infection. FV infection of granulocytes, monocytes, and macrophages strongly increased the cell surface expression of PD-L1 and the recently described ligand HVEM for inhibitory receptors BTLA and CD160. In addition, the infection of human myeloid cells in vitro with HIV also enhanced the expression of PD-L1 and HVEM. In infected mice, the upregulation of inhibitory ligands on infected cells was accompanied by enhanced frequencies of FV-specific CD8+ T cells that express PD-1, and the inhibitory receptors CD160 and BTLA. To define the functional effects of HVEM on activated CD8+ T cells, FV-infected mice were treated with blocking antibodies that prevented the interaction of HVEM with its two receptors, CD160 or BTLA, alone or in combination with anti-PD-L1 antibodies. Blocking the interaction of HVEM with CD160 and BTLA improved the production of cytotoxic molecules and the elimination of FV-infected cells. This effect was augmented when the therapy was combined with anti-PD-L1 antibodies, resulting in an additional expansion of cytotoxic CD8+ T cells. Thus, the ligand HVEM for the inhibitory receptors CD160 and BTLA downregulates the functionality of CD8+ T cells during retroviral infection and are potential targets for the immunomodulatory therapy of chronic viral infections, SI, This work was supported by the Deutsche Forschungsgemeinschaft with grant (DFG Di 714/20-1) to UD, Spanish Ministry of Science and Universities (Grant # PID2019-103984RB-I00), Department of Education of Castilla and Leon Regional Government (Grant # LE-006P20), and Spanish Network of Cancer Research, Ciberonc (Grant # CB16/12/00480) to J-IR-B
Docta Complutense
Publicación Artículo científico (JournalArticle)

CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition

  • Quijada Álamo, Miguel
  • Hernández Sánchez, María
  • Alonso Pérez, Verónica
  • Rodríguez Vicente, Ana E.
  • García Tuñón, Ignacio
  • Martín Izquierdo, Marta
  • Hernández Sánchez, Jesús María
  • Herrero, Ana B.
  • Bastida, José María
  • San Segundo, Laura
  • Gruber, Michaela
  • García, Juan Luis
  • Yin, Shanye
  • Hacken, Elisa ten
  • Benito, Rocío
  • Ordóñez, José Luis
  • Wu, Catherine J.
  • Hernández-Rivas, Jesús María
The deletion of 11q (del(11q)) invariably comprises ATM gene in chronic lymphocytic leukemia (CLL). Concomitant mutations in this gene in the remaining allele have been identified in 1/3 of CLL cases harboring del(11q), being the biallelic loss of ATM associated with adverse prognosis. Although the introduction of targeted BCR inhibition has significantly favored the outcomes of del(11q) patients, responses of patients harboring ATM functional loss through biallelic inactivation are unexplored, and the development of resistances to targeted therapies have been increasingly reported, urging the need to explore novel therapeutic approaches. Here, we generated isogenic CLL cell lines harboring del(11q) and ATM mutations through CRISPR/Cas9-based gene-editing. With these models, we uncovered a novel therapeutic vulnerability of del(11q)/ ATM-mutated cells to dual BCR and PARP inhibition. Ex vivo studies in the presence of stromal stimulation on 38 CLL primary samples confirmed a synergistic action of the combination of olaparib and ibrutinib in del(11q)/ATM-mutated CLL patients. In addition, we showed that ibrutinib produced a homologous recombination repair impairment through RAD51 dysregulation, finding a synergistic link of both drugs in the DNA damage repair pathway. Our data provide a preclinical rationale for the use of this combination in CLL patients with this high-risk cytogenetic abnormality
Docta Complutense
Publicación Artículo científico (JournalArticle)

Clinical, Histopathologic and Genetic Features of Rhabdoid Meningiomas

  • Garrido Ruiz, Patricia Alejandra
  • Hernández Laín, Aurelio
  • Tabernero, María Dolores
<jats:p>Rhabdoid meningiomas (RM) shows heterogeneous histological findings, and a wide variety of chromosomal copy number alterations (CNA) are associated with an unpredictable course of the disease. In this study, we analyzed a series of 305 RM samples from patients previously reported in the literature and 33 samples from 23 patients studied in our laboratory. Monosomy 22-involving the minimal but most common recurrent region loss of the 22q11.23 chromosomal region was the most observed chromosomal alteration, followed by losses of chromosomes 14, 1, 6, and 19, polysomies of chromosomes 17, 1q, and 20, and gains of 13q14.2, 10p13, and 21q21.2 chromosomal regions. Based on their CNA profile, RM could be classified into two genetic subgroups with distinct clinicopathologic features characterized by the presence of (1) chromosomal losses only and (2) combined losses and gains of several chromosomes. The latter displays a higher frequency of WHO grade 3 tumors and poorer clinical outcomes.</jats:p>
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Impact of Epicardial Adipose Tissue on Infarct Size and Left Ventricular Systolic Function in Patients with Anterior ST-Segment Elevation Myocardial Infarction

  • Gavara Doñate, Jose|||0000-0002-3483-7066
  • Merenciano, Héctor|||0000-0002-1734-0381
  • Llopis-Lorente, Jordi|||0000-0002-3958-8062
  • Molina-Garcia, Tamara
  • Perez-Solé, Nerea|||0000-0003-3527-0337
  • de Dios, Elena
  • Marcos-Garces, Víctor
  • Monmeneu, José V.
  • Lopez-Lereu, María P.
  • Canoves, Joaquim
  • Bonanad, Clara
  • Moratal, David|||0000-0002-2825-3646
  • Núñez, Julio|||0000-0003-1672-7119
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Sanchis, Juan|||0000-0003-0797-8709
  • Chorro, Francisco J.
  • Rios-Navarro, Cesar|||0000-0002-6405-6279
  • Bodi, Vicente|||0000-0001-6425-5828
We aimed to assess the correlation of cardiovascular magnetic resonance (CMR)-derived epicardial adipose tissue (EAT) with infarct size (IS) and residual systolic function in ST-segment elevation myocardial infarction (STEMI). We enrolled patients discharged for a first anterior reperfused STEMI submitted to undergo CMR. EAT, left ventricular (LV) ejection fraction (LVEF), and IS were quantified at the 1-week (n = 221) and at 6-month CMR (n = 167). At 1-week CMR, mean EAT was 31 ± 13 mL/m. Patients with high EAT volume (n = 72) showed larger 1-week IS. After adjustment, EAT extent was independently related to 1-week IS. In patients with large IS at 1 week (>30% of LV mass, n = 88), those with high EAT showed more preserved 6-month LVEF. This association persisted after adjustment and in a 1:1 propensity score-matched patient subset. Overall, EAT decreased at 6 months. In patients with large IS, a greater reduction of EAT was associated with more preserved 6-month LVEF. In STEMI, a higher presence of EAT was associated with a larger IS. Nevertheless, in patients with large infarctions, high EAT and greater subsequent EAT reduction were linked to more preserved LVEF in the chronic phase. This dual and paradoxical effect of EAT fuels the need for further research in this field.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Loss of the epithelial marker CDX1 predicts poor prognosis in early-stage CRC patients

  • Solé Font, Laura|||0000-0002-3195-0565
  • Lobo-Jarne, Teresa|||0000-0002-1632-438X
  • Cabré-Romans, Júlia-Jié
  • González, Antón
  • Fernández, Lierni
  • Marruecos, Laura|||0000-0002-4206-709X
  • Guix, Marta|||0000-0002-2143-0697
  • Cuatrecasas, Miriam|||0000-0003-3063-0110
  • López, Sandra
  • Bellosillo Paricio, Beatriz|||0000-0002-5335-2726
  • Torres, Ferran|||0000-0002-7355-7913
  • Iglesias, Mar|||0000-0002-2274-4671
  • Bigas Salvans, Anna|||0000-0003-4801-6899
  • Espinosa, Lluis|||0000-0002-2897-4099
Background: We have previously shown that non-curative chemotherapy imposes fetal conversion and high metastatic capacity to cancer cells. From the set of genes differentially expressed in Chemotherapy Resistant Cells, we obtained a characteristic fetal intestinal cell signature that is present in a group of untreated tumors and is sufficient to predict patient prognosis. A feature of this fetal signature is the loss of CDX1. Methods: We have analyzed transcriptomic data in public datasets and performed immunohistochemistry analysis of paraffin embedded tumor samples from two cohorts of colorectal cancer patients. Results: We demonstrated that low levels of CDX1 are sufficient to identify patients with poorest outcome at the early tumor stages II and III. Presence tumor areas that are negative for CDX1 staining in stage I cancers is associated with tumor relapse. Conclusions: Our results reveal the actual possibility of incorporating CDX1 immunostaining as a valuable biomarker for CRC patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Intracoronary Delivery of Porcine Cardiac Progenitor Cells Overexpressing IGF-1 and HGF in a Pig Model of Sub-Acute Myocardial Infarction

  • Prat-Vidal, Cristina|||0000-0002-5621-1101
  • Crisóstomo, Verónica|||0000-0003-1740-7029
  • Moscoso, Isabel|||0000-0002-6078-4666
  • Báez-Díaz, Claudia
  • Blanco-Blázquez, Virginia|||0000-0003-1971-919X
  • Gómez-Mauricio, Guadalupe
  • Albericio, Guillermo
  • Aguilar, Susana
  • Fernández Santos, María Eugenia|||0000-0001-9229-0022
  • Fernández Avilés, Francisco|||0000-0001-5501-5275
  • Sánchez Margallo, Francisco Miguel|||0000-0003-2138-988X
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Bernad, Antonio
Human cardiac progenitor cells (hCPC) are considered a good candidate in cell therapy for ischemic heart disease, demonstrating capacity to improve functional recovery after myocardial infarction (MI), both in small and large preclinical animal models. However, improvements are required in terms of cell engraftment and efficacy. Based on previously published reports, insulin-growth factor 1 (IGF-1) and hepatocyte growth factor (HGF) have demonstrated substantial cardioprotective, repair and regeneration activities, so they are good candidates to be evaluated in large animal model of MI. We have validated porcine cardiac progenitor cells (pCPC) and lentiviral vectors to overexpress IGF-1 (co-expressing eGFP) and HGF (co-expressing mCherry). pCPC were transduced and IGF1-eGFP pos and HGF-mCherry pos populations were purified by cell sorting and further expanded. Overexpression of IGF-1 has a limited impact on pCPC expression profile, whereas results indicated that pCPC-HGF-mCherry cultures could be counter selecting high expresser cells. In addition, pCPC-IGF1-eGFP showed a higher cardiogenic response, evaluated in co-cultures with decellularized extracellular matrix, compared with native pCPC or pCPC-HGF-mCherry. In vivo intracoronary co-administration of pCPC-IGF1-eGFP and pCPC-HFG-mCherry (1:1; 40 × 10 6 /animal), one week after the induction of an MI model in swine, revealed no significant improvement in cardiac function.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Beta-blocker treatment of patients with atrial fibrillation attenuates spontaneous calcium release-induced electrical activity

  • Jiménez-Sábado, Verónica|||0000-0001-7720-988X
  • Casabella Ramón, Sergi|||0000-0001-7597-350X
  • Llach, Anna|||0000-0002-7486-1079
  • Gich, Ignasi|||0000-0003-3975-6588
  • Casellas Casanovas, Sandra|||0009-0000-5558-3125
  • Ciruela, Francisco|||0000-0003-0832-3739
  • Chen, S.R. Wayne
  • Guerra Ramos, José María|||0000-0001-5397-9177
  • Ginel, Antonino|||0000-0002-8820-7545
  • Benítez, Raúl|||0000-0002-8782-9406
  • Cinca, Juan|||0000-0003-4819-4265
  • Tarifa, Carmen|||0000-0001-8954-6058
  • Madsen, Leif Hove|||0000-0001-5493-3998
Aims: Atrial fibrillation (AF) has been associated with excessive spontaneous calcium release, linked to cyclic AMP (cAMP)-dependent phosphorylation of calcium regulatory proteins. Because β-blockers are expected to attenuate cAMP-dependent signaling, we aimed to examine whether the treatment of patients with β-blockers affected the incidence of spontaneous calcium release events or transient inward currents (I). Methods: The impact of treatment with commonly used β-blockers was analyzed in human atrial myocytes from 371 patients using patch-clamp technique, confocal calcium imaging or immunofluorescent labeling. Data were analyzed using multivariate regression analysis taking into account potentially confounding effects of relevant clinical factors Results: The L-type calcium current (I) density was diminished significantly in patients with chronic but not paroxysmal AF and the treatment of patients with β-blockers did not affect I density in any group. By contrast, the I frequency was elevated in patients with either paroxysmal or chronic AF that did not receive treatment, and β-blocker treatment reduced the frequency to levels observed in patients without AF. Confocal calcium imaging showed that β-blocker treatment also reduced the calcium spark frequency in patients with AF to levels observed in those without AF. Furthermore, phosphorylation of the ryanodine receptor (RyR2) at Ser-2808 and phospholamban at Ser-16 was significantly lower in patients with AF that received β-blockers. Conclusion: Together, our findings demonstrate that β-blocker treatment may be of therapeutic utility to prevent spontaneous calcium release-induced atrial electrical activity; especially in patients with a history of paroxysmal AF displaying preserved I density.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Electrophysiological and histological characterization of atrial scarring in a model of isolated atrial myocardial infarction

  • Amorós Figueras, Gerard|||0000-0002-2109-5550
  • Casabella Ramón, Sergi|||0000-0001-7597-350X
  • Company-Se, Georgina|||0000-0002-0473-4955
  • Arzamendi, Dabit|||0000-0001-7543-5867
  • Jorge, Esther|||0000-0002-2777-0000
  • García Osuna, Álvaro|||0000-0002-6682-0226
  • Macías, Y.
  • Sanchez-Quintana, Damian
  • Rosell Ferrer, Javier|||0000-0002-9691-328X
  • Guerra Ramos, José María|||0000-0001-5397-9177
  • Cinca, Juan|||0000-0003-4819-4265
Characterization of atrial myocardial infarction is hampered by the frequent concurrence of ventricular infarction. Theoretically, atrial infarct scarring could be recognized by multifrequency tissue impedance, like in ventricular infarction, but this remains to be proven. Objective: This study aimed at developing a model of atrial infarction to assess the potential of multifrequency impedance to recognize areas of atrial infarct scar. Seven anesthetized pigs were submitted to transcatheter occlusion of atrial coronary branches arising from the left coronary circumflex artery. Six weeks later the animals were anesthetized and underwent atrial voltage mapping and multifrequency impedance recordings. The hearts were thereafter extracted for anatomopathological study. Two additional pigs not submitted to atrial branch occlusion were used as controls. Selective occlusion of the atrial branches induced areas of healed infarction in the left atrium in 6 of the 7 cases. Endocardial mapping of the left atrium showed reduced multi-frequency impedance (Phase angle at 307 kHz: from -17.1° ± 5.0° to -8.9° ± 2.6°, p <.01) and low-voltage of bipolar electrograms (.2 ± 0.1 mV vs. 1.9 ± 1.5 mV vs., p <.01) in areas affected by the infarction. Data variability of the impedance phase angle was lower than that of bipolar voltage (coefficient of variability of phase angle at307 kHz vs. bipolar voltage:.30 vs.77). Histological analysis excluded the presence of ventricular infarction. Selective occlusion of atrial coronary branches permits to set up a model of selective atrial infarction. Atrial multifrequency impedance mapping allowed recognition of atrial infarct scarring with lesser data variability than local bipolar voltage mapping. Our model may have potential applicability on the study of atrial arrhythmia mechanisms.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Enhancing immunotherapy through -1 upregulation, the promising combination of anti--1 plus m inhibitors

  • Hernández-Prat, Anna|||0000-0002-8233-1035
  • Rodriguez-Vida, Alejo|||0000-0002-7304-6857
  • Cardona, Laura
  • Qin, Mengjuan|||0000-0001-7014-7188
  • Arpí-Llucià, Oriol
  • Soria-Jiménez, Luis|||0000-0002-2182-8953
  • Menéndez, Sílvia|||0000-0002-9116-8743
  • Quimis, Fabricio Gerel
  • Galindo, Miguel
  • Arriola, Edurne|||0000-0001-8960-7519
  • Salido, Marta|||0000-0001-9988-5977
  • Juanpere-Rodero, Nuria
  • Rojo, Federico|||0000-0001-9989-0290
  • Muntasell i Castellví, Aura|||0000-0003-2894-0486
  • Albanell Mestres, Joan|||0000-0003-1239-4580
  • Rovira, Ana|||0000-0003-1301-2599
  • Bellmunt, Joaquim|||0000-0003-2328-3421
Immune checkpoint inhibitors (ICIs) targeting the programmed cell death protein 1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) pathway have transformed urothelial cancer (UC) therapy. The correlation between PD-L1 expression and ICI effectiveness is uncertain, leaving the role of PD-L1 as a predictive marker for ICI efficacy unclear. Among several ways to enhance the efficacy of ICI, trials are exploring combining ICIs with serine/threonine-protein kinase mTOR (mTOR) inhibitors in different tumor types. The potential interaction between mTOR inhibitors and PD-L1 expression in UC has not been well characterized. In our study, we investigated how phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway inhibitors (TAK-228, everolimus and TAK-117) affect PD-L1 expression and function in preclinical bladder cancer cell models. TAK-228 increased cell surface levels of glycosylated PD-L1 in all but one of the seven cell lines, regardless of baseline levels. TAK-228 promoted the secretion of epidermal growth factor (EGF) and interferon-β (IFNβ), both linked to PD-L1 protein induction. Blocking EGF and IFNβ receptors reversed the TAK-228-induced PD-L1 increase. Additionally, TAK-228 enhanced IFN-γ-induced PD-L1 expression and intracellular HLA-I levels in some cells. TAK-228-treated bladder cancer cells exhibited resistance to the cytotoxic effects of peripheral blood mononuclear cells (PBMCs) and cluster of differentiation 8 (CD8)+ T cells. The addition of an anti-PD-L1 antibody diminished this resistance in T24 cells. Increased expression of PD-L1 under TAK-228 exposure was confirmed in patient-derived explants (PDEs) treated ex vivo. These preclinical findings suggest that mTOR inhibition with TAK-228 can increase PD-L1 levels, potentially impacting the specific immune response against UC cells. This highlights the rationale for exploring the combination of mTOR inhibitors with ICIs in patients with advanced UC. mTOR inhibition with TAK-228 can increase PD-L1 levels, potentially impacting the specific immune response against bladder cancer cell lines.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Tumor analysis of MMR genes in Lynch-like syndrome, Challenges associated with results interpretation

  • Rofes, Paula|||0000-0001-6045-7879
  • Dueñas Cid, Nuria|||0000-0001-6624-3265
  • Del Valle, Jesús|||0000-0003-3607-7045
  • Navarro, Matilde
  • Balmaña Gelpí, Judith|||0000-0002-0762-6415
  • Ramon y Cajal, Teresa|||0000-0003-3490-3585
  • Tuset, Noemí
  • Castillo, Carmen
  • González, Sara
  • Brunet, Joan|||0000-0003-1945-3512
  • Capella, Gabriel|||0000-0002-4669-7320
  • Lázaro García, Conxi|||0000-0002-7198-5906
  • Pineda, Marta|||0000-0002-5403-5845
Up to 70% of suspected Lynch syndrome patients harboring MMR deficient tumors lack identifiable germline pathogenic variants in MMR genes, being referred to as Lynch-like syndrome (LLS). Previous studies have reported biallelic somatic MMR inactivation in a variable range of LLS-associated tumors. Moreover, translating tumor testing results into patient management remains controversial. Our aim is to assess the challenges associated with the implementation of tumoral MMR gene testing in routine workflows. Methods: Here, we present the clinical characterization of 229 LLS patients. MMR gene testing was performed in 39 available tumors, and results were analyzed using two variant allele frequency (VAF) thresholds (≥5% and ≥10%). Results and Discussion: More biallelic somatic events were identified at VAF ≥ 5% than ≥10% (35.9% vs. 25.6%), although the rate of nonconcordant results regarding immunohistochemical pattern increased (30.8% vs. 20.5%). Interpretation difficulties question the current utility of the identification of MMR somatic hits in the diagnostic algorithm of suspected LS cases.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

ApoB100 remodeling and stiffened cholesteryl ester core raise LDL aggregation in familial hypercholesterolemia patients

  • La Chica Lhoëst, María Teresa|||0000-0002-9070-5973
  • Martínez, Andrea
  • García Rodríguez, Jesús Eduardo|||0000-0002-7758-6789
  • Dandurand, Jany
  • Polishchuk, Anna
  • Benitez Amaro, Aleyda|||0000-0002-1106-3125
  • Cenarro, Ana
  • Civeira, Fernando|||0000-0001-7043-0952
  • Bernabé, Amable
  • Viladés Medel, David|||0000-0002-3638-9703
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Samouillan, Valerie|||0000-0003-0571-3985
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
Patients with familial hypercholesterolemia (FH) exhibit a significant residual cardiovascular risk. A new cardiovascular risk factor is the susceptibility of individual LDL particles to aggregation. This study examined LDL aggregation and its relationship with LDL lipid composition and biophysical properties in patients with FH compared to controls. LDL aggregation was measured as the change in particle size, assessed by dynamic light scattering, after exposure to sphingomyelinase, which breaks down sphingomyelin in the LDL phospholipid layer. Dynamic light scattering and transmission electron microscopy showed that LDL in FH patients exhibited smaller size and greater susceptibility to aggregation. Biochemical analyses revealed a higher cholesteryl ester (CE)/ApoB100 ratio in LDL from FH patients. Differential scanning calorimetry showed that LDL from FH patients had higher transition temperatures, indicating a more ordered CE core. Fourier transform infrared spectroscopy revealed fewer flexible α-helices (1658 cm⁻ 1) and more stable α-helices (1651 cm⁻ 1) in ApoB100 of LDL from FH patients. These structural changes correlated with higher CE content and increased LDL aggregation. In conclusion, a more ordered CE core in smaller LDL particles, combined with a higher proportion of stable α-helices in ApoB100, promotes LDL aggregation in FH patients. These findings suggest ApoB100 conformational structure as a new potential therapeutic targets within LDL to reduce cardiovascular risk in FH patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Unique Splicing of Lrp5 in the Brain, A New Player in Neurodevelopment and Brain Maturation

  • Luquero, Aureli|||0000-0002-1104-5963
  • Pimentel, Noelia
  • Vilahur, Gemma|||0000-0002-2828-8873
  • Badimon, Lina|||0000-0002-9162-2459
  • Borrell-Pages, Maria|||0000-0002-1759-9756
Low-density lipoprotein receptor-related protein 5 (LRP5) is a constitutively expressed receptor with observed roles in bone homeostasis, retinal development, and cardiac metabolism. However, the function of LRP5 in the brain remains unexplored. This study investigates LRP5's role in the central nervous system by conducting an extensive analysis using RNA-seq tools and in silico assessments. Two protein-coding Lrp5 transcripts are expressed in mice: full-length Lrp5-201 and a truncated form encoded by Lrp5-202. Wt mice express Lrp5-201 in the liver and brain and do not express the truncated form. Lrp5 mice express Lrp5-202 in the liver and brain and do not express Lrp5-201 in the liver. Interestingly, Lrp5 mouse brains show full-length Lrp5-201 expression, suggesting that LRP5 has a role in preserving brain function during development. Functional gene enrichment analysis on RNA-seq unveils dysregulated expression of genes associated with neuronal differentiation and synapse formation in the brains of Lrp5 mice compared to Wt mice. Furthermore, Gene Set Enrichment Analysis highlights downregulated expression of genes involved in retinol and linoleic acid metabolism in Lrp5 mouse brains. Tissue-specific alternative splicing of Lrp5 in Lrp5 mice supports that the expression of LRP5 in the brain is needed for the correct synthesis of vitamins and fatty acids, and it is indispensable for correct brain development.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

1/2 mitogen-activated protein kinase dimerization is essential for the regulation of cell motility

  • de la Fuente-Vivas, Dalia
  • Cappitelli, Vincenzo
  • García-Gómez, Rocío
  • Valero-Díaz, Sara
  • Amato, Camilla
  • Rodriguéz, Javier
  • Duro Sánchez, Santiago|||0000-0002-3829-7562
  • von Kriegsheim, Alexander
  • Grusch, Michael|||0000-0001-5486-9340
  • Lozano, José
  • Arribas, Joaquín V|||0000-0002-0504-0664
  • Casar, Berta|||0000-0002-3058-5631
  • Crespo, Piero|||0000-0003-2825-7783
ERK1/2 mitogen-activated protein kinases (ERK) are key regulators of basic cellular processes, including proliferation, survival, and migration. Upon phosphorylation, ERK becomes activated and a portion of it dimerizes. The importance of ERK activation in specific cellular events is generally well documented, but the role played by dimerization is largely unknown. Here, we demonstrate that impeding ERK dimerization precludes cellular movement by interfering with the molecular machinery that executes the rearrangements of the actin cytoskeleton. We also show that a constitutively dimeric ERK mutant can drive cell motility per se, demonstrating that ERK dimerization is both necessary and sufficient for inducing cellular migration. Importantly, we unveil that the scaffold protein kinase suppressor of Ras 1 (KSR1) is a critical element for endowing external agonists, acting through tyrosine kinase receptors, with the capacity to induce ERK dimerization and, subsequently, to unleash cellular motion. In agreement, clinical data disclose that high KSR1 expression levels correlate with greater metastatic potential and adverse evolution of mammary tumors. Overall, our results portray both ERK dimerization and KSR1 as essential factors for the regulation of cell motility and mammary tumor dissemination. In mammary tumor cells, ERK dimerization is both necessary and sufficient for inducing cellular migration. The scaffold protein KSR1 is a critical element for endowing external agonists, acting through tyrosine kinase receptors, with the capacity to induce ERK dimerization and, subsequently, unleashing cellular motion, as a consequence of which tumor cell migration and metastatic dissemination are promoted.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

CD66b+/CD68+ circulating extracellular vesicles, lactate dehydrogenase and neutrophil-to-lymphocyte ratio can differentiate coronavirus disease 2019 severity during and after infection

  • Suades, Rosa|||0000-0002-0193-3115
  • Greco, M.F.|||0000-0003-3613-5516
  • Prieto, P.
  • Padró, Teresa|||0000-0003-1921-954X
  • Devaux, Yvan|||0000-0002-5321-8543
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Badimon, Lina|||0000-0002-9162-2459
Coronavirus disease 2019 (COVID-19) has been a major public health burden. We hypothesised that circulating extracellular vesicles (cEVs), key players in health and disease, could trace the cell changes during COVID-19 infection and recovery. Therefore, we studied the temporal trend of cEV and inflammatory marker levels in plasma samples of COVID-19 patients that were collected within 24 h of patient admission (baseline, n = 80) and after hospital discharge at day-90 post-admission (n = 59). Inflammatory markers were measured by standard biochemical methods. cEVs were quantitatively and phenotypically characterized by high-sensitivity nano flow cytometry. In patients recovered from COVID-19 lower levels of inflammatory markers were detected. cEVs from vascular (endothelial cells) and blood (platelets, distinct immune subsets) cells were significantly reduced at day-90 compared to admission levels, a pattern also observed for cEVs from progenitor, perivascular and epithelial cells. The best discriminatory power for COVID-19 severity was found for inflammatory markers lactate dehydrogenase and neutrophil-to-lymphocyte ratio and for granulocyte/macrophage-released CD66b/CD68-cEVs. Albeit inflammatory markers were good indicators of systemic inflammatory response and discriminators of COVID-19 remission, they do not completely reveal cell stress and organ damage states. cEVs reaching baseline pre-infection levels at 90 days post-infection in recovered patients discriminate parental cells affected by disease.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

The Influence of Metabolic Risk Factors on the Inflammatory Response Triggered by Myocardial Infarction, Bridging Pathophysiology to Treatment

  • Ramos-Regalado, Lisaidy|||0009-0004-3512-8474
  • Badimon, Lina|||0000-0002-9162-2459
  • Vilahur, Gemma|||0000-0002-2828-8873
  • Alcover, Sebastian|||0000-0003-3699-1769
Myocardial infarction (MI) sets off a complex inflammatory cascade that is crucial for effective cardiac healing and scar formation. Yet, if this response becomes excessive or uncontrolled, it can lead to cardiovascular complications. This review aims to provide a comprehensive overview of the tightly regulated local inflammatory response triggered in the early post-MI phase involving cardiomyocytes, (myo)fibroblasts, endothelial cells, and infiltrating immune cells. Next, we explore how the bone marrow and extramedullary hematopoiesis (such as in the spleen) contribute to sustaining immune cell supply at a cardiac level. Lastly, we discuss recent findings on how metabolic cardiovascular risk factors, including hypercholesterolemia, hypertriglyceridemia, diabetes, and hypertension, disrupt this immunological response and explore the potential modulatory effects of lifestyle habits and pharmacological interventions. Understanding how different metabolic risk factors influence the inflammatory response triggered by MI and unraveling the underlying molecular and cellular mechanisms may pave the way for developing personalized therapeutic approaches based on the patient's metabolic profile. Similarly, delving deeper into the impact of lifestyle modifications on the inflammatory response post-MI is crucial. These insights may enable the adoption of more effective strategies to manage post-MI inflammation and improve cardiovascular health outcomes in a holistic manner.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

SpadaHC, a database to improve the classification of variants in hereditary cancer genes in the Spanish population

  • Moreno-Cabrera, José Marcos|||0000-0001-8570-0345
  • Feliubadaló, Lidia|||0000-0002-1736-0112
  • Pineda, Marta|||0000-0002-5403-5845
  • Prada Dacasa, Patricia|||0000-0003-0689-9072
  • Ramos-Muntada, Mireia|||0000-0002-5531-1442
  • Del Valle, Jesús|||0000-0003-3607-7045
  • Brunet, Joan|||0000-0003-1945-3512
  • Gel, Bernat|||0000-0001-8878-349X
  • Currás-Freixes, M.
  • Calsina Pla Giribert, Bruna|||0000-0002-6922-9415
  • Salazar-Hidalgo, Milton E.
  • Rodríguez-Balada, M.
  • Roig, Bàrbara
  • Fernández-Castillejo, Sara|||0000-0002-8109-9713
  • Durán, Mercedes|||0000-0002-6301-9732
  • Arranz Ledo, Mónica
  • Infante, Mar
  • Castillejo Castillo, Adela|||0000-0002-9581-6285
  • Dámaso, Estela|||0000-0002-9650-7791
  • Soto, José Luis
  • de Miguel, Montserrat
  • Hidalgo Calero, Beatriz
  • Sánchez-Zapardiel, José M.
  • Ramon y Cajal, Teresa|||0000-0003-3490-3585
  • Lasa, Adriana|||0000-0001-9957-9646
  • Gisbert-Beamud, Alexandra|||0000-0001-6515-3081
  • López Novo, Anael
  • Ruiz-Ponte, C.
  • Potrony, Miriam|||0000-0003-2766-0765
  • Álvarez Mora, María Isabel|||0000-0003-3788-8915
  • Osorio, Ana|||0000-0001-8124-3984
  • Lorda Sánchez, Isabel
  • Robledo, Mercedes|||0000-0001-6256-5902
  • Cascón, Alberto|||0000-0003-2119-891X
  • Ruiz, Anna|||0000-0001-7314-5962
  • Spataro, Nino|||0000-0002-2127-2238
  • Hernán Sendra, Imma
  • Borràs, Emma
  • Moles-Fernández, Alejandro|||0000-0003-0252-6084
  • Earl, Julie
  • Cadiñanos, J.
  • Sánchez-Heras, Ana Beatriz|||0000-0003-1742-5374
  • Bigas Salvans, Anna|||0000-0003-4801-6899
  • Capella, Gabriel|||0000-0002-4669-7320
  • Lázaro, C.
Accurate classification of genetic variants is crucial for clinical decision-making in hereditary cancer. In Spain, genetic diagnostic laboratories have traditionally approached this task independently due to the lack of a dedicated resource. Here we present SpadaHC, a web-based database for sharing variants in hereditary cancer genes in the Spanish population. SpadaHC is implemented using a three-tier architecture consisting of a relational database, a web tool and a bioinformatics pipeline. Contributing laboratories can share variant classifications and variants from individuals in Variant Calling Format (VCF) format. The platform supports open and restricted access, flexible dataset submissions, automatic pseudo-anonymization, VCF quality control, variant normalization and liftover between genome builds. Users can flexibly explore and search data, receive automatic discrepancy notifications and access SpadaHC population frequencies based on many criteria. In February 2024, SpadaHC included 18 laboratory members, storing 1.17 million variants from 4306 patients and 16 343 laboratory classifications. In the first analysis of the shared data, we identified 84 genetic variants with clinically relevant discrepancies in their classifications and addressed them through a three-phase resolution strategy. This work highlights the importance of data sharing to promote consistency in variant classifications among laboratories, so patients and family members can benefit from more accurate clinical management.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Screening Strategies to Improve Early Diagnosis in Endometrial Cancer

  • Cabrera, S.
  • de la Calle, Irene|||0000-0002-2227-1640
  • Baulies Caballero, Sonia|||0000-0001-7670-5603
  • Gil-Moreno, Antonio|||0000-0003-1106-5590
  • Colás Ortega, Eva|||0000-0003-0302-4828
Endometrial cancer is the most common gynecological malignancy in high-income countries and the sixth most common cancer in women. Overall incidence has risen in the last few decades as a consequence of the increase in the prevalence of its risk factors, mainly obesity and the aging of the population, and although diagnoses have increased across all age groups, the incidence rates have doubled in women under the age of 40 years. The survival rates of endometrial cancer are highly dependent on its stage at diagnosis, bringing to the fore the importance of early diagnosis. The aim of a screening strategy in this type of tumor should be to detect the disease in the pre-invasive or early stage (before developing myometrial invasion), which would improve cure rates, reduce the morbidity associated with aggressive treatment and offer uterus-sparing management options for younger women. The ideal screening tool in this scenario would be a minimally invasive, inexpensive and easy-to-perform test or auto-test, which could be implemented in a routine gynecologic checkup of patients at-risk or in the general adult population. In this comprehensive review, we aim to define the populations at higher risk of developing endometrial cancer, to assess the performance of current diagnostic tools when used in a screening setting and to discuss the accuracy of new molecular screening strategies.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression

  • Medina-Herrera, A.
  • Vazquez, I.
  • Cuenca, I.
  • Rosa-Rosa, J.M.|||0000-0003-0806-6453
  • Ariceta, Beñat|||0000-0001-8819-402X
  • Jimenez, C.
  • Fernandez-Mercado, M.
  • Larrayoz, M.J.
  • Gutierrez, N.C.
  • Fernandez-Guijarro, M.
  • Gonzalez-Calle, V.
  • Rodriguez-Otero, Paula|||0000-0001-5236-7785
  • Oriol, Albert|||0000-0001-6804-2221
  • Rosiñol, Laura|||0000-0002-2534-9239
  • Alegre, Adrian|||0000-0002-2423-822X
  • Escalante, F.
  • de la Rubia, Javier|||0000-0002-8354-768X
  • Teruel, A.I.
  • De Arriba, Felipe|||0000-0002-4451-1318
  • Hernández, Miguel Teodoro|||0000-0002-6576-7881
  • Lopez-Jimenez, Javier|||0000-0002-2969-3002
  • Ocio, Enrique M.|||0000-0002-5765-0085
  • Puig, Noemí|||0000-0001-7535-3861
  • Paiva, Bruno|||0000-0003-1977-3815
  • Lahuerta, J. J.|||0000-0002-3393-9570
  • Bladé Creixenti, Juan|||0000-0002-4563-3405
  • San Miguel, Jesús|||0000-0002-9183-4857
  • Mateos, M. V.|||0000-0003-2390-1218
  • Martínez-López, Joaquín|||0000-0001-7908-0063
  • Calasanz, M.J.|||0000-0002-0374-3008
  • García-Sanz, Ramón|||0000-0003-4120-2787
  • De Arriba, Felipe|||0000-0002-4451-1318
  • Rios, R.
  • Sureda, Anna|||0000-0002-1238-6970
  • Blanchard, María Jesús
  • Martinez-Martinez, R.
  • Moraleda, J. M.
  • Bargay, Joan|||0000-0002-6739-3916
  • Gironella, Meritxell|||0000-0003-4437-5181
  • Palomera, L.
  • Gonzalez-Montes, Y.
  • Martí, J.M.
  • Krsnik, Isabel|||0000-0002-2912-5072
  • Arguiñano, J.M.
  • González Garcia, Maria Esther|||0000-0002-4238-0377
  • Gonzalez, A.P.
  • Casado Montero, Luis Felipe|||0000-0002-8171-0674
Smoldering multiple myeloma (SMM) precedes multiple myeloma (MM). The risk of progression of SMM patients is not uniform, thus different progression-risk models have been developed, although they are mainly based on clinical parameters. Recently, genomic predictors of progression have been defined for untreated SMM. However, the usefulness of such markers in the context of clinical trials evaluating upfront treatment in high-risk SMM (HR SMM) has not been explored yet, precluding the identification of baseline genomic alterations leading to drug resistance. For this reason, we carried out next-generation sequencing and fluorescent in-situ hybridization studies on 57 HR and ultra-high risk (UHR) SMM patients treated in the phase II GEM-CESAR clinical trial (NCT02415413). DIS3, FAM46C, and FGFR3 mutations, as well as t(4;14) and 1q alterations, were enriched in HR SMM. TRAF3 mutations were specifically associated with UHR SMM but identified cases with improved outcomes. Importantly, novel potential predictors of treatment resistance were identified: NRAS mutations and the co-occurrence of t(4;14) plus FGFR3 mutations were associated with an increased risk of biological progression. In conclusion, we have carried out for the first time a molecular characterization of HR SMM patients treated with an intensive regimen, identifying genomic predictors of poor outcomes in this setting.
Dipòsit Digital de Documents de la UAB
Publicación

Targeting CD38 with isatuximab and a novel CD38/CD3×CD28 trispecific T-cell engager in older patients with acute myeloid leukemia

  • Martín-Sánchez, Esperanza
  • Blanco Fernández, Laura|||0000-0002-1859-0884
  • Kim, Peter S.
  • Bisht, Kamlesh
  • Wang, Hongfang|||0000-0002-1104-1540
  • Van de Velde, Helgi
  • Jelinek, Tomas
  • Simoes, Catia
  • Prosper, Felipe|||0000-0001-6115-8790
  • San Miguel, Jesús|||0000-0002-9183-4857
  • Alfonso-Piérola, Ana|||0000-0002-2478-5354
  • Bergua Burgues, Juan Miguel|||0000-0001-8229-1208
  • Rodríguez-Veiga, Rebeca|||0000-0003-2139-8540
  • Vives Polo, Susana|||0000-0003-2217-5285
  • Martínez-Cuadrón, David|||0000-0001-7540-4091
  • Montesinos, Pau|||0000-0002-3275-5593
  • Paiva, Bruno|||0000-0003-1977-3815
  • Zabaleta, Aintzane|||0000-0003-3474-3040
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Detection of germline CNVs from gene panel data, benchmarking the state of the art

  • Munté, Elisabet|||0000-0001-8396-8284
  • Roca, Carla|||0000-0003-1171-0588
  • Del Valle, Jesús|||0000-0003-3607-7045
  • Feliubadaló, Lidia|||0000-0002-1736-0112
  • Pineda, Marta|||0000-0002-5403-5845
  • Gel, Bernat|||0000-0001-8878-349X
  • Castellanos, Elisabeth|||0000-0002-8133-5325
  • Rivera, Bárbara
  • Cordero, David
  • Lázaro, Contxi
  • Moreno-Cabrera, José Marcos|||0000-0001-8570-0345
Germline copy number variants (CNVs) play a significant role in hereditary diseases. However, the accurate detection of CNVs from targeted next-generation sequencing (NGS) gene panel data remains a challenging task. Several tools for calling CNVs within this context have been published to date, but the available benchmarks suffer from limitations, including testing on simulated data, testing on small datasets, and testing a small subset of published tools. In this work, we conducted a comprehensive benchmarking of 12 tools (Atlas-CNV, ClearCNV, ClinCNV, CNVkit, Cobalt, CODEX2, CoNVaDING, DECoN, ExomeDepth, GATK-gCNV, panelcn.MOPS, VisCap) on four validated gene panel datasets using their default parameters. We also assessed the impact of modifying 107 tool parameters and identified 13 parameter values that we suggest using to improve the tool F1 score. A total of 66 tool pair combinations were also evaluated to produce better meta-callers. Furthermore, we developed CNVbenchmarker2, a framework to help users perform their own evaluations. Our results indicated that in terms of F1 score, ClinCNV and GATK-gCNV were the best CNV callers. Regarding sensitivity, GATK-gCNV also exhibited particularly high performance. The results presented here provide an evaluation of the current state of the art in germline CNV detection from gene panel data and can be used as a reference resource when using any of the tools.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Preferential Genetic Pathways Lead to Relapses in Adult B-Cell Acute Lymphoblastic Leukemia

  • Navas-Acosta, Josgrey del Valle
  • Hernández-Sánchez, Alberto|||0000-0002-6601-3096
  • González, Teresa
  • Villaverde Ramiro, Ángela|||0000-0002-7337-7218
  • Santos, Sandra
  • Miguel, Cristina|||0000-0001-7359-7993
  • Ribera Salas, Jordi|||0000-0003-4796-6470
  • Granada, Isabel|||0000-0002-4275-0104
  • Morgades, Mireia|||0000-0003-0295-2534
  • Sánchez, Ricardo|||0000-0002-6383-0381
  • Such, Esperanza|||0000-0001-6892-403X
  • Barrena, Susana
  • Ciudad Pizarro, Juana
  • Dávila-Valls, Julio|||0000-0002-5185-2073
  • De las Heras, Natalia|||0000-0002-5188-5350
  • García-de Coca, Alfonso|||0000-0002-4942-060X
  • Labrador, Jorge|||0000-0002-3696-0287
  • Queizán, José Antonio
  • Martín, Sandra
  • Orfao, Alberto|||0000-0002-0007-7230
  • Ribera, Jose-Maria|||0000-0003-1042-6024
  • Benito, Rocío|||0000-0001-9781-4198
  • Hernández Rivas, Jesús María|||0000-0002-9661-9371
Adult B-cell acute lymphoblastic leukemia (B-ALL) is characterized by genetic heterogeneity and a high relapse rate, affecting over 40% of adults. However, the mechanisms leading to relapse in adults are poorly understood. Forty-four adult B-ALL patients were studied at both diagnosis and relapse by next-generation sequencing (NGS). Four main genetic pathways leading to relapse in adults were identified: IKZF1 genetic profile, RAS mutations and TP53 alterations in Ph-negative B-ALL and acquisition of ABL1 mutations in Ph-positive patients. The most frequently deleted gene at diagnosis was IKZF1 (52%), and 70% of these patients had IKZF1 profile. Notably, 88% of patients with IKZF1 at diagnosis retained this genetic profile at relapse. Conversely, the acquisition of RAS mutations or the expansion of subclones (normalized variant allele frequency < 25%) present from diagnosis were observed in 24% of Ph-negative patients at relapse. In addition, 24% of relapses in the Ph-negative cohort could potentially be driven by TP53 alterations. Of these cases, five presented from diagnosis, and four emerged at relapse, mostly as "double-hit" events involving both TP53 deletion and mutation. In Ph-positive B-ALL, the main genetic finding at relapse was the acquisition of ABL1 mutations (86%). Three clonal evolution patterns were identified: the persistent clone trajectory (25%), the expanding clone trajectory (11%) and the therapy-boosted trajectory (48%). Our results reveal the presence of preferential biological pathways leading to relapse in adult B-ALL. These findings underscore the need for personalized therapeutic strategies to improve clinical outcomes in adult patients with B-ALL.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Improving Initial Medication Adherence to cardiovascular disease and diabetes treatments in primary care, Pilot trial of a complex intervention

  • Corral-Partearroyo, Carmen|||0000-0001-9517-4916
  • Sánchez-Viñas, Alba|||0000-0001-5020-7534
  • Gil-Girbau, Montserrat|||0000-0002-4396-6492
  • Peñarrubia-María, Maria Teresa
  • Aznar-Lou, Ignacio|||0000-0002-6780-5968
  • Serrano-Blanco, Antoni|||0000-0001-6123-0633
  • Carbonell-Duacastella, Cristina|||0000-0002-8794-5490
  • Gallardo-González, Carmen|||0000-0003-0688-1366
  • Olmos-Palenzuela, María del Carmen
  • Rubio-Valera, Maria|||0000-0003-2856-1697
Introduction: The Initial Medication Adherence (IMA) intervention is a multidisciplinary and shared decision-making intervention to improve initial medication adherence addressed to patients in need of new treatments for cardiovascular diseases and diabetes in primary care (PC). This pilot study aims to evaluate the feasibility and acceptability of the IMA intervention and the feasibility of a cluster-RCT to assess the effectiveness and cost-effectiveness of the intervention. Methods: A 3-month pilot trial with an embedded process evaluation was conducted in five PC centers in Catalonia (Spain). Electronic health data were descriptively analyzed to test the availability and quality of records of the trial outcomes (initiation, implementation, clinical parameters and use of services). Recruitment and retention rates of professionals were analyzed. Twenty-nine semi-structured interviews with professionals (general practitioners, nurses, and community pharmacists) and patients were conducted to assess the feasibility and acceptability of the intervention. Three discussion groups with a total of fifteen patients were performed to review and redesign the intervention decision aids. Qualitative data were thematically analyzed. Results: A total of 901 new treatments were prescribed to 604 patients. The proportion of missing data in the electronic health records was up to 30% for use of services and around 70% for clinical parameters 5 months before and after a new prescription. Primary and secondary outcomes were within plausible ranges and outliers were barely detected. The IMA intervention and its implementation strategy were considered feasible and acceptable by pilot-study participants. Low recruitment and retention rates, understanding of shared decision-making by professionals, and format and content of decision aids were the main barriers to the feasibility of the IMA intervention. Discussion: Involving patients in the decision-making process is crucial to achieving better clinical outcomes. The IMA intervention is feasible and showed good acceptability among professionals and patients. However, we identified barriers and facilitators to implementing the intervention and adapting it to a context affected by the COVID-19 pandemic that should be considered before launching a cluster-RCT. This pilot study identified opportunities for refining the intervention and improving the design of the definitive cluster-RCT to evaluate its effectiveness and cost-effectiveness. Clinical trial registration: ClinicalTrials.gov, identifier NCT05094986.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Enhancing human NK cell antitumor function by knocking out SMAD4 to counteract TGFβ and activin A suppression

  • Rea, Anna|||0000-0003-1307-8045
  • Santana-Hernández, Sara|||0000-0001-7440-8445
  • Villanueva, Javier
  • Sanvicente-García, Marta|||0000-0002-4508-2834
  • Cabo, Mariona
  • Suarez-Olmos, Jesús
  • Quimis, Fabricio
  • Qin, Mengjuan|||0000-0001-7014-7188
  • Llorens, Eduard
  • Blasco-Benito, Sandra
  • Torralba-Raga, Lamberto
  • Perez, Lorena
  • Bhattarai, Bishan
  • Alari Pahissa, Elisenda|||0000-0001-7424-5383
  • Georgoudaki, Anna-Maria
  • Balaguer, Francesc|||0000-0002-0206-0539
  • Juan, Manel|||0000-0002-3064-1648
  • Pardo, Julián|||0000-0003-0154-0730
  • Celià-Terrassa, Toni|||0000-0002-0615-8744
  • Rovira, Ana|||0000-0003-1301-2599
  • Möker, Nina
  • Zhang, Congcong|||0000-0003-3693-4705
  • Colonna, Marco|||0000-0001-5222-4987
  • Spanholtz, Jan|||0000-0001-7152-6956
  • Malmberg, Karl-Johan|||0000-0002-8718-9373
  • Montagut, Clara
  • Albanell Mestres, Joan|||0000-0003-1239-4580
  • Güell, Marc|||0000-0003-4000-7912
  • López-Botet, Miguel|||0000-0003-4882-065X
  • Muntasell i Castellví, Aura|||0000-0003-2894-0486
Transforming growth factor beta (TGFβ) and activin A suppress natural killer (NK) cell function and proliferation, limiting the efficacy of adoptive NK cell therapies. Inspired by the partial resistance to TGFβ of NK cells with SMAD4 haploinsufficiency, we used CRISPR-Cas9 for knockout of SMAD4 in human NK cells. Here we show that SMAD4 NK cells were resistant to TGFβ and activin A inhibition, retaining their cytotoxicity, cytokine secretion and interleukin-2/interleukin-15-driven proliferation. They showed enhanced tumor penetration and tumor growth control, both as monotherapy and in combination with tumor-targeted therapeutic antibodies. Notably, SMAD4 NK cells outperformed control NK cells treated with a TGFβ inhibitor, underscoring the benefit of maintaining SMAD4-independent TGFβ signaling. SMAD4 conferred TGFβ resistance across diverse NK cell platforms, including CD19-CAR NK cells, stem cell-derived NK cells and ADAPT-NK cells. These findings position SMAD4 knockout as a versatile and compelling strategy to enhance NK cell antitumor activity, providing a new avenue for improving NK cell-based cancer immunotherapies.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The Prognostic Significance of Tumor-Infiltrating Lymphocytes, PD-L1, BRCA Mutation Status and Tumor Mutational Burden in Early-Stage High-Grade Serous Ovarian Carcinoma-A Study by the Spanish Group for Ovarian Cancer Research (GEICO)

  • Pizarro, David
  • Romero, Ignacio
  • Pérez-Mies, Belén
  • Redondo Sánchez, Andrés|||0000-0002-7257-5642
  • Caniego-Casas, Tamara
  • Carretero-Barrio, Irene|||0000-0003-1986-2965
  • Cristóbal, Eva
  • Gutiérrez-Pecharromán, Ana
  • Santaballa, Ana|||0000-0001-7763-320X
  • D'Angelo, Emanuela|||0000-0002-6173-1806
  • Hardisson, David|||0000-0002-2183-3699
  • Vieites, Begoña
  • Matías-Guiu, Xavier|||0000-0002-7201-6605
  • Estévez-García, Purificación
  • Guerra, Eva|||0000-0003-1910-4451
  • Prat, Jaime|||0000-0002-9787-3304
  • Poveda, Andrés
  • López Guerrero, José Antonio|||0000-0002-7369-8388
  • Palacios, José|||0000-0002-6730-5066
Early stages are under-represented in studies on the molecular and immune features of high-grade serous ovarian carcinoma (HGSOC), and specific studies focused on early-stage HGSOC are required for a better prognostic stratification and to personalize chemotherapy. The aim of this study was to determine the prognostic significance of CD8+ and CD4+ tumor-infiltrating lymphocytes (TILs), tumoral cell PD-L1 expression, BRCA mutational status and tumor mutation burden (TMB) in early-stage HGSOC. A retrospective study was performed on stage I and II HGSOC from the Molecular Reclassification of Early Stages of Ovarian Cancer (RECLAMO) cohort from the Spanish Group of Ovarian Cancer Research (GEICO). Centralized histological typing was performed based on morphological and immunohistochemical features. Intraepithelial (i) and stromal (s) CD8+ and CD4+ T cells and PD-L1 were evaluated on tissue microarrays by immunohistochemistry. BRCA1 and BRCA2 mutation status and TMB were analyzed in tumor DNA using next-generation sequencing. The study included 124 tumors. High iCD8+ (.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Role of Inflammatory and Proresolving Mediators in Endothelial Dysfunction

  • Briones, Ana|||0000-0001-8218-5579
  • Hernanz, Raquel
  • Garcia Redondo, Ana B.|||0000-0002-5815-3320
  • Rodríguez, Cristina|||0000-0002-6472-5647
  • Blanco-Colio, Luis Miguel|||0000-0002-1560-6609
  • Val-Blasco, Almudena
  • Alonso, María Jesús|||0000-0003-4912-1121
  • Salaices Sanchez, Mercedes|||0000-0003-3323-1692
Excessive local inflammation is a common mechanism in many cardiovascular diseases (CVDs) such as hypertension, atherosclerosis and aortic aneurysms. In endothelial cells, inflammatory cytokines such as interferons, tumour necrosis factor alpha or interleukins increase oxidative stress and contractile prostanoids and the expression of adhesion molecules that reduce nitric oxide (NO) availability and bind leucocytes, thereby impairing endothelial function. Despite this evidence, anti-inflammatory therapies are not yet indicated for the treatment of most CVD. Resolution of inflammation is mediated by a family of specialized pro-resolving mediators (SPMs) that act on cognate G protein-coupled receptors to limit immune cell infiltration and initiate tissue repair. SPMs, generated from omega-3 and omega-6 polyunsaturated fatty acids, belong to four major families: lipoxins, resolvins, protectins and maresins. SPM receptors are expressed in immune and vascular cells where they regulate important processes such as phagocytosis and polarization, production of cytokines, NO and prostacyclin, and modulation of smooth muscle cell phenotype. Growing evidence in animal models demonstrates that activation of SPM receptors can protect vascular function and structure and provide beneficial effects in various CVD. We will review recent advances in the role of inflammation and SPMs in vascular (dys)function in hypertension, atherosclerosis, and aortic aneurysms.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Early-Stage Breast Cancer Detection in Breast Milk

  • Saura Manich, Cristina|||0000-0001-8296-5065
  • Ortiz, Carolina|||0000-0002-5523-829X
  • Matito, Judit|||0000-0001-7560-7737
  • Arenas, Enrique J.|||0000-0001-7076-2666
  • Suñol Camas, Anna
  • Martín, Ágatha|||0000-0003-4818-6433
  • Cordoba Cardona, Octavi|||0000-0002-9591-7430
  • Martínez-Sabadell, Alex|||0000-0002-9477-1396
  • Garcia-Ruiz, Itziar|||0000-0002-0717-7795
  • Miranda, Ignacio|||0000-0002-4813-5946
  • Morales-Comas, Clara|||0000-0001-6771-6749
  • Carrasco, Estela|||0000-0003-1964-7675
  • Viaplana, Cristina|||0000-0001-8904-4330
  • Peg, Vicente|||0000-0002-5203-6166
  • Nuciforo, Paolo|||0000-0003-1380-0990
  • Bayó-Puxan, Neus|||0000-0001-9909-1499
  • González Medina, Alberto, 1990-|||0000-0002-2819-9053
  • Miquel, Josep M.|||0000-0002-9262-4464
  • Gómez-Rey, Marina|||0000-0002-9636-3281
  • Villacampa Javierre, Guillermo|||0000-0003-4868-6585
  • Arévalo, Silvia|||0000-0001-8169-1322
  • Espinosa-Bravo, Martín|||0000-0002-4293-3875
  • Balmaña Gelpí, Judith|||0000-0002-0762-6415
  • Dienstmann, Rodrigo|||0000-0001-5997-318X
  • Arribas, Joaquín V.|||0000-0002-0504-0664
  • Tabernero, Josep|||0000-0002-2495-8139
  • Vivancos, Ana|||0000-0003-2888-6512
  • Sansó, Miriam|||0000-0001-7155-4041
The presence of cell-free tumor DNA was reported in breast milk from patients with breast cancer, and its use as a screening method surpassed plasma liquid biopsy in terms of detecting and molecularly profiling early-stage tumors, even prior to diagnosis. For the first time, we show that BM obtained from patients with breast cancer carries ctDNA, surpassing plasma-based liquid biopsy for detection and molecular profiling of early-stage breast cancer, even prior to diagnosis by image.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Global and Sex-Stratified Genome-Wide Association Study of Long COVID Based on Patient-Driven Symptom Recall

  • Polo-Alonso, Sara
  • Hernáez, Álvaro|||0000-0001-8593-1477
  • Degano, Irene R.|||0000-0003-1914-6934
  • Martí-Lluch, Ruth|||0000-0002-7320-9521
  • Pinsach-Abuin, Mel Lina
  • Elosua, Roberto|||0000-0001-8235-0095
  • Subirana, Isaac|||0000-0003-1676-0197
  • Puigmulé, Marta
  • Pérez, Alexandra|||0000-0001-5344-6573
  • Cruz, Raquel|||0000-0002-6964-8898
  • Diz-de Almeida, Silvia|||0000-0003-2813-8928
  • Puigdecant, Eulàlia
  • Selga, Elisabet|||0000-0002-4290-8370
  • Nogués Solán, Xavier|||0000-0002-5537-1859
  • Masclans, Joan R.|||0000-0002-0809-6823
  • Güerri-Fernández, Robert|||0000-0002-9794-9161
  • Cubero-Gallego, Hector|||0000-0001-9740-827X
  • Tizón-Marcos, Helena|||0000-0001-7942-9413
  • Vaquerizo, Beatriz|||0000-0002-1428-3596
  • Brugada, Ramon|||0000-0001-6607-3032
  • Ramos, Rafel|||0000-0001-7970-5537
  • Camps-Vilaró, Anna|||0000-0001-9644-8421
  • Marrugat, Jaume|||0000-0003-3320-554X
We aimed to explore the global and sex-specific genetic variants associated with long COVID, as defined by patient-driven symptom recall. A 1-year cohort study of 2411 COVID-19 patients collected long COVID symptoms with an open-ended, non-directed questionnaire, and long COVID incidence was determined according to the World Health Organization definition. Global and sex-stratified genome-wide association analyses were conducted by logistic regression models adjusted for age, sex (in the global analysis), and the first 10 principal components. We assessed sex-variant interactions and performed gene-based analyses, gene mapping, and gene-set enrichment analyses. When comparing the 1392 long COVID cases with the non-cases, we identified 23 lead variants from suggestive signals: 13 from the global analysis, 5 from females, and 5 from males. Five variants showed a significant interaction with sex (two in females, three in males). We mapped 15 protein-coding genes related to diseases of the immune and nervous systems and tumoral processes. Notably, CD5 and VPS37C, linked to immune function, were significantly associated with long COVID in men. Our results suggest that persistent immune dysregulation may be involved in the development of precisely defined long COVID.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Generation of chimeric antigen receptor T cells targeting p95HER2 in solid tumors

  • Román Alonso, Macarena|||0000-0001-8128-9528
  • Grinyó-Escuer, Ariadna|||0000-0003-0185-2734
  • Duro Sánchez, Santiago|||0000-0002-3829-7562
  • Rius-Ruiz, Irene
  • Bort-Brusca, Marta
  • Escorihuela, Marta|||0000-0001-9074-2339
  • Maqueda-Marcos, Susana
  • Pérez-Ramos, Sandra|||0000-0002-3612-4027
  • Gago, Judit
  • Nogales, Vanesa
  • Espinosa-Bravo, Martín|||0000-0002-4293-3875
  • Peg, Vicente|||0000-0002-5203-6166
  • Escrivá-de-Romaní, Santiago|||0000-0001-7816-7589
  • Foradada Felip, Laia|||0000-0002-0589-4360
  • Soucek, Laura|||0000-0002-4750-7971
  • Braña, Irene|||0000-0002-1068-9601
  • Galvao, Vladimir
  • Martín-Lluesma, Silvia|||0000-0001-7491-1876
  • Moessner, Ekkehard
  • Klein, Christian|||0000-0001-7594-7280
  • Garralda, Elena|||0000-0002-4412-7842
  • Saura Manich, Cristina|||0000-0001-8296-5065
  • Arribas, Joaquín V.|||0000-0002-0504-0664
The redirection of T lymphocytes against tumor-associated or tumor-specific antigens, using bispecific antibodies or chimeric antigen receptors (CAR), has shown therapeutic success against certain hematological malignancies. However, this strategy has not been effective against solid tumors. Here, we describe the development of CAR T cells targeting p95HER2, a tumor-specific antigen found in HER2-amplified solid tumors. These CAR T cells display robust activity against p95HER2-expressing cell lines but demonstrate limited efficacy against patient-derived xenografts. As p95HER2 is invariably detectable on tumor cells that overexpress HER2, but not those that express HER2 at normal levels, we arm p95HER2-specific CAR T cells with affinity-tuned bispecific antibodies against HER2 and CD3 in order to redirect them only to HER2-amplified cells. The combination of p95HER2.CAR T cells and HER2 x CD3 bispecific antibodies lead to a complete regression in three HER2-positive, patient-derived mouse xenografts tumor models. This combination represents a promising strategy to redirect T cells against a subset of HER2-positive tumors. Chimeric antigen receptor T (CAR-T) cell therapy is efficient in certain haematologic malignancies, but clinical success in solid tumours has been hampered by scarcity of tumour-specific antigens. Here authors show that combination therapy using CAR T cells targeting p95HER2 and bispecific antibodies against HER2 and CD3 consistently leads to complete regression in HER2-positive, patient-derived xenografts tumours in mouse models.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Role of cfDNA and ctDNA to improve the risk stratification and the disease follow-up in patients with endometrial cancer, towards the clinical application

  • Casas-Arozamena, Carlos|||0000-0002-3279-2482
  • Vilar, Ana
  • Cueva, Juan|||0000-0003-1389-4595
  • Arias, Efigenia
  • Sampayo, Victoria
  • Diaz, Eva
  • Oltra, Sara S.
  • Moiola, Cristian Pablo|||0000-0001-7218-0184
  • Cabrera Díaz, Silvia|||0000-0002-3164-6686
  • Cortegoso, Alexandra
  • Curiel, Teresa
  • Abalo, Alicia
  • Pamies Serrano, Mónica
  • Domingo, Santiago
  • Padilla-Iserte, Pablo
  • Arnaez de la Cruz, Marta
  • Hernández Gutierrez, Alicia|||0000-0002-2494-3041
  • García-Pineda, Virginia
  • Ruiz-Bañobre, Juan
  • López, Rafael
  • Matías-Guiu, Xavier|||0000-0002-7201-6605
  • Colás Ortega, Eva|||0000-0003-0302-4828
  • Gil-Moreno, Antonio|||0000-0003-1106-5590
  • Abal Posada, Miguel|||0000-0003-3533-7781
  • Moreno-Bueno, Gema
  • Muinelo-Romay, Laura|||0000-0002-7456-7531
There has been a rise in endometrial cancer (EC) incidence leading to increased mortality. To counter this trend, improving the stratification of post-surgery recurrence risk and anticipating disease relapse and treatment resistance is essential. Liquid biopsy analyses offer a promising tool for these clinical challenges, though the best strategy for applying them in EC must be defined. This study was designed to determine the value of cfDNA/ctDNA monitoring in improving the clinical management of patients with localized and recurrent disease. Plasma samples and uterine aspirates (UA) from 198 EC patients were collected at surgery and over time. The genetic landscape of UAs was characterized using targeted sequencing. Total cfDNA was analyzed for ctDNA presence based on the UA mutational profile. High cfDNA levels and detectable ctDNA at baseline correlated with poor prognosis for DFS (p-value < 0.0001; HR = 9.25) and DSS (p-value < 0.0001; HR = 11.20). This remained clinically significant when stratifying tumors by histopathological risk factors. Of note, cfDNA/ctDNA analyses discriminated patients with early post-surgery relapse and the ctDNA kinetics served to identify patients undergoing relapse before any clinical evidence emerged. This is the most comprehensive study on cfDNA/ctDNA characterization in EC, demonstrating its value in improving risk stratification and anticipating disease relapse in patients with localized disease. CtDNA kinetics assessment complements current strategies to monitor the disease evolution and the treatment response. Therefore, implementing cfDNA/ctDNA monitoring in clinical routines offers a unique opportunity to improve EC management. The study demonstrates that high levels of cfDNA and detectable ctDNA at baseline are strong indicators of poor prognosis. This enables more accurate risk stratification beyond traditional histopathological factors, allowing clinicians to identify high-risk patients who may benefit from more aggressive treatment and closer monitoring. Moreover, longitudinal analysis of cfDNA/ctDNA can detect disease recurrence months before clinical symptoms or imaging evidence appear. This early warning system offers a significant advantage in clinical practice, providing a window of opportunity for early intervention and potentially improving patient outcomes. The online version contains supplementary material available at 10.1186/s13046-024-03158-w.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Melanoma acral en población caucásica, Estudio de cohorte sobre factores epidemiológicos, clinicopatológicos y pronósticos, Acral Melanoma in the Caucasian Population

  • Angel-Baldo, J.
  • Podlipnik, Sebastian|||0000-0003-4150-0522
  • Azón, A.
  • Boada, Aram|||0000-0001-9809-5308
  • Arrieta, A.
  • Marcoval, Joaquim|||0000-0002-6489-1872
  • López Sánchez, Cristina|||0000-0003-1866-6989
  • Sàbat, M.
  • Segura, S.
  • Bodet, D.
  • Curcó, N.
  • Lopez-Castillo, D.
  • Solà, J.
  • Quintana-Codina, M.
  • Baliu-Piqué, C.
  • Just Sarobé, Miquel|||0000-0002-9649-9250
  • Martín-Sala, S.
  • Malvehy, J.
  • Puig, Susana|||0000-0003-1337-9745
  • Carrera, Caty|||0000-0002-0804-0969
  • Marti, R.M.
  • Matas-Nadal, C.
  • Soria-Gili, Xavier
  • Gatius, S.
  • Vilardell, Felip
  • Gil, I.
  • Grau, C.
  • Martínez, F.
  • Lobos, N.
  • Yélamos, Oriol|||0000-0002-8058-3095
  • Dalmau, J.
  • González-Cruz, C.|||0000-0003-0117-8858
  • Hilari, H.
  • Pasquali, P.
  • Sagristà, M.
  • Olivella-Garcés, M.R.
  • Bonfill-Ortí, Montserrat
  • Ramón Ferreres, J.
  • Jaka, A.
  • Quer, A.
  • Richarz, N.
  • Zarzoso Muñoz, I.
  • Zaballos, Pedro
  • Formigon, M.
  • Galvany, L.
  • Alegre, M.
  • Sánchez-Puigdollers, A.
  • Mohino-Farré, N.
  • Masferrer, E.
Introducción: El melanoma acral está asociado con un pronóstico desfavorable. El estudio sobre las características y el pronóstico en los pacientes caucásicos puede ser crucial para comprender las características distintivas de este tumor. Objetivos: Analizar las características epidemiológicas, clinicopatológicas y pronósticas del melanoma acral en los pacientes caucásicos. Material y métodos: Estudio de cohorte retrospectivo de melanoma acral a partir de una base de datos multi-institucional en 20 hospitales españoles, entre enero de 2000 y diciembre de 2019. Resultados: Se identificaron un total de 733 melanomas acrales (edad media: 67,5 años, el 95,2% caucásicos y el 77,5% en los pies). En general, el 77,5% de los casos fueron invasivos. Los melanomas localizados en los pies tuvieron una mayor proporción de casos invasivos (80,8 vs. 69,8%; p = 0,003), estadios III y IV al diagnóstico (24,8 vs. 11,7%; p < 0,001), valores de Breslow más altos (2,8 vs. 2,0 mm; p = 0,021) y una mayor tasa de positividad de biopsia selectiva del ganglio centinela (BSGC) (30,7 vs. 15,7%; p = 0,012). Un mayor grosor de Breslow y una edad de aparición más tardía fueron factores de riesgo para menor supervivencia específica por melanoma. Un mayor grosor de Breslow y la ulceración fueron los factores pronósticos independientes menor supervivencia libre de recaída. La localización del melanoma y el subtipo histopatológico no se asociaron con un peor pronóstico. Las recurrencias fueron frecuentes (27,7%), con a distancia apareciendo antes que las recurrencias locorregionales (1,32 años [IQR: 1,12-1,87] vs. 2,14 años [IQR: 1,68-2,70]; p = 0,015). Conclusión: Este estudio, el mayor en una población predominantemente caucásica, subraya los resultados desfavorables del melanoma acral. Los melanomas en los pies mostraron una detección tardía, mayor proporción de melanomas invasivos, valores de Breslow más profundos, mayor positividad o afectación de BSGC y estadios AJCC más altos. La alta tasa de recurrencia y las metástasis a distancia tempranas enfatizan el papel crítico del seguimiento intensivo y las pruebas de imagen rutinarias para detectar recaídas asintomáticas., Background: Acral melanoma is associated with poor prognosis. Studying the characteristics and prognosis of Caucasian patients is crucial to understand the distinct features of this tumor. Objectives: To analyze the epidemiological, clinicopathological, and prognostic features of acral melanoma in Caucasian patients. Methods: We conducted a retrospective, multicenter, cohort study of acral melanoma from a database across 20 hospitals from South Europe from January 2000 to December 2019. Results: A total of 733 acral melanomas were identified (median age, 67.5 years; 95.2%, Caucasians; 77.5% of which were located on the feet). Overall, 77.5% of cases were invasive melanomas. Foot melanomas had a higher proportion of invasive cases (80.8% vs 69.8%; p = 0.003), stages III and IV at diagnosis (24.8% vs 11.7%; p < 0.001), thicker Breslow depth (2.8 mm vs 2.0 mm; p = 0.021) and a higher rate of positive sentinel lymph node biopsy (SLNB) (30.7% vs 15.7%; p = 0.012). Thicker Breslow depth and later age of onset were risk factors for melanoma-specific survival. Thicker Breslow depth and ulceration were independent prognostic factors of relapse-free survival. Melanoma location and histopathological subtype were not associated with worse prognosis. Recurrences were a common finding (27.7%), with distant metastases appearing earlier than locoregional recurrences (1.32 years [IQR, 1.12-1.87] vs 2.14 years [IQR, 1.68-2.70]; p = 0.015). Conclusion: This study, the largest in a predominantly Caucasian population, underscores the unfavorable outcomes of acral melanoma. Foot melanomas exhibited delayed detection, increased invasiveness, thicker Breslow depth, increased SLNB involvement, and higher AJCC stages. The high recurrence rate and early distant metastases emphasize the critical role of intensive follow-up and routine imaging modalities to detect asymptomatic relapses.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Anatomy of the Isthmus, Unraveling the Tissue Composition of the Ventricular Tachycardia Diastolic Pathway

  • Bisbal, Felipe|||0000-0002-4843-7063
  • Aranyó, Júlia
  • Iraola-Picornell, Georgina
  • Sanchez-Quintana, Damian
  • Martínez-Falguera, Daina|||0000-0002-9439-0542
  • Sarrias, Axel|||0000-0001-6712-3097
  • Fadeuilhe, Edgar|||0000-0003-0079-224X
  • Bazán, Víctor|||0000-0001-8072-7434
  • Teis, Albert|||0000-0002-4820-0736
  • Rodriguez-Leor, Oriol|||0000-0003-2657-5657
  • Villuendas-Sabaté, Roger|||0000-0001-9110-905X
  • Curiel, Carolina
  • Armengol, Maria Pilar
  • Pey, Irina
  • Roura, Santiago|||0000-0003-4063-9661
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
Background: A protected, slow-conducting diastolic pathway (isthmus) is the electrophysiological hallmark of post-myocardial infarction (MI) re-entrant ventricular tachycardia (VT). Contemporary evaluations of the histologic composition promoting slow, protected conduction during VT are lacking. Objectives: The goal of this study was to compare the histologic characteristics of confirmed VT isthmuses (VTIs) and non-isthmus scar (NIS) in a chronic MI swine model. Methods: One month after non-reperfused anterior MI, nine Landrace X Large White pigs with inducible VT underwent high-density activation mapping to define the diastolic corridor. Radiofrequency lesions were created to guide the ex vivo VTI localization. Tissue transverse samples from the labeled VTI and NIS were obtained for further histologic, immunohistochemical, and RNA-sequencing expression analyses. Results: Compared with NIS, VTI showed significantly higher fatty infiltration (P = 0.012) and lower levels of collagen I (P = 0.053), collagen III (P = 0.043), and collagen volume fraction (P = 0.027); there were no differences in overall fibrotic deposition. VTI exhibited greater vascular density compared with NIS (P = 0.018), with arteries and veins primarily surrounded by preserved cardiomyocytes. Compared with NIS, viable cardiomyocytes and fibroblasts in VTI displayed higher densities of connexin 43 and connexin 40 (P = 0.022 and P = 0.004, respectively), despite no differences in cardiac troponin I, sarcoplasmic/endoplasmic reticulum Ca2-ATPase 2, or vimentin expression. Thirty-six genes, involving pathways related to extracellular matrix remodeling, inflammation, and immune response modulation, were differentially expressed between VTI and NIS. Conclusions: The VTI exhibits a distinct histologic composition and differential gene expression compared with the surrounding NIS. Mid-diastolic activation sites showed increased adipocytic deposition, vascularization, and connexin expression, along with lower levels of collagen I, collagen III, and collagen volume fraction.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Tissue characteristics underlying endocardial local impedance subtypes in chronic myocardial infarction

  • Aranyó, Júlia
  • Martínez-Falguera, Daina|||0000-0002-9439-0542
  • Teis, Albert|||0000-0002-4820-0736
  • Fadeuilhe, Edgar|||0000-0003-0079-224X
  • Rodriguez-Leor, Oriol|||0000-0003-2657-5657
  • Bazán, Víctor|||0000-0001-8072-7434
  • Sarrias, Axel|||0000-0001-6712-3097
  • Tebé, Cristian|||0000-0003-2320-1385
  • Villuendas-Sabaté, Roger|||0000-0001-9110-905X
  • Delgado, Victoria|||0000-0002-9841-2737
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
  • Bisbal, Felipe|||0000-0002-4843-7063
Background: Local impedance (LI) mapping is feasible and provides additional tissue characterization of the ventricular tachycardia substrate. Data on tissue composition underlying the LI spectrum are lacking. Objective: To describe the tissue composition underlying different LI subtypes in a chronic myocardial infarction (MI) swine model. Methods: One month after non-reperfused anterior MI, 18 Landrace Large White pigs underwent delayed-enhancement cardiac magnetic resonance (DE-CMR) and endocardial left ventricular (LV) LI mapping. DE-CMR images were post-processed off-line to obtain LV wall thickness, scar subtypes, and border zone (BZ) corridors, and were co-registered with LI maps. Tissue samples were obtained from abnormal LI sites. Results: Low LI zones exhibited more pronounced wall thinning compared to intermediate LI tissue (2.8 ± 0.7 vs 3.8 ± 0.9 mm; P <.001) and correlated with DE-CMR dense endocardial scarring (91.4%) and with epicardial scarring (75% dense and 24% BZ tissue). Intermediate LI tissue exhibited predominantly subendocardial scarring, with more heterogeneous distribution (45% dense, 47% BZ, and 8% healthy tissue) and less epicardial involvement (73% healthy tissue). Most DE-CMR BZ corridors (75.6%) colocalized with intermediate LI tissue. Histologically, tissue from intermediate LI zones displayed less collagen I (P =.008), collagen III (P =.053), and collagen volume fraction (P =.021), and greater vascular density (P =.075), compared to low LI zones. Conclusions: Areas of low LI had a higher proportion of dense, transmural scar and wall thinning compared to intermediate LI areas. DE-CMR BZ corridors colocalized with intermediate LI in most cases. LI subtypes showed distinctive histological composition.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A narrative review of vascular conduits for coronary artery bypass grafting

  • Iraola-Picornell, Georgina
  • Berastegui García, Elisabet|||0000-0002-1766-2970
  • Castells-Sala, Cristina|||0000-0002-7520-5401
  • Martorell, Jordi|||0000-0002-2043-2762
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Muñoz-Guijosa, Christian|||0000-0002-0272-1704
  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
Coronary artery bypass grafting (CABG) involves creating new conduits to restore blood flow to the heart. Using autologous vascular grafts presents challenges, including infection risk after vein harvesting, and scarcity of viable vein tissue. Researchers are exploring tissue-engineered vascular grafts (TEVGs), aiming to create optimal small-diameter vascular graft (SDVG).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Guideline-directed medical therapy after revascularization and outcomes in ischaemic cardiomyopathy

  • Moliner-Abós, Carles|||0000-0002-9264-5804
  • Calvo-Barceló, Maria
  • Solé González, Eduard|||0000-0002-5727-9925
  • Borrellas Martín, Andrea
  • Fluvià Brugués, Paula
  • Sánchez Vega, Jesus
  • Vime Jubany, Joan
  • Ferré Vallverdú, Maria
  • Tauron, Manel|||0000-0002-5864-519X
  • Tobias Castillo, Pablo Eduardo
  • de la Fuente Mancera, Juan Carlos
  • Vilardell Rigau, Pau
  • Vila Olives, Rosa
  • Diez López, Carles
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Arzamendi, Dabit|||0000-0001-7543-5867
  • Ferreira-Gonzalez, Ignacio|||0000-0002-1208-5561
  • Mirabet Pérez, Sonia|||0000-0001-5955-2748
Guideline-directed medical therapy (GDMT) remains the cornerstone for treating patients with heart failure (HF) and reduced ejection fraction (HFrEF) and coronary artery disease (CAD). However, real-world implementation of GDMT (GDMTi) is suboptimal. This subanalysis of the RevascHeart study evaluates the impact of GDMTi on long-term mortality in patients with de novo ischaemic heart failure (HF) undergoing revascularization. Among 409 patients with HFrEF (left ventricular ejection fraction ≤40%) and CAD, 275 one-year survivors who underwent revascularisation shortly after index HF admission were included in this landmark analysis (LA). GDMTi at 12 months was defined as initiation of each recommended drug class, regardless of dose. Primary endpoints were all-cause and cardiovascular mortality by GDMTi. Secondary endpoints included outcomes by revascularisation strategy and temporal trends in GDMTi. Over a median follow-up of 41.6 months, all-cause mortality occurred in 29 GDMTi patients (18%) versus 47 non-GDMTi (42%) and cardiovascular mortality in 10% versus 24%, respectively. After adjustment, GDMTi was not significantly associated with lower all-cause [hazard ratio (HR) 0.63, 95% confidence interval (CI) 0.39-1.02; P = 0.06] or cardiovascular mortality (HR 0.62, 95% CI 0.33-1.18; P = 0.14). GDMTi/coronary artery bypass grafting (CABG) was associated with lower all-cause (HR 0.42, 95% CI 0.20-0.87; P = 0.02) and cardiovascular mortality (HR 0.40, 95% CI 0.16-0.99; P = 0.05). GDMTi use increased progressively over the study period. GDMTi was associated with lower unadjusted mortality, though not significant after adjustment. GDMTi combined with CABG showed the best outcomes. The use of GDMTi improved over time.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Constitutional epimutations in LTBP4, a component of the TGF-β signaling, and in BRCA1, as potential drivers of early-onset colorectal cancer

  • Terradas, Mariona|||0000-0001-7813-1172
  • Mur, Pilar
  • Bousquets-Muñoz, Pablo
  • Puente, Xose S.|||0000-0001-9525-1483
  • Nielsen, Maartje|||0000-0002-5351-1870
  • Lázaro García, Conxi|||0000-0002-7198-5906
  • Moreno Aguado, Victor Raul|||0000-0002-2818-5487
  • Valle, Laura|||0000-0003-0371-0844
  • Morón-Duran, Francisco D.
  • Mengod, Pol
  • Löffler, Chiara M.L.
  • Helderman, Noah C.
  • Terlouw, Diantha
  • Sanjuán, Xavier
  • Viana-Errasti, Julen
  • Capellá, Gabriel
  • van Wezel, Tom
  • Kather, Jakob Nikolas
Background: Constitutional primary monoallelic promoter methylation of hereditary cancer genes, although rare, may explain early-onset cancers without family history. Also, promoter methylation of a hereditary cancer gene secondary to a genetic alteration in a methylation regulatory region can cause a hereditary cancer syndrome. This study investigates constitutional promoter methylation as mechanism of inactivation of cancer predisposition genes in genetically unsolved familial and/or early-onset colorectal cancer (CRC) patients. Results: Bisulfite-treated peripheral blood DNA from 46 early-onset/familial CRC patients was analyzed using the Illumina Infinium MethylationEPIC BeadChip. One early-onset CRC patient exhibited constitutional, likely monoallelic, methylation of CpG island 102 in LTBP4, a gene involved in TGF-β signaling. Somatic methylation of this CpG island is common in CRC, and correlates with LTBP4 downregulation. LTBP4 double knockout mice develop colorectal adenomas and carcinomas, supporting the role of this gene in CRC predisposition. No additional cases with constitutional LTBP4 CpG island 102 methylation or enrichment of deleterious LTBP4 variants in CRC patients compared to controls were found. Another early-onset CRC patient exhibited mosaic BRCA1 promoter methylation, typically associated with increased breast and ovarian cancer risk. No somatic second hit in BRCA1 was detected in the patient's tumor, and homologous recombination deficiency-associated features were inconclusive. Conclusions: Our findings suggest that constitutional methylation of LTBP4 CpG island 102 may be associated with increased CRC risk. Identification of additional cases is needed to confirm the existence of a novel CRC predisposition syndrome driven by epigenetic inactivation of LTBP4, potentially also linked to other clinical phenotypes associated with LTBP4 deficiency, such as pulmonary emphysema. Whether constitutional BRCA1 methylation contributes to CRC risk remains to be determined.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Revascularization and outcomes in ischaemic left ventricular dysfunction after heart failure admission, The RevascHeart study

  • Moliner-Abós, Carles|||0000-0002-9264-5804
  • Calvo-Barceló, Maria
  • Solé González, Eduard|||0000-0002-5727-9925
  • Borrellas Martín, Andrea
  • Fluvià Brugués, Paula
  • Sánchez Vega, Jesús|||0000-0001-7250-8362
  • Tauron, Manel|||0000-0002-5864-519X
  • Tobías-Castillo, Pablo E.|||0000-0003-0304-6197
  • de la Fuente Mancera, Juan Carlos
  • Vilardell Rigau, Pau
  • Vila-Olives, Rosa|||0000-0002-2933-2020
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Arzamendi, Dabit|||0000-0001-7543-5867
  • Ferreira-Gonzalez, Ignacio|||0000-0002-1208-5561
  • Mirabet Pérez, Sonia|||0000-0001-5955-2748
Aims: Despite numerous trials on revascularization in patients with heart failure (HF) and ischaemic left ventricular (LV) dysfunction, its role remains unsettled. Guideline-directed medical therapy (GDMT) for HF has shown benefits on outcomes. This multicentre study aims to compare long-term mortality between revascularization and GDMT in patients with ischaemic LV dysfunction following admission for HF. Methods and results: Between 2012 and 2023, 408 patients admitted for HF with a LV ejection fraction (LVEF) of 40% or less and documented coronary artery disease (CAD) were included. Patients were categorized into two groups based on their initial treatment decision: revascularization (percutaneous coronary intervention [PCI] or coronary artery bypass graft [CABG]) or GDMT. The primary outcome was rate of all-cause or cardiovascular mortality, and secondary outcomes included type of revascularization (PCI vs. CABG) and LV reverse remodelling. After a median 44.6-month follow-up, 100 patients (33%) died in the revascularization group, compared to 44 (43%) in the GDMT group. Multivariate analysis showed no significant benefit of revascularization on all-cause mortality (hazard ratio [HR] 0.81, 95% confidence interval [CI] 0.48-1.39, p = 0.45) or cardiovascular mortality (HR 0.97, 95% CI 0.62-1.52, p = 0.90) compared to GDMT. Neither CABG (HR 0.74, 95% CI 0.51-1.08, p = 0.13) nor PCI (HR 0.98, 95% CI 0.62-1.55, p = 0.93) demonstrated a mortality reduction compared to GDMT. Both groups experienced significant reductions in LV size and improvements in LVEF, greater in the revascularization group. Conclusion: Revascularization did not outperform GDMT in ischaemic LV dysfunction following HF admission in this retrospective analysis. Larger prospective studies are needed to clarify the potential role of revascularization in improving outcomes.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Characterization of hepatic, portal, and renal venous flow patterns by Doppler ultrasound across tricuspid regurgitation grades Caracterización de los patrones de flujo venoso hepático, portal y renal mediante ecografía Doppler según los grados de insuficiencia tricuspídea, Caracterización de los patrones de flujo venoso hepático, portal y renal mediante ecografía Doppler según los grados de insuficiencia tricuspídea

  • Rodríguez-Pérez, Álvaro|||0000-0003-0037-3440
  • Moliner Abós, Carlos|||0000-0002-9264-5804
  • Viladés Medel, David|||0000-0002-3638-9703
  • Fernández Martínez, Juan|||0000-0002-2011-2136
  • Mayol Domingo, josep
  • Ruiz-López, Adrià
  • Salido, Mario|||0000-0002-7898-2329
  • Descalzo, Martin|||0000-0003-3736-7191
  • Pujadas, Sandra|||0000-0001-5232-4865
  • Menduiña, Irene|||0000-0002-9061-0755
  • Bos-Real, L.|||0000-0002-6159-0644
  • Parada Barcia, José A|||0000-0003-1817-9697
  • Barreiro-Pérez, Manuel|||0000-0001-7489-2935
  • Forado Benatar, Ilana|||0000-0002-3871-8451
  • Arenas Loriente, Andrea|||0000-0002-5313-2379
  • Leta, Rubén|||0000-0003-4691-381X
  • Arzamendi, Dabit|||0000-0001-7543-5867
  • Li, Chi Hion|||0000-0001-7556-3711
Introduction and objectives: Hepatic, portal, and intrarenal venous flows are impaired in significant tricuspid regurgitation (TR), but the impact of massive and torrential TR remains unclear. This study assessed these venous flow patterns across the 5-grade TR classification and their potential as grading markers. Methods: Patients with TR were prospectively included from 3 centers. Exclusion criteria were admission for heart failure, cirrhosis, and stage V renal disease. TR severity was classified using biplane vena contracta width and 2-dimensional effective regurgitant orifice area. Venous flow patterns (hepatic vein reverse systolic flow, portal pulsatility fraction, monophasic intrarenal flow, and reverse portal and intrarenal systolic flows) were analyzed for each TR grade. Results: Of the 143 patients (52 grade III, 30 grade IV, 17 grade V TR), worsening TR was associated with progressively abnormal venous flow. Hepatic vein reverse flow had high sensitivity (96%) but lower specificity (73%) for grade III TR and was less useful for grades IV-V. Monophasic intrarenal flow had high specificity (97%) for grade III TR. Portal pulsatility fraction worsened with severity, with cutoffs of ≥ 40% for grade III, ≥ 80% for grade IV, and > 100% for grade V. Reverse portal and intrarenal systolic flows were highly specific for grade V (94% and 97%, respectively). Conclusions: Increasing TR severity correlates with abnormal hepatic, portal, and intrarenal venous flow patterns, which can be assessed through routine echocardiography., Introducción y objetivos: Los flujos venosos hepático, portal e intrarrenal se alteran en la insuficiencia tricuspídea (IT) significativa, pero el impacto de la IT masiva y torrencial no está claro. Este estudio evaluó estos patrones de flujo en los 5 grados de la clasificación de IT y su utilidad como marcadores de gradación. ́ Métodos: Se incluyó prospectivamente a pacientes con IT en 3 centros. Se excluyó a aquellos con ingreso por insuficiencia cardiaca, cirrosis o enfermedad renal estadio V. La gravedad de la IT se clasificó mediante la anchura de la vena contracta biplanar y el área del orificio regurgitante efectiva en 2 dimensiones. Se analizaron los patrones de flujo venoso (flujo sistólico reverso en vena hepática, fracción de pulsatilidad portal, flujo intrarrenal monofásico y flujos sistólicos reversos portal e intrarrenal) según cada grado de IT. Resultados: En 143 pacientes (52 de grado III, 30 de grado IV y 17 de grado V), la IT más grave se asoció a mayores alteraciones del flujo venoso. El flujo reverso en vena hepática tuvo alta sensibilidad (96%), pero menor especificidad (73%) para IT de grado III, y fue menos útil en grados más avanzados. El flujo intrarrenal monofásico mostró una alta especificidad (97%) para la IT de grado III. La fraccioń de pulsatilidad portal aumentó con la gravedad: ≥ 40% en el grado III, ≥ 80% en el grado IV y > 100% en el grado V. Los flujos sistólicos reversos portal e intrarrenal fueron altamente específicos para el grado V (el 94 y el 97%, respectivamente). Conclusiones: La progresión de la IT se asocia con alteraciones progresivas en los flujos venosos hepático, portal e intrarrenal, evaluables mediante ecocardiografía rutinaria.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Iron Deficiency Is Associated With Impaired Myocardial Reperfusion in ST-Segment-Elevation Myocardial Infarction, Influence of the Definition Used

  • Barrabés, José A.|||0000-0001-7062-6277
  • Inserte, Javier|||0000-0003-2283-3591
  • Castellote, Laura
  • Buera Surribas, Irene|||0000-0001-6110-2367
  • Milà Pascual, Laia|||0009-0007-4932-657X
  • Sambola, Antonia
  • Uribarri, Aitor|||0000-0002-6911-7480
  • Vidal Burdeus, María|||0000-0002-9823-5021
  • Aluja, David|||0000-0002-0448-9419
  • Delgado-Tomás, Sara
  • Tobías-Castillo, Pablo E.|||0000-0003-0304-6197
  • Calvo-Barceló, Maria
  • Guala, Andrea|||0000-0002-5006-8164
  • Rodríguez Palomares, José F.|||0000-0002-7229-9780
  • García del Blanco, Bruno|||0000-0002-4527-1600
  • Beneitez Pastor, David|||0000-0002-6541-6600
  • Ferreira-Gonzalez, Ignacio|||0000-0002-1208-5561
The role of iron deficiency (ID) in ST-segment-elevation myocardial infarction (STEMI) remains unclear. This study aimed to assess whether ID is associated with impaired myocardial reperfusion in STEMI and whether this association is affected by ID definition. We included 942 consecutive patients with STEMI successfully treated with primary percutaneous coronary intervention. ID was defined either as recommended by international guidelines or, alternatively, as ferritin <100 ng/mL, transferrin saturation <20%, or serum iron ≤13 μmol/L. In 595 patients, serum soluble transferrin receptor levels were measured. Impaired myocardial reperfusion was defined as lack of ST-segment resolution ≥50% 60 to 90 minutes after percutaneous coronary intervention. Results: ID prevalence varied across these definitions. Impaired reperfusion was present in 12.7% of patients without ID and 41.0% of those with ID defined by transferrin saturation <20% (P<0.001). This association was less pronounced for serum iron ≤13 μmol/L, weaker for guideline criteria, and absent for high (≥1.59 mg/L) soluble transferrin receptor levels or low ferritin. Transferrin saturation <20%, but not ferritin-based criteria, was associated with poorer clinical course and left ventricular function and higher in-hospital mortality and remained an independent predictor of impaired reperfusion after adjusting for baseline predictors and anemia. Conclusions: ID defined by transferrin saturation <20% is strongly related to impaired ST resolution and predicts a worse in-hospital outcome in patients with STEMI treated with primary percutaneous coronary intervention. The association of other ID criteria with myocardial reperfusion or with the clinical course is weaker or absent. The potential preventive or therapeutic strategies targeting ID in STEMI warrant further investigation.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

VEXUS and Hepatorenal Congestion Improvements After Transcatheter Tricuspid Intervention: Clinical and Prognostic Insights

  • Rodríguez-Pérez, Álvaro|||0000-0003-0037-3440
  • Li, Chi-Hion Pedro
  • Forado Benatar, Ilana|||0000-0002-3871-8451
  • Guzman Bofarull, Joan
  • Arenas Loriente, Andrea|||0000-0002-5313-2379
  • Asmarats, Lluís|||0000-0002-3357-5834
  • Moliner-Abós, Carles|||0000-0002-9264-5804
  • Fernández Martínez, Juan|||0000-0002-2011-2136
  • Viladés Medel, David|||0000-0002-3638-9703
  • Ruiz-López, Adrià
  • Santaló-Corcoy, Marcel|||0000-0001-7925-7789
  • Maestro, Alba|||0000-0003-1785-3125
  • Menduiña, Irene|||0000-0002-9061-0755
  • Zegrí-Reiriz, Isabel|||0000-0001-9742-8537
  • Mirabet Pérez, Sonia|||0000-0001-5955-2748
  • Parada Barcia, José A|||0000-0003-1817-9697
  • Barreiro-Pérez, Manuel|||0000-0001-7489-2935
  • Estevez-Loureiro, Rodrigo|||0000-0001-5841-5514
  • Freixa, Xavier|||0000-0002-3203-9060
  • Morr, Carlos Igor
  • Sanchis, Laura|||0000-0003-2516-8953
  • Abdul-Jawad Altisent, Omar|||0000-0002-8884-0172
  • Sitges, Marta|||0000-0003-1300-4732
  • Farrero, Marta|||0000-0002-2404-8821
  • Arzamendi, Dabit|||0000-0001-7543-5867
Transcatheter tricuspid valve intervention (TTVI) improves venous congestion, yet the prognostic role of venous Doppler ultrasound remains unclear. In this prospective multicenter cohort (n=64), hepatic, portal, and intrarenal venous flow were assessed before and 24 hours after TTVI and during 1-year follow-up. Venous congestion improved rapidly, with 66% of patients reclassified to VEXUS ≤1 despite no change in diuretic therapy, and these improvements persisted over time. Persistent post-procedural VEXUS grade 3 was independently associated with increased mortality (HR 5.55; 95% CI 1.60–19.21; p=0.007). Early venous ultrasound assessment may help identify residual risk following TTVI.
Repisalud
Publicación Artículo científico (JournalArticle)

Novel systematic processing of cardiac magnetic resonance imaging identifies target regions associated with infarct-related ventricular tachycardia.

  • Ramos-Prada, Alba
  • Redondo-Rodríguez, Andrés
  • Roca-Luque, Ivo
  • Porta-Sánchez, Andreu
  • Ter Bekke, Rachel M A
  • Quintanilla, Jorge G
  • Sánchez-González, Javier
  • Peinado, Rafael
  • Merino, Jose Luis
  • Cluitmans, Matthijs
  • Holtackers, Robert J
  • Marina-Breysse, Manuel
  • Galán-Arriola, Carlos
  • Enríquez-Vázquez, Daniel
  • Vázquez-Calvo, Sara
  • Alfonso-Almazán, José Manuel
  • Pizarro, Gonzalo
  • Ibáñez, Borja
  • González-Ferrer, Juan José
  • Salgado-Aranda, Ricardo
  • Cañadas-Godoy, Victoria
  • Calvo, David
  • Pérez-Villacastín, Julián
  • Pérez-Castellano, Nicasio
  • Filgueiras-Rama, David
There is lack of agreement on late gadolinium enhancement cardiac magnetic resonance (LGE-CMR) imaging processing for guiding ventricular tachycardia (VT) ablation. We aim at developing and validating a systematic processing approach on LGE-CMR images to identify VT corridors that contain critical VT isthmus sites. This is a translational study including 18 pigs with established myocardial infarction and inducible VT undergoing in vivo characterization of the anatomical and functional myocardial substrate associated with VT maintenance. Clinical validation was conducted in a multicentre series of 33 patients with ischaemic cardiomyopathy undergoing VT ablation. Three-dimensional LGE-CMR images were processed using systematic scanning of 15 signal intensity (SI) cut-off ranges to obtain surface visualization of all potential VT corridors. Analysis and comparisons of imaging and electrophysiological data were performed in individuals with full electrophysiological characterization of the isthmus sites of at least one VT morphology. In both the experimental pig model and patients undergoing VT ablation, all the electrophysiologically defined isthmus sites (n = 11 and n = 19, respectively) showed overlapping regions with CMR-based potential VT corridors. Such imaging-based VT corridors were less specific than electrophysiologically guided ablation lesions at critical isthmus sites. However, an optimized strategy using the 7 most relevant SI cut-off ranges among patients showed an increase in specificity compared to using 15 SI cut-off ranges (70 vs. 62%, respectively), without diminishing the capability to detect VT isthmus sites (sensitivity 100%). Systematic imaging processing of LGE-CMR sequences using several SI cut-off ranges may improve and standardize procedure planning to identify VT isthmus sites.
Repisalud
Publicación Artículo científico (JournalArticle)

RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer.

  • Sanz-Moreno, Adrián
  • Palomeras, Sonia
  • Pedersen, Kim
  • Morancho, Beatriz
  • Pascual, Tomas
  • Galván, Patricia
  • Benítez, Sandra
  • Gomez-Miragaya, Jorge
  • Ciscar, Marina
  • Jimenez, Maria
  • Pernas, Sonia
  • Petit, Anna
  • Soler-Monsó, María Teresa
  • Viñas, Gemma
  • Alsaleem, Mansour
  • Rakha, Emad A
  • Green, Andrew R
  • Santamaria, Patricia G
  • Mulder, Celine
  • Lemeer, Simone
  • Arribas, Joaquin
  • Prat, Aleix
  • Puig, Teresa
  • Gonzalez-Suarez, Eva
  • Sanz-Moreno, Adrián
  • Palomeras, Sonia
  • Pedersen, Kim
  • Morancho, Beatriz
  • Pascual, Tomas
  • Galván, Patricia
  • Benítez, Sandra
  • Gomez-Miragaya, Jorge
  • Ciscar, Marina
  • Jimenez, Maria
  • Pernas, Sonia
  • Petit, Anna
  • Soler-Monsó, María Teresa
  • Viñas, Gemma
  • Alsaleem, Mansour
  • Rakha, Emad A
  • Green, Andrew R
  • Santamaria, Patricia G
  • Mulder, Celine
  • Lemeer, Simone
  • Arribas, Joaquin
  • Prat, Aleix
  • Puig, Teresa
  • Gonzalez-Suarez, Eva
Around 15-20% of primary breast cancers are characterized by HER2 protein overexpression and/or HER2 gene amplification. Despite the successful development of anti-HER2 drugs, intrinsic and acquired resistance represents a major hurdle. This study was performed to analyze the RANK pathway contribution in HER2-positive breast cancer and anti-HER2 therapy resistance.
Repisalud
Publicación Artículo científico (JournalArticle)

The G4 resolvase Dhx36 modulates cardiomyocyte differentiation and ventricular conduction system development

  • Gomez-del Arco, Pablo
  • Isern, Joan
  • Jimenez-Carretero, Daniel
  • Lopez-Maderuelo, Dolores
  • Piñeiro-Sabarís, Rebeca
  • El Abdellaoui-Soussi, Fadoua
  • Torroja, Carlos
  • Vera-Pedrosa, María Linarejos
  • Grima-Terrén, Mercedes
  • Benguria, Alberto
  • Simón-Chica, Ana
  • Queiro-Palou, Antonio
  • Dopazo, Ana
  • Sanchez-Cabo, Fatima
  • Jalife, Jose
  • de la Pompa, Jose Luis
  • Filgueiras-Rama, David
  • Munoz-Canoves, Pura
  • Redondo, Juan Miguel
Extensive genetic studies have elucidated cardiomyocyte differentiation and associated gene networks using single-cell RNA-seq, yet the intricate transcriptional mechanisms governing cardiac conduction system (CCS) development and working cardiomyocyte differentiation remain largely unexplored. Here we show that mice deleted for Dhx36 (encoding the Dhx36 helicase) in the embryonic or neonatal heart develop overt dilated cardiomyopathy, surface ECG alterations related to cardiac impulse propagation, and (in the embryonic heart) a lack of a ventricular conduction system (VCS). Heart snRNA-seq and snATAC-seq reveal the role of Dhx36 in CCS development and in the differentiation of working cardiomyocytes. Dhx36 deficiency directly influences cardiomyocyte gene networks by disrupting the resolution of promoter G-quadruplexes in key cardiac genes, impacting cardiomyocyte differentiation and CCS morphogenesis, and ultimately leading to dilated cardiomyopathy and atrioventricular block. These findings further identify crucial genes and pathways that regulate the development and function of the VCS/Purkinje fiber (PF) network.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Changes in platelet count as a marker of myocardial iron uptake after administration of ferric carboxymaltose in patients with heart failure

  • Mollar, Anna
  • Garcia-Conejo, Celia
  • Revuelta-Lopez, Elena
  • Cardells, Ingrid
  • Lopez, Raquel
  • Canto Serrano, Irene Del
  • de la Espriella, Rafael
  • Lopez-Lereu, Maria P.
  • Monmeneu, Jose Vicente
  • Maceira, Alicia
  • Lakhal-Littleton, Samira
  • Almenar, Luis
  • Cases, Aleix
  • Peiro, Marta
  • Bayes Genis, Antonio
[EN] Iron deficiency (ID) treated with ferric carboxymaltose (FCM) previously showed reduced platelet count; however, no studies have evaluated its biological significance in heart failure. In the current study, we aimed to: (a) assess the changes in platelet count at 7 and 30 days post-FCM, and (b) explore its association with non-invasive surrogates of myocardial iron uptake and left systolic function in patients with ID and heart failure with left ventricular ejection fraction < 50% (HFrEF and HFmrEF). This post-hoc analysis of a randomized, double-blind, FCM vs. placebo clinical trial (Myocardial-IRON Trail) involved 45 outpatients with HFrEF and HFmrEF and ID in which the platelet count value was available. Platelet count, cardiac magnetic resonance T1-mapping and 3D-global longitudinal strain (CMR-GLS) were assessed at baseline, 7, and 30 days. Linear regression models were used to evaluate the between-treatment differences and endpoints. The mean (SD) age was 71 +/- 8 years, and 32 (71%) were men. At 30 days, we found a significant reduction in platelet count in those treated with FCM (p-value = 0.027). In those treated with FCM, the greater 30-day decrease in platelets showed lower 30-day changes in T1-mapping (p = 0.024) and CMR-GLS (p = 0.028). After administration of FCM, we found a significant 30-day reduction in platelet count. The greater platelet count reduction was related to lower myocardial iron repletion and a smaller improvement in left ventricular systolic function., This work was supported in part by an unrestricted grant from Vifor Pharma, CIBER Cardiovascular [grant numbers 16/11/00420 and 16/11/00403], Unidad de Investigacion Clinica y Ensayos Clinicos INCLIVA Health Research Institute, Spanish Clinical Research Network (SCReN; PT13/0002/0031 and PT17/0017/0003), cofounded by Fondo Europeo de Desarrollo Regional-Instituto de Salud Carlos III, and Proyectos de Investigacion de la Seccion de Insuficiencia Cardiaca 2017 from the Sociedad Espanola de Cardiologia.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Predictive Value of Cardiac Magnetic Resonance Feature Tracking after Acute Myocardial Infarction: A Comparison with Dobutamine Stress Echocardiography

  • Valente, Filipa X.
  • Gutiérrez, Laura
  • Rios-Navarro, Cesar
  • Rello, Pau
  • Maymi, Manel
  • Fernandez-Galera, Ruben
  • Monmeneu, Jose V.
  • Sao-Aviles, Augusto
  • Lopez-Lereu, Maria P.
  • Gonzalez-Alujas, M. Teresa
  • Cuellar, Hug
  • Barrabés, José
  • Otaegui, Imanol
  • Gavara-Doñate, Josep|||0000-0002-3483-7066
  • Moratal, David|||0000-0002-2825-3646
[EN] In acute ST-segment elevation myocardial infarction (STEMI) late gadolinium enhancement (LGE) may underestimate segmental functional recovery. We evaluated the predictive value of cardiac magnetic resonance (CMR) feature-tracking (FT) for functional recovery and whether it incremented the value of LGE compared to low-dose dobutamine stress echocardiography (LDDSE) and speckle-tracking echocardiography (STE). Eighty patients underwent LDDSE and CMR within 5-7 days after STEMI and segmental functional recovery was defined as improvement in wall-motion at 6-months CMR. Optimal conventional and FT parameters were analyzed and then also applied to an external validation cohort of 222 STEMI patients. Circumferential strain (CS) was the strongest CMR-FT predictor and addition to LGE increased the overall accuracy to 74% and was especially relevant in segments with 50-74% LGE (AUC 0.60 vs. 0.75, p = 0.001). LDDSE increased the overall accuracy to 71%, and in the 50-74% LGE subgroup improved the AUC from 0.60 to 0.69 (p = 0.039). LGE + CS showed similar value as LGE + LDDSE. In the validation cohort, CS was also the strongest CMR-FT predictor of recovery and addition of CS to LGE improved overall accuracy to 73% although this difference was not significant (AUC 0.69, p = 0.44). Conclusion: CS is the strongest CMR-FT predictor of segmental functional recovery after STEMI. Its incremental value to LGE is comparable to that of LDDSE whilst avoiding an inotropic stress agent. CS is especially relevant in segments with 50-74% LGE where accuracy is lower and further testing is frequently required to clarify the potential for recovery., This research was supported by the Instituto de Salud Carlos III and co-funded by Fondo Europeo de Desarrollo Regional (FEDER) (grant numbers PI17/01836 and CIBERCV16/11/00486). JG and DM acknowledge financial support from the "Agencia Valenciana de la Innovacion, Generalitat Valenciana" (grant) and from the "Conselleria d'Educacio, Investigacio, Cultura i Esport, Generalitat Valenciana" (grant number AEST/2019/037).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Human Mesenchymal Stem Cells Growth and Osteogenic Differentiation on Piezoelectric Poly(vinylidene fluoride) Microsphere Substrates

  • Sobreiro-Almeida, Rita
  • Tamaño-Machiavello, María Noel
  • Carvalho, E.O.
  • Cordon, Lourdes
  • Doria, S.
  • Senent, Leonor
  • Correia, D. M.
  • Ribeiro, C.
  • Lanceros-Méndez, S.
  • Sempere-Talens, Amparo
  • Sabater i Serra, Roser|||0000-0002-5550-7066
  • Gómez Ribelles, José Luís|||0000-0001-9099-0885
[EN] The aim of this work was to determine the influence of the biomaterial environment on human mesenchymal stem cell (hMSC) fate when cultured in supports with varying topography. Poly(vinylidene fluoride) (PVDF) culture supports were prepared with structures ranging between 2D and 3D, based on PVDF films on which PVDF microspheres were deposited with varying surface density. Maintenance of multipotentiality when cultured in expansion medium was studied by flow cytometry monitoring the expression of characteristic hMSCs markers, and revealed that cells were losing their characteristic surface markers on these supports. Cell morphology was assessed by scanning electron microscopy (SEM). Alkaline phosphatase activity was also assessed after seven days of culture on expansion medium. On the other hand, osteoblastic differentiation was monitored while culturing in osteogenic medium after cells reached confluence. Osteocalcin immunocytochemistry and alizarin red assays were performed. We show that flow cytometry is a suitable technique for the study of the differentiation of hMSC seeded onto biomaterials, giving a quantitative reliable analysis of hMSC-associated markers. We also show that electrosprayed piezoelectric poly(vinylidene fluoride) is a suitable support for tissue engineering purposes, as hMSCs can proliferate, be viable and undergo osteogenic differentiation when chemically stimulated., The authors thank the Portuguese Foundation for Science and Technology (FCT) for financial support under project PTDC/EEI-SII/5582/2014, Strategic Funding UID/FIS/04650/2013 and grants SFRH/BPD/90870/2012 (C.R.) and SFRH/BPD/121526/2016 (D.M.C). The authors acknowledge funding by the Spanish Ministry of Economy and Competitiveness (MINECO) through the project MAT2016-76039-C4-3-R (AEI/FEDER, UE) and from the Basque Government Industry Department under the ELKARTEK program. JLGR, LC, RSS and AS acknowledge funding by the Conselleria de Educacion, Investigacion, Cultura y Deporte of the Generalitat Valenciana through PROMETEO/2016/063 project. CIBER-BBN is an initiative funded by the VI National R&D&i Plan 2008-2011, Iniciativa Ingenio 2010, Consolider Program, CIBER Actions and financed by the Instituto de Salud Carlos III with assistance from the European Regional Development. This work was partially financed with FEDER funds (CIBERONC (CB16/12/00284)). The authors acknowledge the assistance and advice of Electron Microscopy Service of the UPV.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Evaluation and assessment of clique arrangements for the estimation of omnipolar electrograms in high density electrode arrays: an experimental animal model study

  • Ruiperez-Campillo, Samuel
  • Crespo, Marina
  • Alberola, Antonio
  • Heimer, Jakob
  • Chorro, Francisco J.
  • Tormos Ferrando, Álvaro|||0000-0002-3280-376X
  • Guill Ibáñez, Antonio|||0000-0001-8546-264X
  • Cebrián Ferriols, Antonio José|||0000-0003-0519-5284
  • Millet Roig, José|||0000-0002-8879-003X
  • Castells, Francisco|||0000-0001-5044-3545
[EN] High-density catheters combined with Orientation Independent Sensing (OIS) methods have emerged as a groundbreaking technology for cardiac substrate characterisation. In this study, we aim to assess the arrangements and constraints to reliably estimate the so-called omnipolar electrogram (oEGM). Performance was evaluated using an experimental animal model. Thirty-eight recordings from nine retrospective experiments on isolated perfused rabbit hearts with an epicardial HD multielectrode were used. We estimated oEGMs according to the classic triangular clique (4 possible orientations) and a novel cross-orientation clique arrangement. Furthermore, we tested the effects of interelectrode spacing from 1 to 4 mm. Performance was evaluated by means of several parameters that measured amplitude rejection ratios, electric field loop area, activation pulse width and morphology distortion. Most reliable oEGM estimations were obtained with cross-configurations and interelectrode spacings = 2 mm. Estimations from triangular cliques resulted in wider electric field loops and unreliable detection of the direction of the propagation wavefront. Moreover, increasing interelectrode distance resulted in increased pulse width and morphology distortion. The results prove that current oEGM estimation techniques are insufficiently accurate. This study opens a new standpoint for the design of new-generation HD catheters and mapping software., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This work was supported by PID2019- 109547RB-I00 (National Research Program, Ministerio de Ciencia e Innovación, Spanish Government) and CIBERCV CB16/11/00486 (Instituto de Salud Carlos III).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Circulating Immune Proteins: Improving the Diagnosis and Clinical Outcome in Advanced Non-Small Cell Lung Cancer

  • Torres-Martínez, Susana
  • Calabuig-Fariñas, Silvia
  • Gallach-Garcia, Sandra
  • Mosqueda, M.
  • Munera Maravilla, Ester
  • Navarro, Lara
  • Blasco-Cordellat, Ana
  • Camps-Herrero, Carlos
  • Sirera Pérez, Rafael|||0000-0001-9162-8490
  • Jantus-Lewintre, Eloisa|||0000-0001-7395-4380
[EN] : Immunotherapy has been proven a viable treatment option for non-small cell lung cancer (NSCLC) treatment in patients. However, some patients still do not benefit. Finding new predictive biomarkers for immunocheckpoint inhibitor (ICI) response will improve treatment management in the clinical routine. In this regard, liquid biopsy is a useful and noninvasive alternative to surgical biopsies. In the present study, we evaluated the potential diagnostic, prognostic, and predictive value of seven different soluble mediators involved in immunoregulation. Fifty-two plasma samples from advanced NSCLC treated in first-line with pembrolizumab at baseline (PRE) and at first response assessment (FR) were analyzed. In terms of diagnostic value, our results revealed that sFGL1, sGAL-3, and sGAL-1 allowed for optimal diagnostic efficacy for cancer patients. Additionally, the combination of sFGL1 and sGAL-3 significantly improved diagnostic accuracy. Regarding the predictive value to assess patients¿ immune response, sCD276 levels at PRE were significantly higher in patients without tumor response (p = 0.035). Moreover, we observed that high levels of sMICB at PRE were associated with absence of clinical benefit (pembrolizumab treatment less than 6 months) (p = 0.049), and high levels of sMICB and sGAL-3 at FR are also related to a lack of clinical benefit (p = 0.027 and p = 0.03, respectively). Finally, in relation to prognosis significance, at PRE and FR, sMICB levels above the 75th percentile are related to poor progression-free survival (PFS) (p = 0.013 and p = 0.023, respectively) and overall survival (OS) (p = 0.001 and p = 0.011, respectively). An increase in sGAL3 levels at FR was associated with worse PFS (p = 0.037). Interestingly, high sGAL-3 at PRE was independently associated with PFS and OS with a hazard ratio (HR) of 2.45 (95% CI 1.14¿5.25; p = 0.021) and 4.915 (95% CI 1.89¿12.73; p = 0.001). In conclusion, plasma levels of sFGL1, sGAL-3, and sGAL-1 could serve as diagnostic indicators and sMICB, sCD276, and sGAL3 were linked to outcomes, suggesting their potential in assessing NSCLC under pembrolizumab treatment. Our results highlight the value of employing soluble immune biomarkers in advanced lung cancer patients treated with pembrolizumab at first-line., This research was founded by Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) (grant number CB16-12-00350), Instituto de Salud Carlos III (PI22/01221, PI22/01277), Generalitat Valenciana (AICO/2021/333). S.T-M. is supported by the Generalitat Valenciana and Fondo Social Europeo fellowship (ACIF/2018/275).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Biocompatibility and internalization assessment of bare and functionalised mesoporous silica nanoparticles

  • Garrido-Cano, Iris
  • Herrera, Guadalupe
  • Cejalvo, Juan Miguel
  • Lluch, Ana
  • Eroles, Pilar
  • Candela-Noguera, Vicente
  • Marcos Martínez, María Dolores|||0000-0001-7079-8589
  • Sancenón Galarza, Félix|||0000-0002-5205-7135
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
[EN] We report herein an evaluation of the effect of several mesoporous silica nanoparticles (MSNs) on the cellular uptake and in vitro cytotoxicity in human cells. Bare MSNs and MSNs functionalized with polyethylene glycol or hyaluronic acid are employed to evaluate uptake efficiency and mechanisms of endocytosis in cancer (MDA-MB-231) and non-cancer (MCF10A) cells. Moreover, changes in viability, cell cycle, oxidative stress, and mitochondrial membrane potential are evaluated. Our results confirm that MSNs are internalized efficiently by human cells and that uptake mechanisms differ for cell types and particles. We also confirm that MSNs are biocompatible materials that do not induce ROS/RNS production, nor changes on mitochondrial membrane potential or cell cycle., The authors want to thank the Spanish Government RTI2018-100910-B-C41 (MCUI/AEI/FEDER, UE) and PI18/01219 (ISCIII), the Generalitat Valenciana (PROMETEO/2018/024 and ACIF/2016/030), and CIBER-BBN (CB07/01/2012) and CIBER-ONC (CB16/12/00481) for support.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Tesis doctoral (DoctoralThesis)

Non-Invasive Immunogram. A Multidimensional Approach to Characterize and Monitor Immune Status in Non-Small Cell Lung Cancer

  • Moreno Manuel, Andrea
[ES] El cáncer de pulmón no microcítico (CPNM) representa un 80% de los casos de cáncer de pulmón, siendo uno de los tipos de cáncer más frecuentes y mortales. El tratamiento con inmunoterapia ha mejorado significativamente el pronóstico de los pacientes en las últimas décadas. No obstante, no todos los pacientes responden al tratamiento, por lo que se necesitan nuevos biomarcadores para predecir qué pacientes se podrían beneficiar de la inmunoterapia. El principal objetivo de esta tesis es obtener nuevos biomarcadores no invasivos para pacientes de CPNM avanzado tratados con inmunoterapia. Se incluyeron 52 pacientes de CPNM en estadios avanzados tratados con anti-PD1 o anti-PD1 en combinación con quimioterapia (anti-PD1+CT) en primera línea. Se analizaron biomarcadores no invasivos en muestras de sangre periférica, obtenidas antes del tratamiento y en la primera evaluación de respuesta. Los biomarcadores analizados en este estudio fueron: i) parámetros hematológicos e inmunológicos, ii) expresión de genes inmunoreguladores en células mononucleares de sangre periférica (PBMCs), iii) repertorio de TCR-ß y iv) genotipo de HLA. También se analizaron 13 controles sanos, y se observó que los pacientes con CPNM presentaron menores niveles de expresión de genes relacionados con las células T. Además, los pacientes con CPNM tenían menor número de clones de TCR-ß. Se analizó el valor predictivo y pronóstico de los potenciales biomarcadores independientemente en pacientes tratados con anti-PD1 o anti-PD+CT. Se encontraron biomarcadores con valor pronóstico, bien en las muestras basales o en las muestras tomadas en la primera evaluación de respuesta. Al utilizar muestras no invasivas, también se pudo estudiar la dinámica de los biomarcadores a lo largo del tratamiento, observando que algunos cambios ocurrían de manera diferencial en pacientes respondedores o dependiendo del tratamiento. La integración de los datos de las variables analizadas ha resultado en una propuesta de un modelo multivariante capaz de predecir qué pacientes tendrán mejor pronóstico, en el subgrupo de pacientes tratados con anti-PD1. Además, se crearon dos inmunogramas no invasivos incluyendo los ratios de los biomarcadores entre muestras tomadas antes y durante el tratamiento. Estos modelos se realizaron específicamente para cada tipo de tratamiento, y podrían ser útiles para monitorizar la respuesta durante el tratamiento. Este estudio resalta el papel de la biopsia líquida como una herramienta no invasiva para analizar biomarcadores de forma integral que permiten caracterizar y monitorizar el estatus inmune en pacientes con CPNM tratados con inmunoterapia o quimioinmunoterapia., [CA] El càncer de pulmó no microcític (CPNM) representa un 80% dels casos de càncer de pulmó, i és un dels tipus de càncer més freqüents i mortals. El tractament amb immunoteràpia ha millorat significativament el pronòstic dels pacients en les últimes dècades. Malgrat això, no tots el pacients responen, per la qual cosa es necessiten nous biomarcadors per predir què pacients es beneficiaran del tractament amb immunoteràpia. El principal objectiu d'aquesta tesi és obtindre nous biomarcadors no invasius per a pacients de CPNM avançat tractats amb immunoteràpia. Es van incloure 52 pacients de CPNM en estadis avançats tractats amb anti-PD1 o anti-PD1 en combinació amb quimioteràpia (anti-PD1+CT) en primera línia. Es van analitzar biomarcadors no invasius a partir de mostres de sang perifèrica, que es van obtindre abans del tractament i en la primera avaluació de resposta. Els potencials biomarcadors analitzats en aquest estudi van ser: i) paràmetres hematològics i immunològics, ii) expressió de gens immunoreguladors en cèl·lules mononuclears de sang perifèrica (PBMCs), iii) repertori de TCR-ß i iv) genotip d'HLA. També es van analitzar 13 controls sans, i es va observar que els pacients amb CPNM presentaven menors nivells d'expressió de gens relacionats amb les cèl·lules T. A més, els pacients amb CPNM tenien menor riquesa de repertori de TCR-ß. S'han analitzat el valor predictiu i pronòstic dels potencials biomarcadors independentment en pacients tractats amb anti-PD1 o anti-PD1+CT. S'han trobat biomarcadors amb valor pronòstic, bé en les mostres basals o en les mostres preses en la primera avaluació de resposta. Com s'han utilitzat mostres no invasives, també s'ha pogut analitzar la dinàmica dels biomarcadores al llarg del tractament, i s'han observat canvis específics de pacients responedors o del tipus de tractament. La integració de les variables analitzades ha resultat en una proposta d'un model multivariant capaç de predir quins pacients amb CPNM tindran millor pronòstic, en el subgrup de pacients tractats amb anti-PD1. També s'han fet dos immunograms no invasius incloent els ràtios dels biomarcadors entre mostres preses abans i durant el tractament. Aquests models son específics per a cada tipus de tractament, i podrien ser útils per a monitorar la resposta durant el tractament. Aquest estudi ressalta el paper de la biòpsia líquida com una eina no invasiva per a analitzar biomarcadors de forma integral que permeten caracteritzar i monitorar l'estatus immune en pacients amb CPNM tractats amb immunoteràpia o quimioimmunoteràpia., [EN] Non-Small Cell Lung Cancer (NSCLC) represents 80% of lung cancer cases, being one of the most frequent and death causing cancers. Recently developed treatments with immunotherapy have improved patient prognosis. However, a significant number of patients do not respond to treatment, thus there is an urgent need for biomarkers to predict which patients will benefit from immunotherapy. The main objective of this thesis was to obtain novel non-invasive biomarkers for advanced-stage NSCLC patients treated with immunotherapy. This study included 52 advanced-stage NSCLC patients treated with Anti-PD1 or Anti-PD1 in combination with chemotherapy (Anti-PD1+CT) in the first line setting. Non-invasive biomarkers were analysed using peripheral blood samples, which were obtained before first cycle and at first response assessment. The potential biomarkers analysed in this study were: i) haematological and immunological parameters, ii) immune-related gene expression analysed on Peripheral Blood Mononuclear Cells (PBMCs), iii) TCR-ß repertoire, and iv) HLA genotype. 13 healthy subjects were also included in this study. NSCLC patients presented lower T cell related gene expression levels than controls. Furthermore, cancer patients had a lower number of unique TCR-ß clones. We have assessed the predictive and prognostic value of the analysed variables independently on patients treated with anti-PD1 or anti-PD1+CT. We found prognostic biomarkers that could be useful to identify patients who benefit from treatment. Since we used non-invasive samples, we also observed differences in immune-related biomarkers at first response assessment in patients responding to treatment. In addition, biomarker dynamics were useful to identify changes occurring throughout treatment. The integration of data from the analysed variables has resulted in a proposal of a multivariate model capable of predicting patients with improved outcomes to treatment with anti PD1 therapy. Moreover, we have developed two non-invasive inmunograms including the ratios of on- and pre-treatment samples, which could be useful to monitor patients throughout treatment. Altogether, this study highlights the role of non-invasive biomarkers to characterize and monitor immune status in NSCLC patients treated with immunotherapy or chemoimmunotherapy., This Thesis was supported by the following grants: Fundación Científica Asociación Española Contra el Cáncer. PRDVA18015MORE; Centro de Investigación Biomédica en Red Cáncer. Project B16/12/00350 e Instituto de Salud Carlos III: PI18/00266
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Cancer Epigenetic Biomarkers in Liquid Biopsy for High Incidence Malignancies

  • Palanca-Ballester, Cora
  • Rodriguez-Casanova, Aitor
  • Torres, Susana
  • Calabuig-Fariñas, Silvia
  • Exposito, Francisco
  • Serrano, Diego
  • Redin, Esther
  • Valencia, Karmele
  • Diaz-Lagares, Angel
  • Montuenga, Luis
  • Sandoval, Juan
  • Calvo, Alfonso
  • Jantus-Lewintre, Eloisa|||0000-0001-7395-4380
[EN] Early alterations in cancer include the deregulation of epigenetic events such as changes in DNA methylation and abnormal levels of non-coding (nc)RNAs. Although these changes can be identified in tumors, alternative sources of samples may offer advantages over tissue biopsies. Because tumors shed DNA, RNA, and proteins, biological fluids containing these molecules can accurately reflect alterations found in cancer cells, not only coming from the primary tumor, but also from metastasis and from the tumor microenvironment (TME). Depending on the type of cancer, biological fluids encompass blood, urine, cerebrospinal fluid, and saliva, among others. Such samples are named with the general term "liquid biopsy" (LB). With the advent of ultrasensitive technologies during the last decade, the identification of actionable genetic alterations (i.e., mutations) in LB is a common practice to decide whether or not targeted therapy should be applied. Likewise, the analysis of global or specific epigenetic alterations may also be important as biomarkers for diagnosis, prognosis, and even for cancer drug response. Several commercial kits that assess the DNA promoter methylation of single genes or gene sets are available, with some of them being tested as biomarkers for diagnosis in clinical trials. From the tumors with highest incidence, we can stress the relevance of DNA methylation changes in the following genes found in LB: SHOX2 (for lung cancer); RASSF1A, RARB2, and GSTP1 (for lung, breast, genitourinary and colon cancers); and SEPT9 (for colon cancer). Moreover, multi-cancer high-throughput methylation-based tests are now commercially available. Increased levels of the microRNA miR21 and several miRNA- and long ncRNA-signatures can also be indicative biomarkers in LB. Therefore, epigenetic biomarkers are attractive and may have a clinical value in cancer. Nonetheless, validation, standardization, and demonstration of an added value over the common clinical practice are issues needed to be addressed in the transfer of this knowledge from "bench to bedside"., A.C. and L.M. were funded by FIMA (Foundation for Applied Medical Research), ISCIIIFondo de Investigación Sanitaria-Fondo Europeo de Desarrollo Regional Una manera de hacer Europa (PI19/00230, to AC; PI19/00098 to LMM), CIBERONC CB16/12/00443, AECC, and Ramón Areces Foundations (all to L.M.). J.S. was funded by FIS grant (PI19/00572) from the FEDER, FSE, Carlos III Health Institute (ISCIII) and INNVA1/2020/71 de la Línea 1 de Valorización y Transferencia a las empresas, de la Agencia Valenciana de la Innovación. E.J-L. was supported by the Spanish Health Institute Carlos III (ISCII, Fondo de Investigación Sanitaria: CB16/12/00350 and PI18/00266). S.T. was supported by the Generalitat Valenciana and Fondo Social Europeo, fellowship ACIF/2018/275. A.D-L. was funded by a contract Juan Rodés from Spanish Health Institute Carlos III (ISCIII) (JR17/00016) and by a research grant (PI18/00307) co-funded by ISCIII and the European Regional Development Fund (FEDER). A.R-C. was supported by the Roche-CHUS Joint Unit (IN853B2018/03) funded by GAIN, Consellería de Economía, Emprego e Industria . Fellowship support: E.R. FPU, Spanish Ministry of Education ; D.S., Juan de la Cierva-Incorporacion, Spanish Ministry of Science and Innovation .
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Longitudinal strain in remote non-infarcted myocardium by tissue tracking CMR: characterization, dynamics, structural and prognostic implications

  • Gavara-Doñate, Josep|||0000-0002-3483-7066
  • Moratal, David|||0000-0002-2825-3646
  • Rodríguez-Palomares, Jose F.
  • Rios-Navarro, Cesar
  • Valente, Filipa
  • Monmeneu, Jose V.
  • Lopez-Lereu, Maria P.
  • Ferreira-González, Ignacio
  • García del Blanco, Bruno
  • Otaegui, Imanol
  • Canoves, Joaquim
  • De Dios, Elena
  • Pérez, Nerea
  • Racugno, Paolo
  • Bonanad, Clara
  • Minana, Gema
[EN] Purpose In ST-segment elevation myocardial infarction (STEMI) patients, longitudinal strain (LS) in remote non-infarcted myocardium (RNM) has not yet been characterized by tissue tracking (TT) cardiovascular magnetic resonance (CMR). In STEMI patients, we aimed to characterize RNM-LS by TT-CMR and to assess both its dynamics and its structural and prognostic implications. Methods We recruited 271 patients with a first STEMI studied with TT-CMR 1 week after infarction. Of these patients, 145 underwent 1-week and 6-month TT-CMR and were used to characterize both the dynamics and the short-term and long-term structural implications of RNM-LS. Based on previously validated data, RNM areas were defined depending on the culprit coronary artery. Results Reduced RNM-LS at 1 week (n = 70, 48%) was associated with larger infarct size and more depressed left ventricular ejection fraction (LVEF) at both the 1-week and 6-month TT-CMR (p value < 0.001). Late normalization of RNM-LS was frequent (28/70, 40%) and independently related to late recovery of LVEF (p value = 0.002). Patients with reduced RNM-LS at 1-week TT-CMR had more major adverse cardiac events (death, heart failure or re-infarction) in both the 271 patients included in the study group (26% vs. 11%, p value = 0.002) and in an external validation cohort made up of 177 STEMI patients (57% vs. 13%, p value < 0.001). Conclusion After STEMI, reduced RNM-LS by TT-CMR is common and is associated with more severe short- and long-term structural damage. There is a beneficial tendency towards recovery of RNM-LS that parallels late recovery of LVEF. More events occur in patients with reduced RNM-LS., This work was supported by the Instituto de Salud Carlos III and co-funded by Fondo Europeo de Desarrollo Regional (FEDER) [Grant Numbers PI17/01836, PIE15/00013, CIBERCV16/11/00486, CIBERCV16/11/00479 and a postgraduate contract FI18/00320 to C. R.-N.] and by the Generalitat Valenciana [Grant Number GV/2018/116]. JG and DM acknowledge financial support from the Agencia Valenciana de la Innovacio, Generalitat Valenciana (Grant INNCAD00/18/026).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Co-culture of multiple myeloma cell lines and bone marrow mesenchymal stem cells in a 3D microgel environment

  • García-Briega, María Inmaculada|||0000-0003-0811-2632
  • Plá-Salom, Júlia
  • Clara-Trujillo, Sandra|||0000-0002-6455-2993
  • Gómez Ribelles, José Luís|||0000-0001-9099-0885
  • Tolosa, Laia
  • Cordón, Lourdes
  • Sempere, Amparo
[EN] This study reproduces the complex relationships between tumour plasma cells and their bone marrow microenvironment in multiple myeloma in vitro. These relationships are established both with other cells and with the extracellular matrix and are key factors in tumour progression, generating resistance to antitumour drugs in the cellular and non-cellular environments. This paper proposes a 3D microenvironment model designed to capture the main components of the multiple myeloma tumour microenvironment. Multiple myeloma cells (MMCs) were dispersed in a microgel medium formed by gel-textured microspheres. The proteins and polysaccharides considered important in the interaction of the MMCs with their non-cellular environment were successfully grafted onto the surface of the microspheres, while human mesenchymal stem cells (MSCs) were cultured in a pellet with non-functionalised microspheres. The MSCs pellet was placed in the well plate together with the microgel and the MMCs and orbitally shaken to maintain them in suspension. The viability, cell cycle and proliferation of the RPMI8226, MM1S and U266 multiple myeloma cell lines and the direct adhesion of MMCs to the MSC pellet were quantified. The results revealed that all three cell lines are able to grow satisfactorily. In addition, the normal behaviour of the MMCs is not modified in any of the culture conditions studied., This research was funded by MCIN/AEI/10.13039/501100011033 Grant PID2019-106099RB-C41. The research was also supported by CIBER - Consorcio Centro de Investigacion Biomedica en Red - CIBER_BBN CB06/01/1026, CIBERONC CB16/12/00284, Instituto de Salud Carlos III, Ministerio de Ciencia e Innovacion. This work was also supported by the Spanish Ministry of Science, Innovation and Universities through Grant No PRE2020-092326 awarded to M <feminine ordinal indicator> Inmaculada Garcia-Briega. This work was also supported by the Spanish Ministry of Science, Innovation and Universities through Grant No PRE2022-000080 awarded to Julia PlaSalom. The authors also thank the microscopy department of the Universitat Politecnica de Valencia for their help and support.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Sex Effect in the Decision to Perform Invasive Coronary Angiography in Patients With Chronic Coronary Syndrome After Undergoing Vasodilator Stress MRI

  • Palau, Patricia
  • Núñez, Julio
  • Monmeneu, José V.
  • Lopez-Lereu, Maria P.
  • Rios-Navarro, Cesar
  • de Dios, Elena
  • Perez-Sole, Nerea
  • Marcos-Garces, Victor
  • Domínguez, Eloy
  • Canoves, Joaquim
  • Miñana, Gema
  • Chorro, Francisco Javier
  • Bodi, Vicente
  • Gavara-Doñate, Josep|||0000-0002-3483-7066
  • Moratal, David|||0000-0002-2825-3646
[EN] Background Stress cardiac MRI permits comprehensive evaluation of patients with known or suspected chronic coronary syndromes (CCS). The impact of sex on the use of invasive cardiac angiography (ICA) after vasodilator stress cardiac MRI is unclear. Purpose To evaluate the impact of sex on ICA use after vasodilator stress cardiac MRI. Study type Retrospective. Population A total of 6229 consecutive patients (age [mean +/- standard deviation] 65.2 +/- 11.5 years, 38.1% women). Field Strength/Sequence A 5-T; a steady-state free-precession cine sequence; stress first-pass perfusion imaging; late enhancement imaging. Assessment Patients underwent vasodilator stress cardiac MRI for known or suspected CCS. The ischemic burden (at stress first-pass perfusion imaging) was computed (17-segment model). Statistical Tests Multivariate logistic regression was used to evaluate the potential differential association between ischemic burden and use of cardiac MRI-related ICA across sex. Results A total of 1109 (17.8%) patients were referred to ICA, among which there were significantly more men (762, 19.7%) than women (347, 14.6%). Overall, after multivariate adjustment, female sex was not associated with lower use of ICA (odds ratio [OR] = 0.99; confidence interval [CI] 95%: 0.84-1.18, P = 0.934). However, significant sex differences were detected across ischemic burden. Whereas women with nonischemic vasodilator stress cardiac MRI (0 ischemic segments) were less commonly submitted to ICA (OR = 0.49; CI 95%: 0.35-0.69) in patients with ischemia (>1 ischemic segment), adjusted use of ICA was more frequent in women than men (OR = 1.27; CI 95%: 1.1-1.5). Data Conclusions In patients with known or suspected CCS submitted to undergo vasodilator stress cardiac MRI, cardiac MRI-related ICA may be overused in men without ischemia. Furthermore, ICA referral in patients with negative ischemia resulted in greater odds of revascularization in men. Evidence Level 3 Technical Efficacy Stage 5., This work was supported by "Instituto de Salud Carlos III" and "Fondos Europeos de Desarrollo Regional FEDER" (grant numbers PI20/00637 and CIBERCV16/11/00486), by Conselleria de Educacio - Generalitat Valenciana (grant number PROMETEO/2021/008), and by the Spanish Society of Cardiology (grant number SEC/FECINV-CLI 21/024).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Identification of a Two-MicroRNA Signature in Plasma as a Novel Biomarker for Very Early Diagnosis of Breast Cancer

  • Adam-Artigues, Anna
  • Garrido-Cano, Iris
  • Carbonell-Asins, Juan Antonio
  • Lameirinhas, Ana
  • Simón, Soraya
  • Ortega-Morillo, Belén
  • Martínez, María Teresa
  • Hernando, Cristina
  • Constâncio, Vera
  • Burgues, Octavio
  • Bermejo, Begoña
  • Henrique, Rui
  • Lluch, Ana
  • Jerónimo, Carmen
  • Eroles, Pilar
  • Cejalvo, Juan Miguel
[EN] The early diagnosis of breast cancer is essential to improve patients' survival rate. In this context, microRNAs have been described as potential diagnostic biomarkers for breast cancer. Particularly, circulating microRNAs have a strong value as non-invasive biomarkers. Herein, we assessed the potential of a microRNA signature based on miR-30b-5p and miR-99a-5p levels in plasma as a diagnostic biomarker for breast cancer. This two-microRNA signature was constructed by Principal Component Analysis and its prognostic value was assessed in a discovery cohort and blindly validated in a second cohort from an independent institution. ROC curve analysis and biomarker performance parameter evaluation demonstrated that our proposed signature presents a high value as a non-invasive biomarker for very early detection of breast cancer. In addition, pathway enrichment analysis identified three of the well-known pathways involved in cancer as targets of the two microRNAs., This study was financed by grants from the Spanish Ministry of Economy and Competitiveness (MINECO) and FEDER funds (PI18/01219 to P.E. and CB16/12/00481 to A.Ll.) and from the Research Centre of the Portuguese Oncology Institute of Porto (PI 74-CBEG-CI-IPOP-19-2015 to C.J.). A.A.-A. and A.L. were funded by Asociación Española Contra el Cáncer (PRDVA18013LLUC and PRDVA19016LAME). V.C. was funded by Liga Portuguesa Contra o Cancro/Fundação PT. J.M.C. was funded by Sociedad Española de Oncología Médica (Río Hortega-SEOM). The authors are grateful to INCLIVA Biobank (PT17/0015/0049; B.000768 ISCIII) and Valencian Biobanking Network integrated into the Spanish National Biobanks Network and nursing staff from all institutions for collaboration.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Residual ST-segment elevation to predict long-term clinical and CMR-derived outcomes in STEMI

  • Merenciano-Gonzalez, Héctor
  • Marcos-Garces, Victor
  • Pedro-Tudela, Ana
  • Lopez-Lereu, Maria P.
  • Monmeneu, José V.
  • Pérez, Nerea
  • Rios-Navarro, César
  • De Dios, Elena
  • Gabaldon-Perez, Ana
  • Albiach, Cristina
  • Racugno, Paolo
  • Bonanad, Clara
  • Canoves, Joaquim
  • Chorro, Francisco J.
  • Bodi, Vicente
  • Gavara-Doñate, Josep|||0000-0002-3483-7066
[EN] Residual ST-segment elevation after ST-segment elevation myocardial infarction (STEMI) has traditionally been considered a predictor of left ventricular (LV) dysfunction and ventricular aneurism. However, the implications in terms of long-term prognosis and cardiac magnetic resonance (CMR)-derived structural consequences are unclear. A total of 488 reperfused STEMI patients were prospectively included. The number of Q wave leads with residual ST-segment elevation> 1 mm (Q-STE) at pre-discharge ECG was assessed. LV ejection fraction (LVEF, %) and infarct size (IS, % of LV mass) were quantifed in 319 patients at 6-month CMR. Major adverse cardiac events (MACE) were defned as all-cause death and/or re-admission for acute heart failure (HF), whichever occurred frst. During a mean follow-up of 6.1 years, 92 MACE (18.9%), 39 deaths and 53 HF were recorded. After adjustment for baseline characteristics, Q-STE (per lead with> 1 mm) was independently associated with a higher risk of long-term MACE (HR 1.24 [1.07¿1.44] per lead, p = 0.004), reduced (< 40%) LVEF (HR 1.36 [1.02¿1.82] per lead, p = 0.04) and large (> 30% of LV mass) IS (HR 1.43 [1.11¿1.85] per lead, p = 0.006) at 6-month CMR. Patients with Q-STE¿ 2 leads (n= 172, 35.2%) displayed lower MACE-free survival, more depressed LVEF, and larger IS at 6-month CMR (p< 0.001 for all comparisons). Residual ST-segment elevation after STEMI represents a universally available tool that predicts worse longterm clinical and CMR-derived structural outcomes., This work was supported by the Instituto de Salud Carlos III and co-funded by Fondo Europeo de Desarrollo Regional (FEDER) (Grants PI20/00637 and CIBERCV16/11/00486, postgraduate contract FI18/00320 to C.R.-N. and CM21/00175 to V.M.-G.), Generalitat Valenciana (Grant PROMETEO/2021/008), and by Sociedad Espanola de Cardiologia (Grant SEC/FECINV-CLI 21/024). J. G. acknowledges financial support from the Agencia Estatal de Investigacion (Grant FJC2020-043981-I/AEI/).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Biomimetic 3D environment based on microgels as a model for the generation of drug resistance in multiple myeloma

  • Marín-Payá, Juan Carlos
  • Díaz-Benito, Blanca
  • Amaro Martins, Luis
  • Cordón, Lourdes
  • Lanceros-Méndez, Senentxu
  • Sempere, Amparo
  • Clara-Trujillo, Sandra|||0000-0002-6455-2993
  • Gallego-Ferrer, Gloria|||0000-0002-2428-0903
  • Gómez Ribelles, José Luís|||0000-0001-9099-0885
[EN] The development of three-dimensional environments to mimic the in vivo cellular response is a problem in the building of disease models. This study aimed to synthesize and validate three-dimensional support for culturing monoclonal plasma cells (mPCs) as a disease model for multiple myeloma. The three-dimensional environment is a biomimetic microgel formed by alginate microspheres and produced on a microfluidic device whose surface has been functionalized by a layer-by-layer process with components of the bone marrow's extracellular matrix, which will interact with mPC. As a proof of concept, RPMI 8226 cell line cells were cultured in our 3D culture platform. We proved that hyaluronic acid significantly increased cell proliferation and corroborated its role in inducing resistance to dexamethasone. Despite collagen type I having no effect on proliferation, it generated significant resistance to dexamethasone. Additionally, it was evidenced that both biomolecules were unable to induce resistance to bortezomib. These results validate the functionalized microgels as a 3D culture system that emulates the interaction between tumoral cells and the bone marrow extracellular matrix. This 3D environment could be a valuable culture system to test antitumoral drugs efficiency in multiple myeloma., Funding by the Generalitat Valenciana PROMETEO/2016/063 project is acknowledged. This work was partially financed with FEDER funds (CIBERONC (CB16/12/00284)). The CIBER-BBN initiative is funded by the VI National R&D&I Plan 2008-2011, Iniciativa Ingenio 2010, Consolider Program. CIBER actions are financed by the Instituto de Salud Carlos III with assistance from the European Regional Development Fund. Financial support from the Portuguese Foundation for Science and Technology (FCT) in the framework of the UID/FIS/04650/2019, PTDC/BTMMAT/28237/2017, and PTDC/EMD-EMD/28159/2017 projects and from the Basque Government Industry Departments under the ELKARTEK programs is also acknowledged.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Effects of the inhibition of late sodium current by GS967 on stretch-induced changes in cardiac electrophysiology

  • Canto Serrano, Irene Del
  • Santamaría, L.
  • Genovés, P.
  • Such-Miquel, Luis
  • Arias-Mutis, Óscar Julián
  • Zarzoso Muñoz, Manuel
  • Soler, C.
  • Parra-Giraldo, G.
  • Alberola, Antonio
  • Such Belenguer, Luis
  • Chorro, F.J.
  • Tormos Ferrando, Álvaro|||0000-0002-3280-376X
[EN] PurposeMechanical stretch increases sodium and calcium entry into myocytes and activates the late sodium current. GS967, a triazolopyridine derivative, is a sodium channel blocker with preferential effects on the late sodium current. The present study evaluates whether GS967 inhibits or modulates the arrhythmogenic electrophysiological effects of myocardial stretch.MethodsAtrial and ventricular refractoriness and ventricular fibrillation modifications induced by acute stretch were studied in Langendorff-perfused rabbit hearts (n=28) using epicardial multiple electrodes and high-resolution mapping techniques under control conditions and during the perfusion of GS967 at different concentrations (0.03, 0.1, and 0.3M).ResultsOn comparing ventricular refractoriness, conduction velocity and wavelength obtained before stretch had no significant changes under each GS967 concentration while atrial refractoriness increased under GS967 0.3M. Under GS967, the stretch-induced changes were attenuated, and no significant differences were observed between before and during stretch. GS967 0.3M diminished the normal stretch-induced changes resulting in longer (less shortened) atrial refractoriness (13826ms vs 95 +/- 9ms; p<0.01), ventricular refractoriness (155 +/- 18ms vs 124 +/- 16 ms; p<0.01) and increments in spectral concentration (23 +/- 5% vs 17 +/- 2%; p<0.01), the fifth percentile of ventricular activation intervals (46 +/- 8ms vs 31 +/- 3ms; p<0.05), and wavelength of ventricular fibrillation (2.5 +/- 0.5cm vs 1.7 +/- 0.3cm; p<0.05) during stretch. The stretch-induced increments in dominant frequency during ventricular fibrillation (control=38%, 0.03M=33%, 0.1M=33%, 0.3M=14%; p<0.01) and the stretch-induced increments in arrhythmia complexity index (control=62%, 0.03M=41%, 0.1M=32%, 0.3M=16%; p<0.05) progressively decreased on increasing the GS967 concentration.Conclusions GS967 attenuates stretch-induced changes in cardiac electrophysiology., This work was supported by the Spanish Ministry of Economy and Competiveness (Carlos III Health Institute)/European Regional Development Fund (FEDER) (Grants FIS PI12/00407, PI15/01408, PIE15/00013, CB16/11/00486) and by the Generalitat Valenciana (Grant PROMETEO FASE II 2014/037).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Biomimetic microspheres for 3D mesenchymal stem cell culture and characterization

  • Clara-Trujillo, Sandra|||0000-0002-6455-2993
  • Gallego-Ferrer, Gloria|||0000-0002-2428-0903
  • Gómez Ribelles, José Luís|||0000-0001-9099-0885
  • Marin-Paya, Juan Carlos
  • Cordón, Lourdes
  • Sempere, Amparo
[EN] Stem cells reside in niches, specialized microenvironments that sustain and regulate their fate. Extracellular matrix (ECM), paracrine factors or other cells are key niche regulating elements. As the conventional 2D cell culture lacks these elements, it can alter the properties of naive stem cells. In this work we designed a novel biomimetic microenvironment for cell culture, consisting of magnetic microspheres, prepared with acrylates and acrylic acid copolymers and functionalized with fibronectin or hyaluronic acid as ECM coatings. To characterize cell proliferation and adhesion, porcine mesenchymal stem cells (MSCs) were grown with the different microspheres. The results showed that the 3D environments presented similar proliferation to the 2D culture and that fibronectin allows cell adhesion, while hyaluronic acid hinders it. In the 3D environments, cells reorganize the microspheres to grow in aggregates, highlighting the advantages of microspheres as 3D environments and allowing the cells to adapt the environment to their requirements., PROMETEO/2016/063 project is acknowledged. This work was partially financed with FEDER funds (CIBERONC (CB16/12/00284)). The CIBER-BBN initiative is funded by the VI National R&D&I Plan 2008-2011, Iniciativa Ingenio 2010, Consolider Program. CIBER actions are financed by the Instituto de Salud Carlos III with assistance from the European Regional Development Fund. This work was also supported by the Spanish Ministry of Science, Innovation and Universities trough Sandra Clara-Trujillo FPU17/05810 grant.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Microvascular injury after acute myocardial infarction. Focus on the catheterization laboratory, Daño microvascular tras un infarto agudo de miocardio. Foco en el laboratorio de hemodinámica

  • Ríos-Navarro, César
  • Bodí, Vicente
  • Gavara-Doñate, Josep|||0000-0002-3483-7066
This study was funded by the Instituto de Salud Carlos III and the European Regional Development Fund (FEDER) (grants PI20/00637, CIBERCV16/11/00486 and FI18/00320), the Conselleria de Educació de la Generalitat Valenciana (PROMETEO/2021/008) and the Agencia Estatal de Investigación (grant FJC2020-043981).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

High-fidelity Cas9-mediated targeting of KRAS driver mutations restrains lung cancer in preclinical models

  • Alvarez-Perez, Juan Carlos
  • Sanjuan-Hidalgo, Juan
  • Arenas, Alberto M.
  • Hernandez-Navas, Ivan
  • Benitez-Cantos, Maria S.
  • Andrades, Alvaro
  • Calabuig-Farinas, Silvia
  • Paz-Ares, Luis
  • Ferrer, Irene
  • Medina, Pedro P.
  • Jantus-Lewintre, Eloisa|||0000-0001-7395-4380
[EN] Missense mutations in the 12th codon of KRAS are key drivers of lung cancer, with glycine-to-cysteine (G12C) and glycine-to-aspartic acid (G12D) substitutions being among the most prevalent. These mutations are strongly associated with poor survival outcomes. Given the critical role of KRAS in lung cancer and other cancers, it remains as a major target for the development of new and complementary treatments. We have developed a CRISPR-High Fidelity (HiFi)-Cas9-based therapy strategy that can effectively and specifically target KRASG12C and KRASG12D mutants, avoiding KRASWT off-targeting and affecting KRAS downstream pathways, thereby significantly reducing tumorgenicity. The delivery of HiFiCas9 components via ribonucleoprotein particles (RNPs) and adenovirus (AdV) effectively abrogates cell viability in KRAS-mutant Non-Small Cell Lung Cancer (NSCLC) preclinical models, including 2D and 3D cell cultures, cell-derived xenografts (CDX), and patient-derived xenograft organoids (PDXO). Our in vitro studies demonstrate that HiFiCas9-based therapy achieves superior KRAS inhibition compared to Sotorasib and effectively circumvents certain resistance mechanisms associated with Sotorasib treatment. Moreover, in vivo delivery using adenoviral particles significantly suppresses tumor growth in preclinical NSCLC models. Collectively, our findings establish HiFiCas9 as an effective therapeutic strategy with promising clinical applications, especially if in vivo delivery methods are further optimized., P.P.M.'s laboratory is supported by the grants PID2021-126111OB-I00 and PID2024-159252OB-I00, funded by the MCIN/AEI/10.13039/501100011033 and by ERDF ("A way to make Europe"), the Spanish Association Against Cancer (LAB-AECC-2018), the Junta de Andalucia (PI-0203-2022 and PI-0228-2024), and the University of Granada (B-CTS-480-UGR20, C-EXP-051-UGR23, C-CTS-149-UGR23). J.S.-H. is supported by a grant from the Scientific Foundation of the Spanish Association Against Cancer in Granada (#PRDGR21428SANJ). J.C.A.-P. was supported by an MSCA-IF-EF-RI 837897 fellowship (Horizon 2020 Framework Programme). A.M.A. was supported by an FPU17/01258 fellowship. A.A. was supported by an FPU17/00067 fellowship (Spanish Ministry of Science, Innovation, and Universities) and by the Programa de Contratos Puente (Plan Propio 2022) of the University of Granada. M.S.B.-C. was supported by an FPU19/00576 fellowship (Spanish Ministry of Science, Innovation, and Universities). E.J.-L.'s laboratory is funded by the Spanish Association Against Cancer (PROYE18012ROSE), the Instituto de Salud Carlos III (PI22/01221), and CIBERONC (CB16/12/00350). We would like to thank Ms. Rosario Martin from Ecija for her donation to promote research into lung cancer. The authors acknowledge the support of the ROLUCAN Association (Rota Lucha Contra el Cancer) for facilitating this research, and the Ph.D program of Biochemistry and Molecular Biology of the University of Granada.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Ranolazine-mediated attenuation of mechanoelectric feedback in atrial myocyte monolayers

  • Del-Canto, Irene
  • Gómez-Cid, Lidia
  • Hernández-Romero, Ismael
  • Fernández-Santos, María Eugenia
  • Atienza, Felipe
  • Such, Luis
  • Fernández-Avilés, Francisco
  • Chorro, Francisco J.
  • Guillem Sánchez, María Salud|||0000-0001-5660-3693
  • Andreu M. Climent|||0000-0002-7260-8811
[EN] Background Mechanical stretch increases Na(+)inflow into myocytes, related to mechanisms including stretch-activated channels or Na+/H(+)exchanger activation, involving Ca(2+)increase that leads to changes in electrophysiological properties favoring arrhythmia induction. Ranolazine is an antianginal drug with confirmed beneficial effects against cardiac arrhythmias associated with the augmentation ofI(NaL)current and Ca(2+)overload. Objective This study investigates the effects of mechanical stretch on activation patterns in atrial cell monolayers and its pharmacological response to ranolazine. Methods Confluent HL-1 cells were cultured in silicone membrane plates and were stretched to 110% of original length. The characteristics ofin vitrofibrillation (dominant frequency, regularity index, density of phase singularities, rotor meandering, and rotor curvature) were analyzed using optical mapping in order to study the mechanoelectric response to stretch under control conditions and ranolazine action. Results HL-1 cell stretch increased fibrillatory dominant frequency (3.65 +/- 0.69 vs. 4.35 +/- 0.74 Hz,p< 0.01) and activation complexity (1.97 +/- 0.45 vs. 2.66 +/- 0.58 PS/cm(2),p< 0.01) under control conditions. These effects were related to stretch-induced changes affecting the reentrant patterns, comprising a decrease in rotor meandering (0.72 +/- 0.12 vs. 0.62 +/- 0.12 cm/s,p< 0.001) and an increase in wavefront curvature (4.90 +/- 0.42 vs. 5.68 +/- 0.40 rad/cm,p< 0.001). Ranolazine reduced stretch-induced effects, attenuating the activation rate increment (12.8% vs. 19.7%,p< 0.01) and maintaining activation complexity-both parameters being lower during stretch than under control conditions. Moreover, under baseline conditions, ranolazine slowed and regularized the activation patterns (3.04 +/- 0.61 vs. 3.65 +/- 0.69 Hz,p< 0.01). Conclusion Ranolazine attenuates the modifications of activation patterns induced by mechanical stretch in atrial myocyte monolayers., This work was supported by the Instituto de Salud Carlos III-FEDER (Fondo Europeo de Desarrollo Regional) (Grant Nos. CB16/11/00486, CB16/11/00292, PI16/01123, PI17/01059, PI17/01106, PI18/01620, and DTS16/0160) and the Generalitat Valenciana (Grant Nos. PROMETEO/2018/078 and APOSTD/2018/181).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Effects of S-Nitrosoglutathione on Electrophysiological Manifestations of Mechanoelectric Feedback

  • Such-Miquel, Luis
  • Canto Serrano, Irene Del
  • Zarzoso Muñoz, Manuel
  • Brines-Ferrando, L.
  • Soler, C.
  • Parra-Giraldo, G.
  • Alberola, Antonio
  • Such Belenguer, Luis
  • Chorro, F.J.
  • Guill Ibáñez, Antonio|||0000-0001-8546-264X
[EN] Electromechanical coupling studies have described the intervention of nitric oxide and S-nitrosylation processes in Ca2+ release induced by stretch, with heterogeneous findings. On the other hand, ion channel function activated by stretch is influenced by nitric oxide, and concentration-dependent biphasic effects upon several cellular functions have been described. The present study uses isolated and perfused rabbit hearts to investigate the changes in mechanoelectric feedback produced by two different concentrations of the nitric oxide carrier S-nitrosoglutathione. Epicardial multielectrodes were used to record myocardial activation at baseline and during and after left ventricular free wall stretch using an intraventricular device. Three experimental series were studied: (a) control (n=10); (b) S-nitrosoglutathione 10 mu M (n=11); and (c) S-nitrosoglutathione 50 mu M (n=11). The changes in ventricular fibrillation (VF) pattern induced by stretch were analyzed and compared. S-nitrosoglutathione 10 mu M did not modify VF at baseline, but attenuated acceleration of the arrhythmia (15.6 +/- 1.7 vs. 21.3 +/- 3.8Hz; p<0.0001) and reduction of percentile 5 of the activation intervals (42 +/- 3 vs. 38 +/- 4ms; p<0.05) induced by stretch. In contrast, at baseline using the 50 mu M concentration, percentile 5 was shortened (38 +/- 6 vs. 52 +/- 10ms; p<0.005) and the complexity index increased (1.77 +/- 0.18 vs. 1.27 +/- 0.13; p<0.0001). The greatest complexity indices (1.84 +/- 0.17; p<0.05) were obtained during stretch in this series. S-nitrosoglutathione 10 mu M attenuates the effects of mechanoelectric feedback, while at a concentration of 50 mu M the drug alters the baseline VF pattern and accentuates the increase in complexity of the arrhythmia induced by myocardial stretch., Carlos III Health Institute/FEDER funds (Spanish Ministry of Economy and Competitiveness): Grants FIS PI12/00407, PI15/01408, PIE15/00013, and RETIC “RIC” RD12/0042/0048. Generalitat Valenciana: Grant PROMETEO FASE II 2014/037.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

EpCAM and microvascular obstruction in patients with STEMI: a cardiac magnetic resonance study

  • Ríos-Navarro, César
  • Núñez, Julio
  • Revuelta-López, Elena
  • Monmeneu, José V.
  • López-Lereu, Maria P.
  • de Dios, Elena
  • Pérez-Solé, Nerea
  • Vila, José M.
  • Oltra, Ricardo
  • Chorro, Francisco J.
  • Bayés-Genís, Antonio
  • Bodi, Vicente
  • Gavara-Doñate, Josep|||0000-0002-3483-7066
[EN] Introduction and objectives: Microvascular obstruction (MVO) is negatively associated with cardiac structure and worse prognosis after ST-segment elevation myocardial infarction (STEMI). Epithelial cell adhesion molecule (EpCAM), involved in epithelium adhesion, is an understudied area in the MVO setting. We aimed to determine whether EpCAM is associated with the appearance of cardiac magnetic resonance (CMR)-derived MVO and long-term systolic function in reperfused STEMI. Methods: We prospectively included 106 patients with a first STEMI treated with percutaneous coronary intervention, quantifying serum levels of EpCAM 24 hours postreperfusion. All patients underwent CMR imaging 1 week and 6 months post-STEMI. The independent correlation of EpCAM with MVO, systolic volume indices, and left ventricular ejection fraction was evaluated. Results: The mean age of the sample was 59 +/- 13 years and 76% were male. Patients were dichotomized according to median EpCAM (4.48 pg/mL). At 1-week CMR, lower EpCAM was related to extensive MVO (P = .021) and larger infarct size (P = .019). At presentation, EpCAM values were significantly associated with the presence of MVO in univariate (OR, 0.58; 95%CI, 0.38-0.88; P = .011) and multivariate logistic regression models (OR, 0.55; 95%CI, 0.35-0.87; P= .010). Although MVO tends to resolve at chronic phases, decreased EpCAM was associated with worse systolic function: reduced left ventricular ejection fraction (P = .009) and higher left ventricular end-systolic volume (P = .043). Conclusions: EpCAM is associated with the occurrence of CMR-derived MVO at acute phases and long term adverse ventricular remodeling post-STEMI. (C) 2021 Published by Elsevier Espana, S.L.U. on behalf of Sociedad Espanola de Cardiologia., [ES] Introducción y objetivos La obstrucción microvascular (OMV) se asocia negativamente con la estructura cardiaca y el pronóstico de los pacientes tras un infarto agudo de miocardio con elevación del segmento ST (IAMCEST). El factor epithelial cell adhesion molecule (EpCAM), implicado en la cohesión de las células epiteliales, está poco estudiado en el contexto de la OMV. Por ello, el objetivo de este estudio es evaluar en una cohorte de pacientes con IAMCEST la asociación entre la concentración de EpCAM circulante con la extensión de la OMV, determinada por resonancia magnética cardiaca (RMC), y la función sistólica en fases crónicas. Métodos Se incluyó prospectivamente a 106 pacientes con un primer IAMCEST tratados con angioplastia primaria percutánea. La concentración sérica de EpCAM se determinó 24 h tras la reperfusión coronaria. Se estudió a todos los pacientes mediante RMC a la semana y a los 6 meses del IAMCEST. Se evaluó la correlación entre los valores de EpCAM circulante con la OMV, los índices de función sistólica y la fracción de eyección del ventrículo izquierdo. Resultados La media de edad de la cohorte era 59 ± 13 años y el 76% eran varones. Se dicotomizó a los pacientes según la mediana de EpCAM (4,48 pg/ml). Se observó que los pacientes que tenían valores más bajos de EpCAM presentaban una mayor extensión de la OMV (p = 0,021) y un mayor tamaño de infarto (p = 0,019) en los estudios de RMC realizados 1 semana después del evento cardiovascular. Respecto a las variables de presentación, la concentración de EpCAM se asoció significativamente con la presencia de OMV en análisis de regresión logística binaria univariable (OR = 0,58; IC95%, 0,38-0,88; p = 0,011) y multivariable (OR = 0,55; IC95%, 0,35-0,87; p = 0,010). A pesar de que la OMV tiende a resolverse espontáneamente en fases crónicas, unos valores más bajos de EpCAM se correlacionaron con una peor función sistólica: fracción de eyección del ventrículo izquierdo deprimida (p = 0,009) y mayor volumen telesistólico del ventrículo izquierdo (p = 0,043). Conclusiones Tras un IAMCEST, la concentración de EpCAM circulante en fase aguda se asocia con la extensión de la OMV evaluada mediante RMC y con un peor remodelado ventricular en fase crónica., This study was funded by Instituto de Salud Carlos III and Fondos Europeos de Desarrollo Regional FEDER [research grants PI17/01836, PI20/00637 and CIBERCV16/11/00486, and a postgraduate contract FI18/00320 to C. Rios-Navarro].
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Involvement of microRNAs-449/FASN axis in response to trastuzumab therapy in HER2-positive breast cancer

  • Lameirinhas, Ana
  • Torres-Ruiz, Sandra
  • Garrido-Cano, Iris
  • Hernando, Cristina
  • Martínez, Maria Teresa
  • Rovira, Ana
  • Albanell, Joan
  • Zazo, Sandra
  • Rojo, Federico
  • Bermejo, Begoña
  • Lluch, Ana
  • Cejalvo, Juan Miguel
  • Tormo, Eduardo
  • Eroles, Pilar
[EN] The anti-HER2 monoclonal antibody trastuzumab and new derivative formulations are the standard treatment for HER2-positive breast cancer. However, after 1 to 5 years of treatment, some patients acquire resistance to therapy, leading to relapse. The microRNA-449 family members were downregulated in HER2-positive breast cancer cell lines and low levels were associated with patients' worse prognosis. Moreover, trastuzumab-resistant HER2-positive breast cancer cell lines showed lower microRNAs-449 and higher Fatty Acid Synthase (FASN) expression, compared to sensitive cell lines. The direct regulation of FASN by microRNA-449a and microRNA-449b-5p was demonstrated. Moreover, microRNAs-449 overexpression and FASN inhibition decreased cell proliferation and sensitized cells to trastuzumab treatment by inhibiting the PI3K/AKT signaling pathway. Together, these results suggest the microRNAs-449/FASN axis as a potential therapeutic target in combination with anti-HER2 agents to overcome trastuzumab resistance and to improve treatment response in HER2-positive breast cancer patients., This work was supported by the Spanish Government and cofinanced by FEDER Funds (AES Program, grants PI21/01351, PI21/00002, PI21/00142; CIBERONC, Biomedical Research Networking Centre for Cancer CB16/12/00241 and CB16/12/00481). AL was founded by Asociacion Espanola Contra el Cancer (PRDVA19016LAME). STR was founded by Conselleria d'Educacio, Investigacio, Cultura iEsport, Generalitat Valenciana (ACIF/2019/119). IGC was founded by Margarita Salas postdoctoral grant (European Union-Next generation EU). JMC was founded by Sociedad Espanola de Oncologia Medica (Rio Hortega-SEOM).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

A Sonic Hedgehog Pathway Score to Predict the Outcome of Resected Non-Small Cell Lung Cancer Patients

  • Herreros-Pomares, Alejandro|||0000-0003-3838-097X
  • Jantus-Lewintre, Eloisa|||0000-0001-7395-4380
  • Doria, Paula
  • Gallach, Sandra
  • Meri-Abad, Marina
  • Guijarro, Ricardo
  • Calabuig-Fariñas, Silvia
  • Camps, Carlos
[EN] Background Mutations and deregulations in components of the Hedgehog (Hh) pathway have been associated with cancer onset and tumor growth in different malignancies, but their role in non-small cell lung cancer (NSCLC) remains unclear. This study aims to investigate the expression pattern of the main components of the Hh pathway in tumor and adjacent normal tissue biopsies of resected NSCLC patients. Methods The relative expression of GLI1, PTCH1, SHH, and SMO was analyzed by quantitative polymerase chain reaction (PCR) in a cohort of 245 NSCLC patients. Results were validated in an independent cohort of NSCLC patients from The Cancer Genome Atlas (TCGA). Results We found that SMO and GLI1 were overexpressed in the tumor compared with normal-paired tissue, whereas PTCH1 and SHH were underexpressed. In addition, patients with higher expression levels of PTCH1 presented better outcomes. A gene expression score, called the Hedgehog Score, was calculated using a multivariable model including analyzed components of the Hh signaling pathway. NSCLC patients with a high Hedgehog Score had significantly shorter relapse-free survival (RFS) and overall survival (OS) than patients with a low score, especially at stage I of the disease. Similarly, patients in the adenocarcinoma (ADC) subcohort had shorter RFS and OS. Multivariate Cox analysis exhibited that the Hedgehog Score is an independent prognostic biomarker for OS in both the entire training cohort and the ADC subcohort. The Hedgehog Score was validated in an independent cohort of NSCLC patients from TCGA, which confirmed its prognostic value. Conclusions Our results provide relevant prognostic data for NSCLC patients and support further studies on the Hh pathway., This work was supported by grant no. CB16/12/00350 from the Centro de Investigacion Biomedica en Red de Cancer (CIBEROnc) and Grant No. PI18/00266 from the Instituto de Salud Carlos III (ISCIII).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Oral microbiome in Proliferative Verrucous Leukoplakia exhibits loss of diversity and enrichment of pathogens

  • Herreros-Pomares, Alejandro|||0000-0003-3838-097X
  • Jantus-Lewintre, Eloisa|||0000-0001-7395-4380
  • Llorens, Carlos
  • Soriano, Beatriz
  • Zhang, Feiyu
  • Gallach, Sandra
  • Bagán, Leticia
  • Murillo, Judith
  • Bagan, José
[EN] Objectives: Oral microbiome plays an important role in oral diseases. Among them, proliferative verrucous leucoplakia (PVL) is an uncommon form of progressive multifocal leukoplakia with a worryingly rate of malignant transformation. Here, we aimed to characterize the oral microbiome of PVL patients and compare it with those of healthy controls. Material and methods: Oral biopsies from ten PVL patients and five healthy individuals were obtained and used to compare their microbial communities. The sequence of the V3-V4 region of 16S rRNA gene was used as the taxonomic basis to estimate and analyze the composition and diversity of bacterial populations present in the samples. Results: Our results show that the oral microbial composition and diversity are significantly different among PVL patients and healthy donors. The average number of observed operational taxonomic units (OTUs) was higher for healthy donors than for PVL, proving a loss of diversity in PVL. Several OTUs were found to be more abundant in either group. Among those that were significantly enriched in PVL patients, potential protumorigenic pathogens like Oribacterium sp. oral taxon 108, Campylobacter jejuni, uncultured Eubacterium sp., Tannerella, and Porphyromonas were identified. Conclusion: Oral microbiome dysbiosis was found in patients suffering from PVL. To the best of our knowledge, this is the first study investigating the oral microbiome alterations in PVL and, due to the limited number of participants, additional studies are needed. Oral microbiota-based biomarkers may be helpful in predicting the risks for the development of PVL., This work was supported by PI19/00790 from Fondo de Inves-tigacion Sanitaria, ISCIII (PI: Jose Bagan) , CB16/12/00350 from CIBERONC and IDI-2020-133875-a from MICINN.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Plasma fibroblast activation protein is decreased in acute heart failure despite cardiac tissue upregulation

  • Delgado-Arija, Marta
  • Genovés, Patricia
  • Pérez-Carrillo, Lorena
  • González-Torrent, Irene
  • Giménez-Escamilla, Isaac
  • Martínez-Dolz, Luis
  • Portolés, Manuel
  • Tarazón, Estefanía
  • Roselló-Lletí, Esther
[EN] Background Cardiac fibroblast activation protein (FAP) has an emerging role in heart failure (HF). A paradoxical reduction in its levels in pathological conditions associated with acute processes has been observed. We aimed to identify FAP cardiac tissue expression and its relationship with the main cardiac fibrosis-related signaling pathways, and to compare plasma FAP levels in acute and chronic HF patients. Methods Transcriptomic changes were assessed via mRNA/ncRNA-seq in left ventricle tissue from HF patients (n¿=¿57) and controls (n¿=¿10). Western blotting and immunohistochemistry were used to explore FAP protein levels and localization in cardiac tissue. ELISA was performed to examine plasma FAP levels in acute HF (n¿=¿48), chronic HF (n¿=¿15) and control samples (n¿=¿7). Results FAP overexpression in cardiac tissue is related to the expression of molecules directly involved in cardiac fibrosis, such as POSTN, THBS4, MFAP5, COL1A2 and COL3A1 (P¿<¿0.001), and is directly and inversely related to pro- and antifibrotic microRNAs, respectively. The observed FAP overexpression is not reflected in plasma. Circulating FAP levels were lower in acute HF patients than in controls (P¿<¿0.05), while chronic HF patients did not show significant changes. The clinical variables analyzed, such as functional class or etiology, do not affect plasma FAP concentrations. Conclusions We determined that in HF cardiac tissue, FAP is related to the main cardiac fibrosis signaling pathways as well as to pro- and antifibrotic microRNAs. Additionally, an acute phase of HF decreases plasma FAP levels despite the upregulation observed in cardiac tissue and regardless of other clinical conditions., This work was supported by the National Institute of Health Fondo de Investigaciones Sanitarias del Instituto de Salud Carlos III [Projects: PI20/01469 and PI20/00071 co-funded by European Union; Miguel Servet contracts: CP18/00145 co-funded by European Union, European Social Fund (ESF) The ESF invests in your future and CP21/00041 co-funded by European Union; contract FI21/00186 and FI21/00034]; Consorcio Centro de Investi&#8209; gación Biomédica en Red [CIBERCV, under Grant CB16/11/00261]; Ministry of Universities and the European Recovery, Transformation and Resilience Plan (PRTR, Next Generation EU) [ Ayuda Margarita Salas para la formación de jóvenes doctores : contract: MS21-162]; Ministry of Science and Innovation (MCIN, 10.13039/501100011033) and State Investigation Agency (AEI) [Project CNS2022-135769] co-funded by European Union Next Generation EU and PRTR; Conselleria de educación, universidades y empleo [Project CIA&#8209; ICO/2022/246, contract CIACIF/2022/429].
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Contribución de congreso (ConferenceOutput)

Developing experimental design and analysis skills in Biomedical Engineering. A laboratory experiment proposal

  • Del-Canto, Irene
  • Morales-Tatay, José Manuel
  • Moratal, David|||0000-0002-2825-3646
[EN] Learning-teaching process in the area of Biomedical Engineering requires the acquisition of skills related to the formulation and resolution of problems in biology and medicine through the use of innovative technologies, and the ability to effectively use biomedical instrumentation and the processing and analyzing methods for studying the complex systems and processes of the human body. In order to deepen the acquisition of some omics-related disciplines, the objective of the present work is the development of a laboratory experiment in the field of molecular imaging, whose purpose is the metabolomic study (acquisition and data processing) of biological samples by Nuclear Magnetic Resonance (NMR) spectroscopy. The proposed laboratory experiment is carried out in groups of 15 students and it is structured in two different sessions. The first session is held at the facilities of the Molecular and Metabolomic Imaging Laboratory of the Unitat Central d¿Investigació de Medicina of University of Valencia, and during the session each student performs the sample collection and treatment of their own biological sample (urine), whose metabolomic study is desired, following the appropriate laboratory protocol. After preparation, the acquisition of the NMR spectra corresponding to each of the samples is carried out. All students introduce their samples into the NMR spectrometer and observe the different phases of the acquisition process (frequency tuning and matching, sequence specification, pulse calculation, etc.) to obtain the NMR spectrum. In the second session, which takes place in a computer classroom of the Universitat Politècnica de València, the purpose is the use of different methods of analysis and observation to identify and quantify the metabolites from the NMR spectra acquired during the first session. Firstly, signal processing techniques are used to process the NMR spectra (phase correction, baseline correction and spectrum reference), and then a total of 10 selected metabolites contained in the urine are quantified, using specific software for its application to the field of metabolomics. Finally, the students create a table that collects the data of the subjects (themselves, anonimized) and metabolite concentration, and perform the multivariate statistical analysis: principal component analysis (PCA) and partial least squares discriminant analysis (PLSDA). Through the performed analysis, each student establishes one metabolic profile and obtains conclusions from it, such as the determination of a characteristic metabolomic fingerprint associated with variables such as the sex of the person providing the sample, or the determination of a smoker profile, among others. Through the completion of the proposed laboratory experiment, students will acquire general and specific outcomes in the Biomedical Engineering field: 1) implementation and management of adequate experiments (preparation of biological samples), 2) use of innovative technologies (process of acquisition of NMR spectra), 3) application of scientific methods to perform the analysis of data (signal processing), 4) selection and performance of observation methods (statistical analysis) to assess the results and build conclusions, 5) to carry out a simple metabolic study that allows to verify the metabolic impact of some variable as smoking, and 6) to propose new working hypotheses based on the results obtained and expected results., This work was supported by Conselleria d¿Educació of Generalitat Valenciana [grants number GV/2018/111 and APOSTD/2018/181] and Instituto de Salud Carlos III-FEDER (Fondo Europeo de Desarrollo Regional) [grant number CB16/11/00486].
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Chamber-Specific Structural, Fibrotic, and Molecular Remodeling of the Heart in Experimental Metabolic Syndrome

  • Arias-Mutis, Oscar J.
  • Bizy, Alexandra
  • Genoves, Patricia
  • Ortiz-Guzman, Johan E.
  • Lucia-Garcia, Antonio
  • Ruiz-Sauri, Amparo
  • Rios-Navarro, César
  • Such-Miquel, Luis
  • Alberola, Antonio
  • Chorro, Francisco J.
  • Zarzoso, Manuel
  • Calvo Saiz, Conrado Javier
[EN] Metabolic syndrome (MetS) drives cardiac remodeling and fibrosis, contributing to diastolic dysfunction and heart failure with preserved ejection fraction, but chamber-specific mechanisms remain poorly defined. New Zealand White rabbits were fed a high-fat/high-sucrose diet for 28 weeks to induce experimental MetS. Systemic phenotype, cardiac structure (echocardiography), myocardial fibrosis (Picrosirius red histology), myosin/collagen gene expression (qRT-PCR), and chamber-specific proteomics were assessed across left/right atria and ventricles. The model reproduced central obesity, glucose intolerance, dyslipidemia, and mild hypertension, with concentric left ventricular hypertrophy and selective ventricular fibrosis, as follows: increased collagen in left ventricle (LV) and right ventricle (RV), unchanged in atria. Ventricular alpha-myosin heavy-chain gene expression was upregulated, while collagen I and alpha-smooth muscle actin transcripts showed ventricular-specific downregulation. Proteomics revealed atrial metabolic and cytoskeletal adaptations with minimal extracellular matrix involvement; ventricles displayed early profibrotic cues (galectin-3 in LV), metabolic inefficiency (impaired glycolysis/ATP production in LV; lipid oxidation shift in RV), and diminished provisional matrix support. Conclusions: concentric LV hypertrophy and great vessel enlargement occurred without systolic/diastolic dysfunction; ventricular-selective fibrosis, alpha-myosin heavy-chain upregulation, type I collagen/alpha-smooth muscle actin downregulation, and chamber-specific proteomic changes showed atrial adaptation versus ventricular early profibrotic/metabolic inefficiency., This research was funded by Generalitat Valenciana (GV2015-062 and CIAICO/2023/013) to M.Z. and Instituto de Salud Carlos III (CB16/11/00486, PI21/01984) to F.J.C. and M.Z.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Performance assessment of electrode configurations for the estimation of omnipolar electrograms from high density arrays

  • Castells, Francisco|||0000-0001-5044-3545
  • Millet Roig, José|||0000-0002-8879-003X
  • Ruiperez-Campillo, Samuel
  • Segarra, Izan
  • Cervigon, Raquel
  • Casado-Arroyo, Rubén
  • Merino, José Luis
[EN] Objective: The aim of this study is to propose a method to reduce the sensitivity of the estimated omnipolar electrogram (oEGM) with respect to the angle of the propagation wavefront. Methods: A novel configuration of cliques taking into account all four electrodes of a squared cell is proposed. To test this approach, simulations of HD grids of cardiac activations at different propagation angles, conduction velocities, interelectrode distance and electrogram waveforms are considered. Results: The proposed approach successfully provided narrower loops (essentially a straight line) of the electrical field described by the bipole pair with respect to the conventional approach. Estimation of the direction of propagation was improved. Additionally, estimated oEGMs presented larger amplitude, and estimations of the local activation times were more accurate. Conclusions: A novel method to improve the estimation of oEGMs in HD grid of electrodes is proposed. This approach is superior to the existing methods and avoids pitfalls not yet resolved., This work was supported by PID2019-109547RB-I00 (National Research Program, Ministerio de Ciencia e Innovacion, Spanish Government) and CIacBERCV CB16/11/00486 (Instituto de Salud Carlos III). We would like express our gratitute to the Rafael del Pino Foundation and La Caixa Foundation for the support and contribution to the academic training of one first author of the manuscript (S. Ruiperez-Campillo).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Characterization of Circulating T Cell Receptor Repertoire Provides Information about Clinical Outcome after PD-1 Blockade in Advanced Non-Small Cell Lung Cancer Patients

  • Dong, Ning
  • Moreno-Manuel, Andrea
  • Calabuig-Fariñas, Silvia
  • Gallach, Sandra
  • Zhang, Feiyu
  • Blasco, Ana
  • Aparisi, Francisco
  • Meri-Abad, Marina
  • Guijarro, Ricardo
  • Camps, Carlos
  • Sirera Pérez, Rafael|||0000-0001-9162-8490
  • Jantus-Lewintre, Eloisa|||0000-0001-7395-4380
[EN] Despite the success of immunotherapies in lung cancer, development of new biomarkers for patient selection is urgently needed. This study aims to explore minimally invasive approaches to characterize circulating T cell receptor beta chain (TCR-ß) repertoire in a cohort of advanced non-small cell lung cancer (NSCLC) patients treated with first-line pembrolizumab. Peripheral blood samples were obtained at two time points: i) pretreatment (PRE) and ii) first response assessment (FR). Next-generation sequencing (NGS) was used to analyze the hypervariable complementary determining region 3 (CDR3) of TCR-ß chain. Richness, evenness, convergence, and Jaccard similarity indexes plus variable (V) and joining (J)-gene usage were studied. Our results revealed that increased richness during treatment was associated with durable clinical benefit (DCB; p = 0.046), longer progression-free survival (PFS; p = 0.007) and overall survival (OS; p = 0.05). Patients with Jaccard similarity index ¿0.0605 between PRE and FR samples showed improved PFS (p = 0.021). Higher TRBV20-1 PRE usage was associated with DCB (p = 0.027). TRBV20-1 levels ¿9.14% in PRE and ¿9.02% in FR significantly increased PFS (p = 0.025 and p = 0.016) and OS (p = 0.035 and p = 0.018). Overall, analysis of circulating TCR-ß repertoire may provide information about the immune response in anti-PD-1 treated NSCLC patients; in this scenario, it can also offer important information about the clinical outcome., This research was funded by Centro de Investigacion Biomedica en Red de Cancer, grant number CB16-12-00350, and Instituto de Salud Carlos III, grant number PI18/00266.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Prediction of Left Ventricular Thrombus After Myocardial Infarction: A Cardiac Magnetic Resonance-Based Prospective Registry

  • Bertolín-Boronat, Carlos
  • Marcos-Garcés, Víctor
  • Merenciano-Gonzalez, Héctor
  • Perez, Nerea
  • Pérez del Villar, Candelas
  • Lopez-Lereu, Maria P.
  • Monmeneu, Jose V.
  • Herrera Flores, Cristian
  • Domenech-Ximenos, Blanca
  • Lopez Fornas, F
  • Rios-Navarro, César
  • De Dios, Elena
  • Ortiz-Perez, Jose T.
  • Gavara-Doñate, Josep|||0000-0002-3483-7066
  • Moratal, David|||0000-0002-2825-3646
[EN] Background: Left ventricular thrombus (LVTh) is a severe complication after ST-segment elevation myocardial infarction (STEMI). Objectives: We aim to predict LVTh occurrence by cardiac magnetic resonance (CMR) using clinical, echocardiographic, and electrocardiographic (ECG) variables readily available at admission. Methods: We included 590 reperfused STEMI patients who underwent early (1-week) and/or late (6-month) CMR in our institution. Baseline clinical, echocardiographic (left ventricular ejection fraction -LVEF-) and ECG data (summatory of ST-segment elevation -sum-STE- and Q-wave and residual ST-elevation >1 mm -Q-STE-) during admission were registered. Multivariate binary logistic regression models and receiver operating characteristic curves were computed for LVTh prediction. Results: LVTh was detected by CMR in 43 (7.3 %) patients and was predicted by previous chronic coronary syndrome (CCS, HR 4.74 [1.82-12.35], p = 0.001), anterior STEMI (HR 10.93 [2.47-48.31], p = 0.002), LVEF (HR 0.96 [0.93-0.99] per %, p = 0.008), maximum sum-STE (HR 1.04 [1.01-1.07] per mm, p = 0.04), and Q-STE (HR 1.31 [1.08-1.6] per lead, p = 0.008). High-risk patients with both major (anterior STEMI and Q-STE in >= 1 leads) and 1-3 minor (CCS, maximum sum-STE >10 mm, LVEF <50%) factors showed the highest LVTh risk (19.6 % within 6 months). The model showed excellent discrimination ability (area under the curve=0.85 [0.81-0.9], p < 0.001). Simplified 4-variable (excluding sum-STE) and 3-variable (also excluding CCS) risk scores showed similar discrimination ability and were externally validated. Conclusions: LVTh within 6 months post-STEMI can be predicted using pre-discharge clinical (anterior infarction and CCS), echocardiographic (LVEF), and ECG (sum-STE and Q-STE) data. Our results can help select patients who should undergo CMR after STEMI for LVTh detection., This work was supported by Instituto de Salud Carlos III, Fondos Europeos de Desarrollo Regional FEDER and Fondo Social Europeo Plus (FSE+) (grant numbers PI20/00637, PI23/01150, CIBERCV16/11/00486, CIBERCV16/11/00420, CIBERCV16/11/00479, CIBERCV16/11/00292 and postgraduate contracts CM21/00175, CM23/00246 and CM23/00238) and by Conselleria de Innovacion, Universidades, Ciencia y Sociedad Digital of the Generalitat Valenciana (PROMETEO/2021/008).Dr. Marcos-Garces acknowledges funding from the Instituto de Salud Carlos III and co-funding from Fondo Social Europeo Plus (FSE+) (grant JR23/00032), as well as a GE 2023 grant from the Conselleria de Innovacion, Universidades, Ciencia y Sociedad Digital of the Generalitat Valenciana (CIGE/2022/26).Dr. Gavara has received financial support from the Agencia Estatal de Investigacion (grant FJC2020-043981-I/AEI/10.13039/501100011033).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

EGM analyzer: A modular software platform for visualization and analysis of cardiac electrograms

  • Elisa
  • Raúl
  • Castells, Francisco|||0000-0001-5044-3545
  • Millet Roig, José|||0000-0002-8879-003X
  • Ruiperez-Campillo, Samuel
  • Cervigon, Raquel
[EN] Background and Objectives: The analysis of intracardiac electrograms (EGMs) is crucial for understanding the electrophysiological mechanisms underlying cardiac arrhythmias. However, the diversity of mapping systems and data formats poses challenges for data integration, visualization, and the comparison of electrophysiological biomarkers. In this work, we develop a modular and extensible software platform for the visualization, analysis, and comparison of intracardiac electrograms and related biomarkers in both research and clinical contexts. Methods: A custom software tool was developed with an interactive graphical user interface (GUI) capable of loading, processing, and visualizing cardiac mapping data. The platform supports three-dimensional (3D) representations of cardiac geometries and allows users to display multiple biomarkers including peak-to-peak amplitude, local activation times (LATs), ablation points, and other derived metrics. The tool enables the visual ization of unipolar and bipolar electrograms, as well as the computation of omnipolar signals. The open-source software is made available. Results: The platform provides a unified environment for handling heterogeneous electrophysiological data. Users can visualize cardiac geometries, overlay various signal-derived maps, and interactively inspect local elec trograms. The modular design enables the integration of new biomarkers and analytical methods with minimal effort, facilitating both clinical interpretation and research development. Conclusions: This software bridges a key gap in electrophysiological data analysis by enabling consistent visual ization and comparison of intracardiac signals across datasets and biomarkers. Its modular and extensible design supports ongoing research in cardiac electrophysiology and provides clinicians with an intuitive environment for multimodal analysis., This work has been supported by PID2022-142514OB-I00 (National Research Program, Ministerio de Ciencia e Innovacion, Spanish Government) , CIBERCV CB16/11/00486 (Instituto de Salud Carlos III, Spain) and FPU22/02462 (Ministerio de Ciencia e Innovacion, Spanish Government) .
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Incidence, Outcomes, and Predictors of Ventricular Thrombus after Reperfused ST-Segment-Elevation Myocardial Infarction by Using Sequential Cardiac MR Imaging

  • Cambronero-Cortinas, E.
  • Bonanad, C.
  • Monmeneu, J.V.
  • López-Lereu, M.P.
  • De Dios, E.
  • Rios, C.
  • Perez, N.
  • Racugno, P.
  • Paya, A.
  • Escribano, D.
  • Minana, G.
  • Pellicer, M.
  • Cànoves, J.
  • Nunez, J.
  • Chorro, F.J.
  • Bodi, V.
  • Gavara-Doñate, Josep|||0000-0002-3483-7066
  • Moratal, David|||0000-0002-2825-3646
[EN] Purpose: To characterize the incidence, outcomes, and predictors of left ventricular (LV) thrombus by using sequential cardiac magnetic resonance (MR) imaging after ST-segment-elevation myocardial infarction (STEMI). Materials and Methods: Written informed consent was obtained from all patients, and the study protocol was approved by the committee on human research. In a cohort of 772 patients with STEMI, 392 (mean age, 58 years; range, 24-89 years) were retrospectively selected who were studied with cardiac MR imaging at 1 week and 6 months. Cardiac MR imaging guided the initiation and withdrawal of anticoagulants. Patients with LV thrombus at 6 months were restudied at 1 year. For predicting the occurrence of LV thrombus, a multiple regression model was applied. Results: LV thrombus was detected in 27 of 392 patients (7%): 18 (5%) at 1 week and nine (2%) at 6 months. LV thrombus resolved in 22 of 25 patients (88%) restudied within the first year. During a mean follow-up of 181 weeks 6 168, patients with LV thrombus displayed a very low rate of stroke (0%), peripheral embolism (0%), and severe hemorrhage (n = 1, 3.7%). LV ejection fraction (LVEF) less than 50% (P < .001) and anterior infarction (P = .008) independently helped predict LV thrombus. The incidence of LV thrombus was as follows: (a) nonanterior infarction, LVEF 50% or greater (one of 135, 1%); (b) nonanterior infarction, LVEF less than 50% (one of 50, 2%); (c) anterior infarction, LVEF 50% or greater (two of 92, 2%); and (d) anterior infarction, LVEF less than 50% (23 of 115, 20%) (P < .001 for the trend). Conclusion: Cardiac MR imaging contributes information for the diagnosis and therapy of LV thrombus after STEMI. Patients with simultaneous anterior infarction and LVEF less than 50% are at highest risk. (C) RSNA, 2017, Study supported by Instituto de Salud Carlos III and FEDER (CB16/11/00486, PI14/00271, PIE15/00013) and Generalitat Valenciana (PROMETEO/2013/007).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Stress cardiac magnetic resonance for mortality prediction and decision-making: registry of 2496 elderly patients with chronic coronary syndrome, Resonancia magnética cardiaca de estrés para predecir mortalidad y toma de decisiones: registro de 2.496 pacientes mayores con síndrome coronario crónico

  • Gabaldón-Pérez, Ana
  • Bonanad, Clara
  • García-Blas, Sergio
  • Ríos-Navarro, César
  • Pérez-Solé, Nerea
  • de Dios, Elena
  • Marcos-Garcés, Víctor
  • Merenciano-González, Hector
  • Monmeneu, José V.
  • López-Lereu, María P.
  • Núñez, Julio
  • Chorro, Francisco J.
  • Bodí, Vicente
  • Gavara-Doñate, Josep|||0000-0002-3483-7066
[ES] Introducción y objetivos: El tratamiento del paciente mayor con síndrome coronario crónico (SCC) es un reto. Se exploró el valor pronóstico y la utilidad para la toma de decisiones de la carga isquémica determinada mediante resonancia magnética cardiaca (RMC) de estrés con vasodilatador en pacientes mayores con SCC. Métodos: Se incluyo¿ a 2.496 pacientes mayores de 70 años estudiados con una RMC de estrés con vasodilatador por SCC conocido o sospechado. La carga isquémica (número de segmentos con déficit de perfusión inducido por el estrés) se calculo¿ siguiendo el modelo de 17 segmentos. Posteriormente se analizó de manera retrospectiva su asociación con la mortalidad por cualquier causa y el efecto de la revascularización guiada por la RMC. Resultados: Durante una mediana de seguimiento de 4,58 años, se registraron 430 muertes (17,2%). Una mayor carga isquémica fue un predictor independiente de mortalidad: razón de riesgos, 1,04; intervalos de confianza del 95%, 1,01-1,07 por cada segmento adicional isquémico; p = 0,006). Esta asociación también ocurrió en los mayores de 80 años y en las mujeres (p < 0,001). Se detectó una interacción entre la revascularización y la mortalidad hacia un efecto deletéreo a baja carga isquémica y un efecto protector en caso de isquemia grave., [EN] Introduction and objectives: The management of elderly patients with chronic coronary syndrome (CCS) is challenging. We explored the prognostic value and usefulness for decision-making of ischemic burden determined by vasodilator stress cardiac magnetic resonance (CMR) imaging in elderly patients with known or suspected CCS. Methods: The study group comprised 2496 patients older than 70 years who underwent vasodilator stress CMR for known or suspected CCS. The ischemic burden (number of segments with stress-induced perfusion deficit) was calculated following the 17-segment model. Subsequently, we retrospectively analyzed its association with all-cause mortality and the effect of CMR-guided revascularization. Results: During a median follow-up of 4.58 years, there were 430 deaths (17.2%). A higher ischemic burden was an independent predictor of mortality (HR, 1.04; 95%CI, 1.01-1.07 for each additional ischemic segment; P = .006). This association was also found in patients older than 80 years and in women (P < .001). An interaction between revascularization and mortality was detected toward deleterious consequences at low ischemic burden and a protective effect in patients with extensive ischemia. Conclusions: Vasodilator stress CMR is a valuable tool to stratify risk in elderly patients with CCS and might be helpful to guide decision-making in this scenario., This study has been jointly funded by the Instituto de Salud Carlos III, the Fondo Europeo de Desarrollo Regional (FEDER) and the Sociedad Espanola de Cardiologia and Fundacion Espanola del Corazon [References: PI17/01836, CIBERCV16/11/00486 and SEC/FEC-INV-CLI 21/024].
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Exercise ECG Testing and Stress Cardiac Magnetic Resonance for Risk Prediction in Patients With Chronic Coronary Syndrome

  • Marcos-Garces, Victor
  • Merenciano-Gonzalez, Héctor
  • Gabaldon-Perez, Ana
  • Nuñez-Marin, Gonzalo
  • Lorenzo-Hernandez, Miguel
  • Pérez, Nerea
  • Rios-Navarro, César
  • De Dios, Elena
  • Bonanad, Clara
  • Racugno, Paolo
  • Lopez-Lereu, Maria Pilar
  • Monmeneu, Jose Vicente
  • Chorro, Francisco Javier
  • Bodi, Vicente
  • Gavara-Doñate, Josep|||0000-0002-3483-7066
[EN] Purpose: Vasodilator stress cardiac magnetic resonance (VS-CMR) has become crucial in the workup of patients with known or suspected chronic coronary syndrome (CCS). Whether traditional exercise ECG testing (ExECG) contributes prognostic information beyond VS-CMR is unclear. Methods: We retrospectively included 288 patients with known or suspected CCS who had undergone ExECG and subsequent VS-CMR in our institution. Clinical, ExECG, and VS-CMR variables were recorded. We defined the serious adverse events (SAE) as a combined endpoint of acute coronary syndrome, admission for heart failure, or all-cause death. Results: During a mean follow-up of 4.2 +/- 2.15 yr, we registered 27 SAE (15 admissions for acute coronary syndrome, eight admissions for heart failure, and four all-cause deaths). Once adjusted for clinical, ExECG, and VS-CMR parameters associated with SAE, the only independent predictors were HRmax in ExECG (HR = 0.98: 95% CI, 0.96-0.99; P = .01) and more extensive stress-induced perfusion defects (PDs, number of segments) in VS-CMR (HR = 1.19: 95% CI, 1.07-1.34; P < .01). Adding HRmax significantly improved the predictive power of the multivariable model for SAE, including PDs (continuous reclassification improvement index: 0.47: 95% CI, 0.10-0.81; P < .05). The annualized SAE rate was 1% (if PD < 2 segments and HRmax > 130 bpm), 2% (if PD < 2 segments and HRmax <= 130 bpm), 3.2% (if PD >= 2 segments and HRmax > 130 bpm), and 6.3% (if PD >= 2 segments and HRmax <= 130 bpm), P < .01, for the trend. In patients on beta-blocker therapy, however, only PDs in VS-CMR, but not HRmax, predicted SAE. Conclusions: We conclude that ExECG contributes significantly to prognostic information beyond VS-CMR in patients with known or suspected CCS., This study was funded by "Instituto de Salud Carlos III" and "Fondos Europeos de Desarrollo Regional FEDER" (PIE15/00013, PI17/01836, PI20/00637, and CIBERCV16/11/00486 grants) and by Generalitat Valenciana (GV/2018/116 grant).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Adult Neural Stem Cell Migration Is Impaired in a Mouse Model of Alzheimer&apos, s Disease

  • Esteve, Daniel
  • Molina-Navarro, María Micaela
  • Martínez-Varea, Noelia
  • Blanco-Gandia, Mari Carmen
  • Rodríguez-Arias, Marta
  • García-Verdugo, Jose Manuel
  • Viña, José
  • Lloret, Ana
  • Giraldo, Esther|||0000-0001-5488-3011
[EN] Neurogenesis in the adult brain takes place in two neurogenic niches: the ventricular-subventricular zone (V-SVZ) and the subgranular zone. After differentiation, neural precursor cells (neuroblasts) have to move to an adequate position, a process known as neuronal migration. Some studies show that in Alzheimer's disease, the adult neurogenesis is impaired. Our main aim was to investigate some proteins involved both in the physiopathology of Alzheimer's disease and in the neuronal migration process using the APP/PS1 Alzheimer's mouse model. Progenitor migrating cells are accumulated in the V-SVZ of the APP/PS1 mice. Furthermore, we find an increase of Cdh1 levels and a decrease of Cdk5/p35 and cyclin B1, indicating that these cells have an alteration of the cell cycle, which triggers a senescence state. We find less cells in the rostral migratory stream and less mature neurons in the olfactory bulbs from APP/PS1 mice, leading to an impaired odour discriminatory ability compared with WT mice. Alzheimer's disease mice present a deficit in cell migration from V-SVZ due to a senescent phenotype. Therefore, these results can contribute to a new approach of Alzheimer's based on senolytic compounds or pro-neurogenic factors., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This work was supported by the following grants: Instituto de Salud Carlos III CB16/10/00435 (CIBER-FES), (PID2019-110906RB-I00/AEI/10.13039/501100011033) from the Spanish Ministry of Innovation and Science, PROMETEO/2019/097 from `Conselleria, de Sanitat de la Generalitat Valenciana' and EU Funded H2020-DIABFRAIL-LATAM (Ref: 825546), European Joint Programming Initiative `A Healthy Diet for a Healthy Life' (JPI HDHL) and of the ERA-NET Cofound ERA-HDHL (GA No 696295 of the EU Horizon 2020 Research and Innovation Programme). Part of the equipment employed in this work has been funded by Generalitat Valenciana and co-financed with ERDF funds (OP ERDF of Comunitat Valenciana 2014-2020). Special Research Actions from University of Valencia (REF: UV-INV-AE-1546096).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Disruption of MCL1/BOK transmembrane interaction as a novel strategy to induce cell death in tumours

  • Buffa, M.
  • Leiva, D.
  • García-Jareño, A.
  • Garcés-Flores, M.
  • Díaz, E.
  • Lucantoni, F.
  • Telechea, M.
  • Chen, L.
  • Lucendo, E.
  • Shalaby, R.
  • Lolicato, F.
  • Kulig, W.
  • García-Sáez, A.J.
  • Moreno-Bueno, G.
  • Sancho, M.
  • Orzáez-Calatayud, Mar
[EN] MCL1, an anti-apoptotic BCL-2 family member, is frequently overexpressed in multiple tumour types and correlates with poor prognosis; however, targeting its cytosolic domain to release pro-apoptotic effectors has been limited by cardiotoxicity in clinical trials. In this study, we describe a chemically mediated disruption of the MCL1/BOK transmembrane interaction that induces tumour cell death without affecting viability in 3D cardiomyocyte cultures. Molecular dynamics simulations and LUV-based assays converged to show that the MBoIN179 disrupts transmembrane dimerization, thereby restoring BOK pore formation inhibited by MCL1. In cells, interference with the MCL1/BOK transmembrane interaction promoted relocalization of BOK from the endoplasmic reticulum to mitochondria, where it engaged a BOK-dependent cell death program in both 2D and 3D breast cancer models, leading to reduced tumour growth and metastasis in vivo. Analysis of patient tumour microarrays further showed that BOK is overexpressed in aggressive breast cancer subtypes and correlates with poor prognosis. Together, these findings identify the MCL1/BOK transmembrane interaction as a tumour-selective vulnerability that can be engaged to promote antitumour responses with cardiac safety, highlighting transmembrane interactions as viable molecular targets., These results are part of the project PID2023-148234NB-I00, funded by MCIU/AEI/ 10.13039/501100011033 and ERDF/EU, project PT23/00177, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, and the project CIPROM/2022/62, funded by the Department of Education, Culture, Universities and Employment of the Generalitat Valenciana (PROMETEO). A part of the work was also supported by grants from the Spanish Ministry of Economy and Innovation (PID2019- 104644RB-I00 -GMB-) and the Instituto de Salud Carlos III (CIBERONC, CB16/12/00295 -GMB). MB is funded by a predoctoral fellowship (GRISOLIAP/2021/132) from Generalitat Valenciana and by an EMBO Scientific Exchange Grant (11082) for a research stay in the laboratory of Ana García-Sáez. DL is funded by a predoctoral fellowship (PRDVA21475LEIV) from the Spanish Cancer Association (AECC). RS and AGS are partially funded by the Deutsche Forschungsgemeinschaft (CRC1403, project 414786233; TRR353, project 471011418). This work is also supported by grants of the Deutsche Forschungsgemeinschaft (DFG) to FL (SFB-1638/1 511488495 - Z01).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

3D biomimetic microgel platform for multiple myeloma: Approaching tumor microenvironment on cell lines and patient-derived cells

  • García-Briega, María Inmaculada|||0000-0003-0811-2632
  • Ródenas Rochina, Joaquín|||0000-0001-5764-207X
  • Gómez Ribelles, José Luís|||0000-0001-9099-0885
  • Carroll, Alison
  • Rossi, Ludovica
  • Vicente Tomás, Carolina
  • Garcia Garay, Maricarmen
  • Andreu Lapiedrad, Rafael
  • Cordon, Lourdes
  • Sempere, Amparo
[EN] This work aimed to develop and characterize a three-dimensional culture platform that recreates the tumor microenvironment of multiple myeloma cells (MMCs), focusing on how atypical plasma cells (aPCs) interact with other bone marrow cells and extracellular matrix (ECM) components to develop drug resistance. The biomimetic platform consists of a static system based on a conical agarose geometry that facilitates the agglomeration and proliferation of aPCs. Magnetic alginate microgels, manufactured by microfluidics, configure the ECM through a layer-by-layer functionalization with collagen, hyaluronic acid, chondroitin sulfate, and heparin. In addition, bone marrow mesenchymal stem cell (BMMSC) pellets were integrated to simulate direct and indirect interactions between BMMSCs and MMCs. The platform has been validated with three lines of MMCs (RPMI8226, MM1S, U266) and the patients' mononuclear cell fraction collected from bone marrow aspirates extracted in two Spanish Hospitals. The microgel analysis aimed to verify stability and to characterize the presence of the different coatings. Biological studies have investigated the proliferation and resistance to drug treatments in MM cell lines. In addition, patient-derived cells were cultured for up to 14 days to study the survival and possible immunophenotypic changes of the atypical plasma cell (aPC) fraction., This work has been supported by PID2022-138572OB-C41 project funded by MCIN/AEI/10.13039/501100011033/FEDER, UE, and by the Spanish Ministry of Science, Innovation and Universities through Grant No PRE2020-092326 awarded to Ma Inmaculada Garcia-Briega. The research was also supported by CIBER-Consorcio Centro de Investigacion Biomedica en Red-CB06/01/1026, and CIBERONC CB16/12/00284, Instituto de Salud Carlos III, Ministerio de Ciencia e Innovacion. In addition, Erasmus + and Erasmus European projects grants awarded to Ludovica Rossi and Alison Carroll supported this work. The authors also thank the IIS La Fe Scientific Support Platforms, Biobank, and Cellular Biology for their help and support in this project.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

From 12 to 1 ECG lead: multiple cardiac condition detection mixing a hybrid machine learning approach with a one-vs-rest classification strategy

  • Jiménez-Serrano, Santiago|||0000-0003-2917-6053
  • Calvo Saiz, Conrado Javier
  • Millet Roig, José|||0000-0002-8879-003X
  • Castells, Francisco|||0000-0001-5044-3545
  • Rodrigo, Miguel
[EN] Objective: Detecting different cardiac diseases using a single or reduced number of leads is still challenging. This work aims to provide and validate an automated method able to classify ECG recordings. Performance using complete 12-lead systems, reduced lead sets, and single-lead ECGs is evaluated and compared. Approach: Seven different databases with 12-lead ECGs were provided during the PhysioNet/Computing in Cardiology Challenge 2021, where 88,253 annotated samples associated with none, one, or several cardiac conditions among 26 different classes were released for training, whereas 42,896 hidden samples were used for testing. After signal preprocessing, 81 features per ECG-lead were extracted, mainly based on heart rate variability, QRST patterns and spectral domain. Next, a One-vs-Rest classification approach made of independent binary classifiers for each cardiac condition was trained. This strategy allowed each ECG to be classified as belonging to none, one or several classes. For each class, a classification model among two binary Supervised Classifiers and one Hybrid Unsupervised-Supervised classification system was selected. Finally, we performed a 3-fold cross-validation to assess the system's performance. Main results: Our classifiers received scores of 0.39, 0.38, 0.39, 0.38, and 0.37 for the 12, 6, 4, 3 and 2-lead versions of the hidden test set with the Challenge evaluation metric (CM). Also, we obtained a mean G-score of 0.80, 0.78, 0.79, 0.79, 0.77 and 0.74 for the 12, 6, 4, 3, 2 and 1-lead subsets with the public training set during our 3-fold cross-validation. Significance: We proposed and tested a machine learning approach focused on flexibility for identifying multiple cardiac conditions using one or more ECG leads. Our minimal-lead approach may be beneficial for novel portable or wearable ECG devices used as screening tools, as it can also detect multiple and concurrent cardiac conditions., This work was supported by PID2019-109547RB-I00 (National Research Program, Ministerio de Ciencia e Innovación, Spanish Government) and CIBERCV CB16/11/00486 (Instituto de Salud Carlos III).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Impact of Persistent Microvascular Obstruction Late After STEMI on Adverse LV Remodeling A CMR Study

  • Bodi, Vicente
  • Lopez-Lereu, Maria P.
  • Monmeneu, Jose V.
  • De Dios, Elena
  • Pérez-Sole, Nerea
  • Bonanad, Clara
  • Marcos-Garces, Victor
  • Cánoves, Joaquín
  • Minana, Gema
  • Nunez, Julio
  • Chorro, Francisco J.
  • Rodríguez-Palomares, Jose F.
  • Freixa, Andrea
  • Gavara-Doñate, Josep|||0000-0002-3483-7066
  • Moratal, David|||0000-0002-2825-3646
[EN] The present study confirms that a spontaneous tendency towards microvascular repair occurs in the majority of STEMI patients with altered microvasculature in acute phase, and this is related to less LV dilation in the following months. In a small percentage of patients, however, MVO persists in chronic phase after STEMI, and is associated with deleterious effects in terms of LV remodeling. MVO persists in a small percentage of patients in chronic phase after STEMI and exerts deleterious effects in terms of LV remodeling. These findings fuel the need for further research on microvascular injury repair., This work was supported by Instituto de Salud Carlos III and Fondos Europeos de Desarrollo Regional FEDER (grant numbers PI20/00637, CIBERCV16/11/00486, CIBERCV16/11/00420, CIBERCV16/11/00479, and a postgraduate contract CM21/00175 to V.M.- G.), by Conselleria de Educacion-Generalitat Valenciana ( PROMETEO/2021/008) and by Sociedad Española de Cardiologia (grant SEC/ FEC-INV- CLI 21/024). Dr Gavara has received financial support from the Agencia Estatal de Investigacion (grant FJC2020-043981-I/AEI/10.13039/501100011033). Dr Moratal has received financial support from the Conselleria d'Educacio, Investigacio, Cultura i Esport, Generalitat Valenciana (grants AEST/2019/037, AEST/2020/029). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Non-invasive characterisation of macroreentrant atrial tachycardia types from a vectorcardiographic approach with the slow conduction region as a cornerstone

  • Ruipérez-Campillo, Samuel
  • Castrejón, Sergio
  • Martínez, Marcel
  • Cervigón, Raquel
  • Meste, Olivier
  • Merino, José Luis
  • Millet Roig, José|||0000-0002-8879-003X
  • Castells, Francisco|||0000-0001-5044-3545
[EN] Background and objectives: Macroreentrant atrial tachyarrhythmias (MRATs) can be caused by different reentrant circuits. The treatment for each MRAT type may require ablation at different sites, either at the right or left atria. Unfortunately, the reentrant circuit that drives the arrhythmia cannot be ascertained previous to the electrophysiological intervention. Methods: A noninvasive approach based on the comparison of atrial vectorcardiogram (VCG) loops is proposed. An archetype for each group was created, which served as a reference to measure the similarity between loops. Methods were tested in a variety of simulations and real data obtained from the most common right (peritricuspid) and left (perimitral) macroreentrant circuits, each divided into clockwise and counterclockwise subgroups. Adenosine was administered to patients to induce transient AV block, allowing the recording of the atrial signal without the interference of ventricular signals. From the vectorcardiogram, we measured intrapatient loop consistence, similarity of the pathway to archetypes, characterisation of slow velocity regions and pathway complexity. Results: Results show a considerably higher similarity with the loop of its corresponding archetype, in both simulations and real data. We found the capacity of the vectorcardiogram to reflect a slow velocity region, consistent with the mechanisms of MRAT, and the role that it plays in the characterisation of the reentrant circuit. The intra-patient loop consistence was over 0.85 for all clinical cases while the similarity of the pathway to archetypes was found to be 0.85 +/- 0.03, 0.95 +/- 0.03, 0.87 +/- 0.04 and 0.91 +/- 0.02 for the different MRAT types (and p < 0 . 02 for 3 of the 4 groups), and pathway complexity also allowed to discriminate among cases (with p < 0 . 05 ). Conclusions: We conclude that the presented methodology allows us to differentiate between the most common forms of right and left MRATs and predict the existence and location of a slow conduction zone. This approach may be useful in planning ablation procedures in advance., This work was supported by PID2019-109547RB-I00 (National Research Program, Ministerio de Ciencia e Innovacion, Spanish Government), CIBERCV CB16/11/00486 (Instituto de Salud Carlos III) and PROMETEOII/2014/037 (Generalitat Valenciana).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Vector Field Heterogeneity for the Assessment of Locally Disorganised Cardiac Electrical Propagation Wavefronts From High-Density Multielectrodes

  • Pancorbo, Lucía
  • Ruiperez-Campillo, Samuel
  • Tormos, Álvaro
  • Cervigón, Raquel
  • Alberola, Antonio
  • Chorro, Francisco Javier
  • Guill Ibáñez, Antonio|||0000-0001-8546-264X
  • Millet Roig, José|||0000-0002-8879-003X
  • Castells, Francisco|||0000-0001-5044-3545
[EN] High-density multielectrode catheters are becoming increasingly popular in cardiac electrophysiology for advanced characterisation of the cardiac tissue, due to their potential to identify impaired sites. These are often characterised by abnormal electrical conduction, which may cause locally disorganised propagation wavefronts. To quantify it, a novel heterogeneity parameter based on vector field analysis is proposed, utilising finite differences to measure direction changes between adjacent cliques. The proposed Vector Field Heterogeneity metric has been evaluated on a set of simulations with controlled levels of organisation in vector maps, and a variety of grid sizes. Furthermore, it has been tested on animal experimental models of isolated Langendorff-perfused rabbit hearts. The proposed parameter exhibited superior capturing ability of heterogeneous propagation wavefronts compared to the classical Spatial Inhomogeneity Index, and simulations proved that the metric effectively captures gradual increments in disorganisation in propagation patterns. Notably, it yielded robust and consistent outcomes for $\mathbf {4\times 4}$ grid sizes, underscoring its suitability for the latest generation of orientation-independent cardiac catheters., This work was supported in part by the National Research Program, Ministerio de Ciencia e Innovación, Spanish Government under Grants PID2019- 109547RB-I00 and PID2022-142514OB-I00, and in part by Instituto de Salud Carlos II under Grant CIBERCV CB16/11/00486.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

G9a/DNMT1 co-targeting inhibits non-small cell lung cancer growth and reprograms tumor cells to respond to cancer-drugs through SCARA5 and AOX1

  • Exposito, Francisco
  • Redrado, Miriam
  • Serrano, Diego
  • Calabuig-Fariñas, Silvia
  • Bao-Caamano, Aida
  • Gallach-Garcia, Sandra
  • Díaz-Lagares, Ángel
  • Rodriguez-Casanova, Aitor
  • Sandoval, Juan
  • San Jose-Eneriz, Edurne
  • Garcia, Javier
  • Redin, Esther
  • Senent, Yaiza
  • Leon, Sergio
  • Jantus-Lewintre, Eloisa|||0000-0001-7395-4380
[EN] The treatment of non-small cell lung cancer (NSCLC) patients has significantly improved with recent therapeutic strategies; however, many patients still do not benefit from them. As a result, new treatment approaches are urgently needed. In this study, we evaluated the antitumor efficacy of co-targeting G9a and DNMT1 enzymes and its potential as a cancer drug sensitizer. We observed co-expression and overexpression of G9a and DNMT1 in NSCLC, which were associated with poor prognosis. Co-targeting G9a/DNMT1 with the drug CM-272 reduced proliferation and induced cell death in a panel of human and murine NSCLC cell lines. Additionally, the transcriptomes of these cells were reprogrammed to become highly responsive to chemotherapy (cisplatin), targeted therapy (trametinib), and epigenetic therapy (vorinostat). In vivo, CM-272 reduced tumor volume in human and murine cell-derived cancer models, and this effect was synergistically enhanced by cisplatin. The expression of SCARA5 and AOX1 was induced by CM-272, and both proteins were found to be essential for the antiproliferative response, as gene silencing decreased cytotoxicity. Furthermore, the expression of SCARA5 and AOX1 was positively correlated with each other and inversely correlated with G9a and DNMT1 expression in NSCLC patients. SCARA5 and AOX1 DNA promoters were hypermethylated in NSCLC, and SCARA5 methylation was identified as an epigenetic biomarker in tumors and liquid biopsies from NSCLC patients. Thus, we demonstrate that co-targeting G9a/DNMT1 is a promising strategy to enhance the efficacy of cancer drugs, and SCARA5 methylation could serve as a non-invasive biomarker to monitor tumor progression., This work has been funded by: FIMA, ISCIII-Fondo de Investigacion Sanitaria-FondoEuropeo de Desarrollo Regional 'Una manera de hacer Europa' (PI22/01253 to AC, PI22/0451 to LMM, CIBERONC CB16/12/00443 to LMM, CB16/12/00486 to FP, CB16/12/00350 to EJL), MICIN PID2022-137965OB-I00 to JS. Fellowship support: FE, Asociacion de Amigos de la Universidad de Navarra" in association with "La Caixa" Banking Foundation; DS, Juan de la Cierva-Incorporacion.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Whole exome sequencing and machine learning germline analysis of individuals presenting with extreme phenotypes of high and low risk of developing tobacco-associated lung adenocarcinoma

  • Patino-Garcia, Ana
  • Guruceaga, Elizabeth
  • Andueza, Maria Pilar
  • Ocón, Marimar
  • Sokoudjou, Jafait Junior Fodop
  • de Villalonga Zornoza, Nicolás
  • Alkorta-Aranburu, Gorka
  • Tamayo Uria, Ibon
  • Gurpide, Alfonso
  • Camps, Carlos
  • Navamuel-Andueza, Maria
  • Sanmamed, Miguel F.
  • Melero, Ignacio
  • Elgendy, Mohamed
  • Jantus-Lewintre, Eloisa|||0000-0001-7395-4380
[EN] Background Tobacco is the main risk factor for developing lung cancer. Yet, while some heavy smokers develop lung cancer at a young age, other heavy smokers never develop it, even at an advanced age, suggesting a remarkable variability in the individual susceptibility to the carcinogenic effects of tobacco. We characterized the germline pro fi le of subjects presenting these extreme phenotypes with Whole Exome Sequencing (WES) and Machine Learning (ML). Methods We sequenced germline DNA from heavy smokers who either developed lung adenocarcinoma at an early age ( extreme cases ) or who did not develop lung cancer at an advanced age ( extreme controls ), selected from databases including over 6600 subjects. We selected individual coding genetic variants and variant -rich genes showing a signi fi cantly different distribution between extreme cases and controls. We validated the results from our discovery cohort, in which we analysed by WES extreme cases and controls presenting similar phenotypes. We developed ML models using both cohorts. Findings Mean age for extreme cases and controls was 50.7 and 79.1 years respectively, and mean tobacco consumption was 34.6 and 62.3 pack -years. We validated 16 individual variants and 33 variant -rich genes. The gene harbouring the most validated variants was HLA-A in extreme controls (4 variants in the discovery cohort, p = 3.46E-07; and 4 in the validation cohort, p = 1.67E-06). We trained ML models using as input the 16 individual variants in the discovery cohort and tested them on the validation cohort, obtaining an accuracy of 76.5% and an AUC-ROC of 83.6%. Functions of validated genes included candidate oncogenes, tumoursuppressors, DNA repair, HLA-mediated antigen presentation and regulation of proliferation, apoptosis, in fl ammation and immune response. Interpretation Individuals presenting extreme phenotypes of high and low risk of developing tobacco -associated lung adenocarcinoma show different germline pro fi les. Our strategy may allow the identi fi cation of high -risk subjects and the development of new therapeutic approaches., We particularly acknowledge our patients for their participation and the Biobank of the University of Navarra and Hospital General of Valencia for their collaboration. We are thankful to Dr. Paul Miller, University of Navarra, for English editing of the manuscript and to Pablo Esquiroz for fi gure editing. This work was funded by the Spanish Society of Medical Oncology, Fundacion SEOM and Fundacion Salud 2000 and by an unrestricted grant from Roche. CC and EJ work is supported by the Spanish Health Institute Carlos III (ISCII, Fondo de Investigacion Sanitaria: CB16/12/00350) . ME has received funding from the European Research Council (ERC) under Horizon 2020 research and innovation programme (Onco-Energetics_OFF, Grant agreement No. 852761) and the DFG (German Research Foundation) Project No. EL 1081/2-1. RP work is supported by the Spanish Health Institute Carlos III (ISCII, Fondo de Investigacion Sanitaria: PI20/12/00419) . This work was supported by FIMA, CIBERONC (CB16/12/00443) , Spanish Ministry of Economy and Innovation and Fondo de Investigacion Sanitaria Fondo Europeo de Desarrollo Regional (PI22/00451; to L.M. Montuenga) and Lung Ambition Alliance grant (to Luis M. Montuenga) . IO declares declares research grants and support from a Ramon y Cajal contract RYC2019-028578-I, a Gipuzkoa Fellows grant 2022-FELL-000003-01, and grant PID2021-126718OA-I00 funded by MCIN/AEI/10.13039/501100011033. MH declares research grants and support from MCIN/AEI/10.13039/501100011033 [grant number PID2020-114394RA-C33] and Ramon y Cajal contract RYC2021-033127-I.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Left ventricular remodeling after myocardial infarction pathophysiology, diagnostic approach and management during Cardiac Rehabilitation

  • Marcos-Garcés, Víctor
  • Bertolín-Boronat, Carlos
  • Merenciano-Gonzalez, Héctor
  • Martínez Mas, Maria Luz
  • Climent Alberola, Josefa Inés
  • Lopez Bueno, Laura
  • Paya Rubio, Alfonso
  • Pérez-Solé, Nerea
  • Rios-Navarro, César
  • De Dios, Elena
  • Rodríguez-Palomares, Jose F.
  • Ortiz-Perez, Jose T.
  • Sanchis, Juan
  • Gavara-Doñate, Josep|||0000-0002-3483-7066
  • Moratal, David|||0000-0002-2825-3646
[EN] Despite the improvement in prognosis in patients with acute myocardial infarction (AMI), a significant proportion of survivors still experience heart failure (HF)-related adverse outcomes. Adverse left ventricular remodeling (LVR), which refers to a progressive dilation of left ventricular (LV) end-diastolic and end-systolic volumes, usually accompanied by a deterioration in LV systolic function, occurs frequently and underlies most cases of HF development after AMI. In this review, we discuss the current definitions of post-AMI LVR, the most appropriate imaging modalities for its detection, and the pathophysiological mechanisms by which Cardiac Rehabilitation (CR) can improve LVR-including exercise interventions, cardiovascular risk factors control, and pharmacological therapy optimization. Finally, we provide up-to-date recommendations for the follow-up and management of LVR in post-AMI patients enrolled in CR and outline future prospects on this topic., This research was funded by the Instituto de Salud Carlos III, Fondos Europeos de Desarrollo Regional FEDER and Fondo Social Europeo Plus (FSE+) (grant numbers PI23/01150, PI15/00531, CB16/11/00486, CB16/11/00420, and CB16/11/00479 and postgraduate contracts CM21/00175 and CM23/00246) and by Conselleria de Educacion of the Generalitat Valenciana (CIPROM/2024/028). Dr. Marcos-Garces acknowledges funding from the Instituto de Salud Carlos III and co-funding from Fondo Social Europeo Plus (FSE+) (grant JR23/00032), as well as a GE 2023 grant from the Conselleria de Innovacion, Universidades, Ciencia y Sociedad Digital of the Generalitat Valenciana (CIGE/2022/26). Dr. Ortiz-Perez acknowledges partial financial support from Fundacio La Marato de TV3 (grant number 20153030-31-32), Siemens Healthcare, and La Caixa Banking Foundation (HR17-00527). Dr. Gavara acknowledges funding from the Conselleria de Educacion-Generalitat Valenciana and co-funding from Fondo Social Europeo Plus (grant number CIAPOS/2023/247). Dr. Moratal has received financial support from the Conselleria d'Educacio, Investigacio, Cultura i Esport, Generalitat Valenciana (grants AEST/2019/037 and AEST/2020/029).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Soluble galectin-3 as a microenvironment-relevant immunoregulator with prognostic and predictive value in lung adenocarcinoma

  • Torres-Martínez, Susana
  • Calabuig-Fariñas, Silvia
  • Moreno-Manuel, Andrea
  • Bertolini, Giulia
  • Escorihuela, Eva
  • Duréndez-Sáez, Elena
  • Guijarro, Ricardo
  • Blasco, Ana
  • Roz, Luca
  • Camps, Carlos
  • Herreros-Pomares, Alejandro|||0000-0003-3838-097X
  • Jantus-Lewintre, Eloisa|||0000-0001-7395-4380
[EN] Despite the success of therapies in lung cancer, more studies of new biomarkers for patient selection are urgently needed. The present study aims to analyze the role of galectin-3 (GAL-3) in the lung tumor microenvironment (TME) using tumorspheres as a model and explore its potential role as a predictive and prognostic biomarker in non-small cell lung cancer patients. For in vitro studies, lung adenocarcinoma (LUAD) and lung squamous carcinoma (LUSC) primary cultures from early-stage patients and commercial cell lines were cultured, using tumorsphere-forming assays and adherent conditions for the control counterparts. We analyzed the pattern of secretion and expression of GAL-3 using reverse transcription-quantitative real-time PCR (RTqPCR), immunoblot, immunofluorescence, flow cytometry, and immunoassay analysis. Our results using three-dimensional (3D) models of lung tumor cells revealed that soluble GAL-3 (sGAL-3) is highly expressed and secreted. To more accurately mimic the TME, a co-culture of tumorspheres and fibroblasts was used, revealing that GAL-3 could be important as an immunomodulatory molecule expressed and secreted in the TME, modulating immunosuppression through regulatory T cells (T-REGS ). In the translational phase, we confirmed that patients with high expression levels of GAL-3 had more T-REGS , which suggests that tumors may be recruiting this population through GAL-3. Next, we evaluated levels of sGAL-3 before surgery in LUAD and LUSC patients, hypothesizing that sGAL-3 could be used as an independent prognostic biomarker for overall survival and relapse-free survival in early-stage LUAD patients. Additionally, levels of sGAL-3 at pretreatment and first response assessment from plasma to predict clinical outcomes in advanced LUAD and LUSC patients treated with first-line pembrolizumab were evaluated, further supporting that sGAL-3 has a high efficiency in predicting durable clinical response to pembrolizumab with an area under curve of 0.801 (P = 0.011). Moreover, high levels might predict decreased progression-free survival and OS to anti-PD-1 therapy, with sGAL-3 being a prognosis-independent biomarker for advanced LUAD., The authors ED-S and AM-M have a predoctoral fellowship (PRDVA18015MORE) from Scientific Foundation of Asociacion Espanola Contra el Cancer,Valencia (AECC Valencia). LR is supported by the Italian Association for Cancer Research (AIRC)(IG21431). ST-M is supported by the Generalitat Valenciana and Fondo Social Europeo fellowship(ACIF/2018/275). AH-P is supported by Ayudas Margarita Salas from Ministerio de Universidades, UnionEuropea-Next generation EU. This research was founded by Centro de Investigacion Biomedica en Red de Cancer (CIBERONC) (grant number CB16-12-00350), Instituto de Salud Carlos III (PI18/00266, PI22/01221, PI22/01277 and IFEQ21/00194), Generalitat Valenciana (AICO/2021/333) and ERA-NETEURONANOMED III project METASTARG (Grant Number JTC 2018-045).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Tesis doctoral (DoctoralThesis)

Estudio del papel físiopatológico del colágeno en la insufíciencia cardiaca. Implicaciones en el remodelado ventricular

  • Gil Cayuela, Carolina
[ES] La insuficiencia cardiaca (IC) es un síndrome multifactorial resultado de una compleja red de alteraciones estructurales, funcionales y moleculares que conducen a la progresión de la disfunción ventricular. La IC es denominador común de la mayoría de cardiopatías y su complejidad da lugar a diagnósticos y tratamientos imprecisos que comportan el aumento progresivo de su prevalencia, morbimortalidad y coste sanitario. Es por ello que existe la necesidad de desarrollar nuevas estrategias, a través de la investigación básica y clínica, que permitan diagnósticos más precisos y tratamientos más eficaces que las terapias actuales. Dicha compleja red de alteraciones en la morfología, composición e interacciones entre los distintos componentes del corazón se conoce como remodelado cardiaco. Histopatológicamente, el remodelado se caracteriza por proliferación y migración celular, fibrosis cardiaca, hipertrofia de cardiomiocitos y por muerte celular necrótica y apoptótica. Subyacente a estos procesos podemos encontrar, entre otros, alteraciones del metabolismo del colágeno que pueden conducir a rigidez ventricular y/o debilitamiento de las uniones estructurales y dilatación cardiaca, cuya progresión producirá disfunción ventricular e IC. El principal objetivo de esta tesis es estudiar la fibrosis miocárdica y el remodelado cardiaco en pacientes con IC (miocardiopatía isquémica, MCI; y miocardiopatía dilatada, MCD) a través del análisis de expresión de las moléculas de colágeno, así como investigar la relevancia de las posibles alteraciones de su expresión mediante el estudio de las relaciones con distintos marcadores moleculares del proceso de remodelado y con parámetros de disfunción ventricular. Los resultados obtenidos muestran un aumento en la expresión de colágenos fibrilares y no fibrilares en ambas cardiomiopatías, destacando el porcentaje de genes codificantes de colágenos no fibrilares que se encuentran alterados y que no habían sido descritos en la IC hasta ahora. Los cambios en la expresión de algunos de estos colágenos fueron validados por PCR cuantitativa en tiempo real y, mediante western blot, se determinó que la alteración en la expresión se mantenía a nivel proteico. En cuanto al estudio de la relación entre los cambios de la expresión de estos genes con parámetros de función y remodelado ventricular, así como con marcadores de fibrosis, hipertrofia y apoptosis por ser los principales procesos que subyacen al remodelado cardiaco, observamos que, en la MCI, la sobre-expresión de COL4A5 y COL16A1 está relacionada significativamente con la fracción de acortamiento y con los diámetros tele-sistólico y tele-diastólico del ventrículo izquierdo, respectivamente; mientras que, en la MCD, la sobre-expresión de COL8A1 se relaciona con el índice de masa ventricular izquierdo. Además, encontramos relaciones significativas entre la alteración de estos colágenos y los marcadores moleculares de los principales procesos biológicos que tienen lugar durante el remodelado ventricular. En definitiva, estos resultados confirman la hipótesis de la existencia de una alteración en la expresión de los genes que codifican colágenos fibrilares y no fibrilares que podría estar participando de forma crucial en el desarrollo de remodelado cardiaco, proporcionando nuevas dianas para futuras investigaciones que permitan dilucidar el papel de estos colágenos y ofrecer nuevas opciones terapéuticas para las personas que padecen IC., [CA] La insuficiència cardíaca (IC) és una síndrome multifactorial resultat d'una complexa xarxa d'alteracions estructurals, funcionals i moleculars que conduïxen a la progressió de la disfunció ventricular. La IC es denominador comú de la majoria de cardiopaties i la seua complexitat dóna lloc a diagnòstics i tractaments imprecisos que comporten l'augment progressiu de la seua prevalença, morbimortalitat i cost sanitari. Es per això que existix la necessitat de desenvolupar noves estratègies, a través de la investigació bàsica i clínica, que permeten diagnòstics més precisos i tractaments més eficaços que les teràpies actuals. Dita complexa xarxa d'alteracions en la morfologia, composició i interaccions entre els distints components del cor es coneix com remodelat cardíac. Histopatològicament, el remodelat es caracteritza per proliferació i migració cel·lular, fibrosi cardíaca, hipertròfia de cardiomiòcits i per mort cel·lular necròtica i apoptótica. Subjacent a estos processos podem trobar, entre altres, alteracions del metabolisme del col·lagen que poden conduir a rigidesa ventricular i/o debilitament de les unions estructurals i dilatació cardíaca, la progressió dels quals produirà disfunció ventricular i IC. El principal objectiu d'esta tesi és estudiar la fibrosi miocardíaca i el remodelat cardíac en pacients amb IC (miocardiopatia isquèmica, MCI; i miocardiopatia dilatada, MCD) a través de l'anàlisi d'expressió de les molècules de col·lagen, així com investigar la rellevància de les possibles alteracions de la seua expressió mitjançant l'estudi de les relacions amb distints marcadors moleculars del procés de remodelat i amb paràmetres de disfunció ventricular. Els resultats obtinguts mostren un augment en la expressió de col·làgens fibril·lars i no fibril·lars en ambdues cardiomiopaties, destacant el percentatge de gens que codifiquen col·làgens no fibril·lars que es troben alterats i que no han sigut descrits en la IC fins ara. Els canvis en la expressió d'alguns d'estos col·làgens, van ser validats per PCR quantitativa en temps real i, mitjançant western blot, es determinà que l'alteració en l'expressió es mantenia a nivell proteic. En quant al estudi de la relació entre els canvis de l'expressió d'aquestos gens amb paràmetres de funció i remodelat ventricular, així com amb marcadors de fibrosi, hipertrofia i apoptosis per ser els principals processos subjacents al remodelat cardíac, vam observar que, en la MCI, la sobre-expressió de COL4A5 i COL16A1 està relacionada significativament amb la fracció d'acurtament i amb els diàmetres tele-sistòlic i tele-diastòlic del ventricle esquerre, respectivament; mentre que, en la MCD, la sobre-expressió de COL8A1 es relaciona amb l'índex de massa ventricular esquerre. A més, trobarem relacions significatives entre l'alteració d'aquestos col·làgens i els marcadors moleculars dels principals processos biològics que es produeixen durant el remodelat ventricular. En definitiva, estos resultats confirmen la hipòtesi de l'existència d'una alteració en la expressió dels gens que codifiquen col·làgens fibril·lars i no fibril·lars que podrien estar participant de forma crucial en el desenvolupament de remodelat cardíac, proporcionant noves dianes per a futures investigacions que permeten dilucidar el paper d'estos col·làgens i oferir noves opcions terapèutiques per a les persones que pateixen IC., [EN] Heart failure (HF) is a multifactorial syndrome resulting from a complex network of structural, functional and molecular alterations that ultimately lead to ventricular dysfunction. HF is the common denominator in most heart diseases, and its complexity originates imprecise diagnoses and treatments, so that its prevalence, morbidity and mortality increase progressively. For this reason, there is a significant requirement to develop new strategies through basic scientific and clinical research that will enable more accurate diagnoses and more effective treatments than are currently available. The complex network of alterations in the morphology, composition, and interactions between different components of the heart is known as cardiac remodelling. Histopathologically, remodelling is characterised by cell proliferation and migration, fibrosis, cardiomyocyte hypertrophy, and apoptotic and necrotic cell death. Underlying these processes, we have found, among others, alterations in collagen turnover within the myocardium that may lead to ventricular stiffness and/or weakening of structural linkages and cardiac dilation. Progression of these states is accompanied by ventricular dysfunction and HF. The main objective of this thesis is to study myocardial fibrosis and cardiac remodelling in patients with HF (ischaemic cardiomyopathy, ICM, and dilated cardiomyopathy, DCM) through analysis of the expression of collagen molecules, as well as to investigate the relevance of possible alterations in their expression by studying relationships with molecular markers of the remodelling process and with parameters of ventricular dysfunction. Our results show an increase in the expression of both fibrillar and non-fibrillar collagens in both cardiomyopathies, highlighting changes in the number of non-fibrillar collagen genes that have not previously been described in HF. Changes in the expression of some of these collagens were validated by quantitative real-time PCR. Alterations in expression at protein level were shown by western blot. Regarding the relationship between changes in collagen gene expression and parameters of ventricular remodelling and function, as well as with markers of fibrosis, hypertrophy, and apoptosis, the main processes underlying cardiac remodelling, we observed that in patients with ICM, COL4A5 and COL16A1 overexpression is significantly related to the shortening fraction and left ventricular end-systolic and end-diastolic diameters, respectively; whereas in the DCM group, COL8A1 overexpression is related to left ventricular mass index. In addition, we observed significant relationships between the changes in these collagens and established molecular markers for the major biological processes that occur during ventricular remodelling. In conclusion, these results support the hypothesis that alterations in the expression of genes encoding fibrillar and non-fibrillar collagens might be crucially involved in the development of cardiac remodelling. This in turn will identify new targets for future work aimed at elucidating the role of these collagens, and offer new therapeutic options for patients with HF., “Cinética del transporte núcleo-citoplasmático de los cardiomiocitos humanos en la insuficiencia cardiaca. Análisis celular y de expresión génica”. PI-10/00275, Instituto de Salud Carlos III, Fondo de Investigaciones Sanitarias (FIS). IP: Dr. J. Miguel Rivera Otero. “Alteraciones moleculares y estructurales en la insuficiencia cardiaca”. RD12/0042/0003, Red de Investigación Cardiovasular (RIC), Instituto de Salud Carlos III, Fondo de Investigaciones Sanitarias (FIS). IP: Dr. J. Miguel Rivera Otero. “Transporte núcleo-citoplasma y cambios de expresión génica en la insuficiencia cardiaca. Puesta en marcha de una nueva estrategia terapéutica”. PI-13/00100, Instituto de Salud Carlos III, Fondo de Investigaciones Sanitarias (FIS). IP: Dr. J. Miguel Rivera Otero. “Seguimiento de pacientes sometidos a trasplante cardiaco. Estudio de marcadores de rechazo implicados en el transporte núcleo-citoplasma”. PI-14/01506, Instituto de Salud Carlos III, Fondo de Investigaciones Sanitarias (FIS). IP: Dra. Esther Roselló Lletí. “Daño miocárdico y sus consecuencias. Identificación de nuevos biomarcadores en insuficiencia cardiaca”. CB16/11/00261, Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III. IP: Dr. J. Miguel Rivera Otero. Fondo Europeo de Desarrollo Regional (FEDER).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Magnetic Resonance Assessment of Left Ventricular Ejection Fraction at Any Time Post-Infarction for Prediction of Subsequent Events in a Large Multicenter STEMI Registry

  • Gavara-Doñate, Josep|||0000-0002-3483-7066
  • Moratal, David|||0000-0002-2825-3646
  • Marcos-Garces, Victor
  • Lopez-Lereu, Maria P.
  • Monmeneu, José V.
  • Rios-Navarro, César
  • De Dios, Elena
  • Pérez, Nerea
  • Merenciano, Héctor
  • Gabaldon, Ana
  • Cànoves, Joaquim
  • Racugno, Paolo
  • Bonanad, Clara
  • Miñana, Gema
  • Nunez, Julio
  • Nunez, Eduardo
[EN] Background Magnetic resonance imaging (MRI) is the most accurate imaging technique for left ventricular ejection fraction (LVEF) quantification, but as yet the prognostic value of LVEF assessment at any time after ST-segment elevation myocardial infarction (STEMI) for subsequent major adverse cardiac event (MACE) prediction is uncertain. Purpose To explore the prognostic impact of MRI-derived LVEF at any time post-STEMI to predict subsequent MACE (cardiovascular death or re-admission for acute heart failure). Study Type Prospective. Population One thousand thirteen STEMI patients were included in a multicenter registry. Field Strength/Sequence 1.5-T. Balanced steady-state free precession (cine imaging) and segmented inversion recovery steady-state free precession (late gadolinium enhancement) sequences. Assessment Post-infarction MRI-derived LVEF (reduced [r]: <40%; mid-range [mr]: 40%-49%; preserved [p]: >= 50%) was sequentially quantified at 1 week and after >3 months of follow-up. Statistical Tests Multi-state Markov model to determine the prognostic value of each LVEF state (r-, mr- or p-) at any time point assessed to predict subsequent MACE. A P-value During a 6.2-year median follow-up, 105 MACE (10%) were registered. Transitions toward improved LVEF predominated and only r-LVEF (at any time assessed) was significantly related to a higher incidence of subsequent MACE. The observed transitions from r-LVEF, mr-LVEF, and p-LVEF states to MACE were: 15.3%, 6%, and 6.7%, respectively. Regarding the adjusted transition intensity ratios, patients in r-LVEF state were 4.52-fold more likely than those in mr-LVEF state and 5.01-fold more likely than those in p-LVEF state to move to MACE state. Nevertheless, no significant differences were found in transitions from mr-LVEF and p-LVEF states to MACE state (P-value = 0.6). Data Conclusion LVEF is an important MRI index for simple and dynamic post-STEMI risk stratification. Detection of r-LVEF by MRI at any time during follow-up identifies a subset of patients at high risk of subsequent events. Level of Evidence 2 Technical Efficacy Stage 2, This work was supported by "Instituto de Salud Carlos III," "Fondos Europeos de Desarrollo Regional FEDER" (grants PI15/00531, PI17/01836, PI20/00637, and CIBERCV16/11/00486), and "Marato TV3" (grant 20153030-31-32), a grant from the Catalonian Society of Cardiology 2015 and a grant from La Caixa Foundation (HR17-00527). David Moratal and Jose Gavara acknowledge financial support from the "Conselleria d'Educacio, Investigacio, Cultura i Esport, Generalitat Valenciana" (grants AEST/2019/037 and AEST/2020/029), "Agencia Valenciana de la Innovacion, Generalitat Valenciana" (ref. INNCAD00/19/085 and INNCAD/2020/84), and "Centro para el Desarrollo Tecnologico Industrial" (Programa Eurostars-2, actuacion Interempresas Internacional), Spanish "Ministerio de Ciencia, Innovacion y Universidades" (ref. CIIP-20192020).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Assessment of remote ventricular dysfunction by cardiac magnetic resonance feature tracking strain in chronic infarction

  • Del Canto, I.
  • Lopez-Lereu, M. -p.
  • Monmeneu, J. V.
  • Chorro, F. J.
  • Bodi, V.
  • Moratal, David|||0000-0002-2825-3646
[EN] Aim To quantify regional LV deformation parameters in subjects with chronic myocardial infarction (MI) by the combination of CMR feature tracking (CMR-FT) and LGE images to assess segmental myocardial function in remote myocardium and to evaluate their relationships with infarct size and post-infarction LV global function. Materials and Methods CMR-images (SSFP cine and LGE) were acquired from 34 chronic MI patients and 32 healthy volunteers included in this retrospective study. LV ejection fraction (LVEF), infarct size (IS), CMR-FT regional circumferential, radial and longitudinal strain (CS, RS, LS), time-to-peak strain (TTP-CS, TTP-RS, TTP-LS) and rotation were measured. Results CS, RS and LS were greater for remote, adjacent and border zones than for infarct areas (p<0.01); TTP-CS, TTP-RS and TTP-LS values were shorter for remote and border zones than for infarct areas (p<0.05). Maximum apical rotation was found at the border zone (p<0.05). Remote CS, RS and LS in MI were significantly lower than in healthy subjects (p<0.01). Remote CS and LS correlated with IS (CS: r=0.75, LS: r=0.82, p<0.0001) and LVEF (CS: r=-0.87, LS: r=-0.83, p<0.001). In ROC analysis for the detection of contractile dysfunction in RM, IS and LVEF performed best with AUCs of 0.98 and 0.94, showing cut-off values of 17 % and 54 %, respectively. Conclusions Quantitative assessment of LV strain and rotation provides deformation characteristics of infarct, border and remote areas in patients with chronic MI, relating contractile dysfunction in remote areas to the extent of the infarcted region, which could offer useful clinical insights into the LV remodeling process., This work was supported by the Conselleria d'Educacio, Investigacio, Cultura i Esport, Generalitat Valenciana (grant CIGE/2023/88), the Agencia Valenciana de la Innovacion Generalitat Valenciana (grant INNCAD00/19/085) and the Spanish Ministry of Economy and Competiveness (Carlos III Health Institute)/European Regional Development Fund (grants CB16/11/00486 and PIE15/00013).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

miR-99a-5p modulates doxorubicin resistance via the COX-2/ABCG2 axis in triple-negative breast cancer: from the discovery to in vivo studies

  • Garrido-Cano, Iris
  • Adam-Artigues, Anna
  • Lameirinhas, Ana
  • Blandez, Juan F.
  • Rojo, Federico
  • Zazo, Sandra
  • Madoz-Gúrpide, Juan
  • Lluch, Ana
  • Bermejo, Begoña
  • Cejalvo, Juan Miguel
  • Eroles, Pilar
  • Candela-Noguera, Vicente
  • Sancenón Galarza, Félix|||0000-0002-5205-7135
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
This work was supported by Spanish Government and cofinanced by FEDER Funds (PI18/01219, PI21/01351, PI18/00382, and RTI2018-100910-B-C41), CIBERBBN (CB07/01/2012), CIBERONC (CB16/12/00481) and the Generalitat Valenciana (project PROMETEO 2018/024). I.G.-C. was funded by Generalitat Valenciana (ACIF/2016/030), A.A. and A.L. were funded by Asociación Española Contra el Cancer. J.F.B., was funded by Instituto de Salud Carlos III and the European Social Fund for the financial support Sara Borrell (CD19/00038), V.C.-N., was funded by Ministerio de Ciencia e Innovación (FPU grant), and J.M.C. was funded by Sociedad Española de Oncología Médica (Río Hortega-SEOM). We are especially grateful to the associations Amunt Contra el Cáncer, Asociación de la Lucha Contra el Cáncer de Montesa, and Corazón Solidario Contra el Cáncer. Funding for open access charge: Universitat Politècnica de València.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

The art of selecting the ECG input in neural networks to classify heart diseases: a dual focus on maximizing information and reducing redundancy

  • Elisa
  • Castells, Francisco|||0000-0001-5044-3545
  • Millet Roig, José|||0000-0002-8879-003X
  • Ruiperez-Campillo, Samuel
  • Casado-Arroyo, Rubén
  • Merino, José Luis
  • Vogt, Julia E.
[EN] Background and Objectives Accurate diagnosis of cardiovascular diseases often relies on the electrocardiogram (ECG). Since the cardiac vector is located within a three-dimensional space and the standard ECG comprises 12 projections or leads derived from it, redundant information is inherently present. This study aims to quantify this redundancy and its impact on classification tasks using Convolutional Neural Networks (CNNs) in cardiovascular diseases.Methods We employed signal theory and mutual information to introduce a novel redundancy metric and explored techniques for redundancy augmentation and reduction. This involved lead selection and transformation to evaluate the effects on neural network performance.Results Our findings indicate that optimizing input configurations through redundancy reduction techniques can enhance the performance of deep learning models in cardiovascular diagnostics, provided that the information is preserved and minimally distorted.Conclusion For the first time, this research has quantified the redundancy present in the input by validating various redundancy reduction techniques using a CNN. This discovery paves the way for advancing biomedical signal processing research, simplifying model complexity, and enhancing diagnostic performance in cardiovascular medicine within reduced lead systems, such as Holter monitors or wearables., The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work has been supported by PID 2022-142514OB-I00 (National Research Program, Ministerio de Ciencia e Innovacion, Spanish Government) and CIBERCV CB16/11/00486 (Instituto de Salud Carlos III).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Vasodilator Stress CMR and All-Cause Mortality in Stable Ischemic Heart Disease A Large Retrospective Registry

  • Marcos-Garces, Victor
  • Monmeneu, Jose V.
  • Lopez-Lereu, Maria P.
  • Bosch, María J.
  • Merlos, Pilar
  • Pérez, Nerea
  • Rios-Navarro, César
  • De Dios, Elena
  • Bonanad, Clara
  • Racugno, Paolo
  • Bellver Navarro, Alejandro
  • Ventura Perez, Bruno
  • Aguilar Botella, Jose
  • Ventura, Silvia
  • Gavara-Doñate, Josep|||0000-0002-3483-7066
  • Moratal, David|||0000-0002-2825-3646
[EN] OBJECTIVES: This study explored the association of ischemic burden, as measured by vasodilator stress cardiovascular magnetic resonance (CMR), with all-cause mortality and the effect of revascularization on all-cause mortality in patients with stable ischemic heart disease (SIHD). Background: In patients with SIHD, the association of ischemic burden, derived from vasodilator stress CMR, with all-cause mortality and its role for decision-making is unclear. METHODS: The registry consisted of 6,389 consecutive patients (mean age: 65 +/- 12 years; 38% women) who underwent vasodilator stress CMR for known or suspected SIHD. The ischemic burden (at stress first-pass perfusion imaging) was computed (17-segment model). The effect of CMR-related revascularization (within the following 3 months) on all-cause mortality was retrospectively explored using the electronic regional health system registry. RESULTS: During a 5.75-year median follow-up, 717 (11%) deaths were documented. In multivariable analyses, more extensive ischemic burden (per 1-segment increase) was independently related to all-cause mortality (hazard ratio: 1.04; 95% confidence interval: 1.02 to 1.07; p < 0.001). In 1,032 1:1 matched patients using a limited number of variables (516 revascularized, 516 non-revascularized), revascularization within the following 3 months was associated with less all-cause mortality only in patients with extensive CMR-related ischemia (>5 segments, n = 432; 10% vs. 24%; p = 0.01). CONCLUSIONS: In a large retrospective registry of unselected patients with known or suspected SIHD who underwent vasodilator stress CMR, extensive ischemic burden was related to a higher risk of long-term, all-cause mortality. Revascularization was associated with a protective effect only in the restricted subset of patients with extensive CMR-related ischemia. Further research will be needed to confirm this hypothesis-generating finding., Dr. Marcos-Garces and Mr. Gavara contributed equally to the study. This work was supported by the Instituto de Salud Carlos III and co-funded by Fondo Europeo de Desarrollo Regional (FEDER) (grant numbers PI17/01836, PIE15/00013, CIBERCV16/11/00486). The authors have reported that they have no relationships relevant to the contents of this paper to disclose.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

MiRNA-449 family is epigenetically repressed and sensitizes to doxorubicin through ACSL4 downregulation in triple-negative breast cancer

  • Torres-Ruiz, Sandra
  • Garrido-Cano, Iris
  • Lameirinhas, Ana
  • Burgués, Octavio
  • Hernando, Cristina
  • Martínez, Maria Teresa
  • Rojo, Federico
  • Bermejo, Begoña
  • Tapia, Marta
  • Carbonell-Asins, Juan Antonio
  • Peña, Carlos Javier
  • Lluch, Ana
  • Cejalvo, Juan Miguel
  • Tormo, Eduardo
  • Eroles, Pilar
[EN] Despite progress in breast cancer treatment, a significant portion of patients still relapse because of drug resistance. The involvement of microRNAs in cancer progression and chemotherapy response is well established. Therefore, this study aimed to elucidate the dysregulation of the microRNA-449 family (specifically, microRNA-449a, microRNA-449b-5p, and microRNA-449c-5p) and its impact on resistance to doxorubicin, a commonly used chemotherapeutic drug for the treatment of triple-negative breast cancer. We found that the microRNA-449 family is downregulated in triple-negative breast cancer and demonstrated its potential as a diagnostic biomarker. Besides, our findings indicate that the downregulation of the microRNA-449 family is mediated by the microRNAs-449/SIRT1-HDAC1 negative feedback loop. Moreover, it was found that the microRNA-449 family dysregulates the fatty acid metabolism by targeting ACSL4, which is a potential prognostic biomarker that mediates doxorubicin response through regulation of the drug extrusion pump ABCG2. Altogether, our results suggest that the microRNA-449 family might be a potential therapeutic target for the treatment of triple-negative breast cancer since it is implicated in doxorubicin response through ACSL4/ABCG2 axis regulation. Ultimately, our results also highlight the value of microRNAs-449 and ACSL4 as diagnostic and prognostic biomarkers in triple-negative breast cancer., This work was supported by the Spanish Government and cofinanced by FEDER Funds (AES Program, grants PI21/01351, PI21/00142, CIBERONC, Biomedical Research Networking Centre for Cancer CB16/12/00241, and CB16/12/00481). STR was founded by Conselleria d'Educacio, Investigacio, Cultura i Esport, Generalitat Valenciana (ACIF/2019/119). IGC was founded by Margarita Salas's postdoctoral grant (European Union-Next generation EU). AL was founded by Asociacion Espanola Contra el Cancer(PRDVA19016LAME). JMC was founded by Sociedad Espanola de Oncologia Medica(Rio Hortega-SEOM)
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Prognostic role of persistent angina after percutaneous revascularization in chronic coronary syndrome with altered angiography and stress CMR

  • Pérez-Solé, Nerea
  • De Dios, Elena
  • Monmeneu, José V.
  • Lopez-Lereu, Maria P.
  • Gavara, Jose
  • Rios-Navarro, César
  • Marcos-Garces, Victor
  • Merenciano, Héctor
  • Bonanad, Clara
  • Cànoves, Joaquim
  • Platero, Felix
  • Ventura, Andrea
  • Bayes-Genis, Antoni
  • Sanz, Jorge
  • Moratal, David|||0000-0002-2825-3646
[EN] Introduction and objectives: In patients with established chronic coronary syndrome (CCS), the significance of persistent angina is controversial. We aimed to evaluate the prognostic role of persistent angina in symptomatic CCS patients with abnormal stress cardiovascular magnetic resonance (CMR) and altered angiographic findings undergoing percutaneous revascularization. Methods: We analyzed 334 CCS patients with Canadian Cardiovascular Society angina class > 2, perfusion deficits on stress CMR and severe lesions in angiography who underwent medical therapy optimization plus CMR-guided percutaneous revascularization. We investigated the association of persistent angina at 6 months postintervention with subsequent cardiac death, myocardial infarction, and hospital admission. Results: All patients had angina class > 2 (mean: 2.8 f 0.7), abnormal stress CMR (mean ischemic burden: 5.8 f 2.7 segments), and severe angiographic lesions. The angina resolution rates were 81% at 6 months, and 81%, 81%, and 77% at 1, 2, and 5 years, respectively. During a median follow-up of 8.9 years, persistent angina was independently associated with higher rates of subsequent cardiac death (13% vs 4%; HR, 3.7; 95%CI, 1.59.2; P = .005), myocardial infarction (24% vs 6%; HR, 4.9; 95%CI, 2.4-9.9; P < .001), and hospital admission for heart failure (27% vs 13%; HR, 2.7; 95%CI, 1.5-5.2; P = .001). Conclusions: In CCS patients with robust diagnostic evidence from symptoms, stress CMR, and angiography, persistent angina after percutaneous revascularization is a strong predictor of subsequent cardiac death, myocardial infarction, and hospital admission for heart failure., This work was supported by Instituto de Salud Carlos III and Fondos Europeos de Desarrollo Regional FEDER (grant numbers PI23/01150, CIBERCV16/11/00486, CIBERCV16/11/00403, CIBERCV16/11/00261, CIBERCV16/11/00420, CB16/11/00360) , and by Conselleria de Educacion - Generalitat Valenciana (PROMETEO/2021/008) .
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Profile of the Roche cobas (R) EGFR mutation test for non-small cell lung cancer

  • Malapelle, Umberto
  • Reclusa, P.
  • Calabuig-Farinas, S.
  • Blasco, Ana
  • Pisapia, P.
  • Rolfo, C.
  • Camps, Carlos
  • Sirera Pérez, Rafael|||0000-0001-9162-8490
  • Jantus-Lewintre, Eloisa|||0000-0001-7395-4380
[EN] Introduction: The discovery of driver mutations in non-small cell lung cancer (NSCLC) has led to the development of genome-based personalized medicine. Fifteen to 20% of adenocarcinomas harbor an epidermal growth factor receptor (EGFR) activating mutation associated with responses to EGFR tyrosine kinase inhibitors (TKIs). Individual laboratories' expertise and the availability of appropriate equipment are valuable assets in predictive molecular pathology, although the choice of methods should be determined by the nature of the samples to be tested and whether the detection of only well-characterized EGFR mutations or rather, of all detectable mutations, is required.Areas covered: The EGFR mutation testing landscape is manifold and includes both screening and targeted methods, each with their own pros and cons. Here we review one of these companion tests, the Roche cobas (R) EGFR mutation test v2, from a methodological point of view, also exploring its liquid-biopsy applications.Expert commentary: The Roche cobas (R) EGFR mutation test v2, based on real time RT-PCR, is a reliable option for testing EGFR mutations in clinical practice, either using tissue-derived DNA or plasma-derived cfDNA. This application will be valuable for laboratories with whose purpose is purely diagnostic and lacking high-throughput technologies., This work was partially supported by FEDER, CIBERONC, grant number [CB16/12/00350].
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Clustering and machine learning framework for medical time series classification

  • Ruiperez-Campillo, Samuel
  • Reiss, Michael
  • Elisa
  • Cebrián Ferriols, Antonio José|||0000-0003-0519-5284
  • Millet Roig, José|||0000-0002-8879-003X
  • Castells, Francisco|||0000-0001-5044-3545
[EN] Background and motivation: The application of artificial intelligence in medical research, particularly unsupervised learning techniques, has shown promising potential. Medical time series data poses a unique challenge for analysis due to its complexity. Existing unsupervised learning methods often fail to effectively classify these variations, highlighting a gap in current approaches. We introduce a methodological clustering classification framework designed to accurately handle such data, aiming for improved classification tasks in biomedical signals. Methods: To address these challenges, we introduce a novel approach for the analysis and classification of medical time series data. Our method integrates agglomerative hierarchical clustering with Hilbert vector space representations of medical signals and biological sequences. We rigorously define the mathematical principles and conduct evaluations using simulations of cardiac signals, real-world neural signal datasets, open-source protein sequences, and the MNIST dataset for illustrative purposes. Results: The proposed method exhibited a 96% success rate in classifying protein sequences by function and effectively identifying families within a large protein set. In cardiac signal analysis, it retained 0.996 variance in a condensed 6-dimensional space, accurately classifying 87.4% of simulated atrial flutter groups and 99.91% of main groups when excluding conduction direction. For neural signals, it demonstrated near-perfect tracking accuracy of neural activity in mouse brain recordings, as confirmed by expert evaluations. Conclusion: Our proposed method offers a novel, translational approach for the treatment and classification of medical and biological time series, addressing some of the prevalent challenges in the field and paving the way for more reliable and effective biomedical signal analysis., This work was supported by PID2019-109547RB-I00 (National Research Program, Ministerio de Ciencia e Innovación, Spanish Government) and CIBERCV CB16/11/00486 (Instituto de Salud Carlos III).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Delivery of miR-200c-3p Using Tumor-Targeted Mesoporous Silica Nanoparticles for Breast Cancer Therapy

  • Garrido-Cano, Iris
  • Adam-Artigues, Anna
  • Lameirinhas, Ana
  • Blandez, Juan F.
  • Lluch, Ana
  • Bermejo, Begoña
  • Cejalvo, Juan Miguel
  • Eroles, Pilar
  • Candela-Noguera, Vicente
  • Sancenón Galarza, Félix|||0000-0002-5205-7135
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
[EN] Despite advancesin breast cancer treatment, it remainsthe leadingcause of cancer-related death in women worldwide. In this context,microRNAs have emerged as potential therapeutic targets but stillpresent some limitations for in vivo applications.Particularly, miR-200c-3p is a well-known tumor suppressor microRNAthat inhibits tumor progression and metastasis in breast cancer throughdownregulating ZEB1 and ZEB2. Basedon the above, we describe the design and validation of a nanodeviceusing mesoporous silica nanoparticles for miR-200c-3p delivery forbreast cancer treatment. We demonstrate the biocompatibility of thesynthesized nanodevices as well as their ability to escape from endosomes/lysosomesand inhibit tumorigenesis, invasion, migration, and proliferationof tumor cells in vitro. Moreover, tumor targetingand effective delivery of miR-200c-3p from the nanoparticles in vivo are confirmed in an orthotopic breast cancer mousemodel, and the therapeutic efficacy is also evidenced by a decreasein tumor size and lung metastasis, while showing no signs of toxicity.Overall, our results provide evidence that miR-200c-3p-loaded nanoparticlesare a potential strategy for breast cancer therapy and a safe andeffective system for tumor-targeted delivery of microRNAs., This research was supported by project PID2021-126304OB-C41 funded by MCIN/AEI/10.13039/501100011033/ and by European Regional Development Fund A way of doing Europe. Also, this study forms part of the Advanced Materials program (MFA/2022/049) and was supported by MCIN with funding from European Union NextGeneration EU(PRTR-C17.I1) and by Generalitat Valenciana. This study was also supported by Generalitat Valenciana (CIPROM/2021/007). This research was also supported by CIBER Consorcio Centro de Investigación Biomédica en Red CIBER-BBN(CB07/01/2012), CIBERONC(CB16/12/00481), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación. This work was also supported by Spanish Government and cofinanced by FEDER Funds (PI18/01219, PI21/01351) .I.G.-C. was funded by Margarita Salas post doctoral grant (European Union-Nextgeneration EU). A.A.-A. and A.L. were funded by Asociación Española Contra el Cancer.J.F.B. was funded by Instituto de Salud Carlos III and the European Social Fund for the financial support 'Sara Borrell' (CD19/00038). V.C.-N. was funded by Ministerio de Ciencia e Innovacio¿n (FPU grant), and J.M.C. was funded by Sociedad Española de Oncología Médica (Río Hortega-SEOM)